US20160024087A1 - Mlk inhibitors and methods of use - Google Patents
Mlk inhibitors and methods of use Download PDFInfo
- Publication number
- US20160024087A1 US20160024087A1 US14/876,345 US201514876345A US2016024087A1 US 20160024087 A1 US20160024087 A1 US 20160024087A1 US 201514876345 A US201514876345 A US 201514876345A US 2016024087 A1 US2016024087 A1 US 2016024087A1
- Authority
- US
- United States
- Prior art keywords
- chosen
- compound
- recited
- optionally substituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 94
- 239000003112 inhibitor Substances 0.000 title claims description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 316
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 64
- 239000003814 drug Substances 0.000 claims abstract description 60
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 27
- 230000005764 inhibitory process Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- -1 NS(O)2CH3 Chemical group 0.000 claims description 145
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 37
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 33
- 102100025184 Mitogen-activated protein kinase kinase kinase 13 Human genes 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 21
- 230000001629 suppression Effects 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 18
- 125000002619 bicyclic group Chemical group 0.000 claims description 18
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 11
- 125000003368 amide group Chemical group 0.000 claims description 11
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 230000035755 proliferation Effects 0.000 claims description 10
- 230000004083 survival effect Effects 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 210000002865 immune cell Anatomy 0.000 claims description 9
- 230000002093 peripheral effect Effects 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 8
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 230000004766 neurogenesis Effects 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 201000001119 neuropathy Diseases 0.000 claims description 7
- 230000007823 neuropathy Effects 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 210000000653 nervous system Anatomy 0.000 claims description 6
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 208000008960 Diabetic foot Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 201000005569 Gout Diseases 0.000 claims description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 5
- 201000001431 Hyperuricemia Diseases 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 206010054805 Macroangiopathy Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- 208000027626 Neurocognitive disease Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- 208000017442 Retinal disease Diseases 0.000 claims description 5
- 206010038923 Retinopathy Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
- 210000002064 heart cell Anatomy 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 5
- 201000008980 hyperinsulinism Diseases 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 206010062198 microangiopathy Diseases 0.000 claims description 5
- 210000000274 microglia Anatomy 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 230000003959 neuroinflammation Effects 0.000 claims description 5
- 230000003955 neuronal function Effects 0.000 claims description 5
- 230000003961 neuronal insult Effects 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000002207 retinal effect Effects 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 230000001720 vestibular Effects 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 206010011878 Deafness Diseases 0.000 claims description 3
- 206010011903 Deafness traumatic Diseases 0.000 claims description 3
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims description 3
- 206010033109 Ototoxicity Diseases 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 210000003027 ear inner Anatomy 0.000 claims description 3
- 230000010370 hearing loss Effects 0.000 claims description 3
- 231100000888 hearing loss Toxicity 0.000 claims description 3
- 208000016354 hearing loss disease Diseases 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 3
- 231100000262 ototoxicity Toxicity 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 230000009692 acute damage Effects 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 2
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 claims 4
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 58
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 abstract description 23
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- 239000000203 mixture Substances 0.000 description 113
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 97
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 88
- 238000004128 high performance liquid chromatography Methods 0.000 description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 238000002360 preparation method Methods 0.000 description 44
- 235000019439 ethyl acetate Nutrition 0.000 description 43
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 42
- 230000014759 maintenance of location Effects 0.000 description 41
- 239000000243 solution Substances 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 229910001868 water Inorganic materials 0.000 description 39
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 38
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- 238000009472 formulation Methods 0.000 description 35
- 238000010898 silica gel chromatography Methods 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- 239000012044 organic layer Substances 0.000 description 33
- 108010041596 mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 31
- 239000000651 prodrug Substances 0.000 description 31
- 229940002612 prodrug Drugs 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 25
- 0 [1*]CC1=C(C[2*]C[14*])C=C2C(=N1)N([5*])c([4*])c2([13*])[Y]([3*])[Y][Y] Chemical compound [1*]CC1=C(C[2*]C[14*])C=C2C(=N1)N([5*])c([4*])c2([13*])[Y]([3*])[Y][Y] 0.000 description 25
- 229940079593 drug Drugs 0.000 description 25
- CGKLYWOFLUIKCX-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-b]pyrazin-2-one Chemical compound C1=CN=C2NC(=O)NC2=N1 CGKLYWOFLUIKCX-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 229910000029 sodium carbonate Inorganic materials 0.000 description 19
- RULQUTYJXDLRFL-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC(OC)=C1OC RULQUTYJXDLRFL-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- HXITXNWTGFUOAU-UHFFFAOYSA-N dihydroxy-phenylborane Natural products OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- LAQJGAKLLZAETL-UHFFFAOYSA-N 2h-pyrazin-3-one Chemical compound O=C1CN=CC=N1 LAQJGAKLLZAETL-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000013268 sustained release Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- RAOZYYPRJSSMQE-UHFFFAOYSA-N 5-(3,4,5-trimethoxyphenyl)-1-(2-trimethylsilylethoxymethyl)-3h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3CC(=O)N(COCC[Si](C)(C)C)C3=NC=2)=C1 RAOZYYPRJSSMQE-UHFFFAOYSA-N 0.000 description 7
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- SKIWCHGADZGKSB-UHFFFAOYSA-N 5-bromo-3-(1h-indol-5-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(Br)C=C2C(C=2C=C3C=CNC3=CC=2)=C1 SKIWCHGADZGKSB-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000013265 extended release Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000000105 evaporative light scattering detection Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical group OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 5
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- MUMJRQNVMWXASS-UHFFFAOYSA-N 3,3,5-tribromo-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-2-one Chemical compound BrC1=CN=C2N(COCC[Si](C)(C)C)C(=O)C(Br)(Br)C2=C1 MUMJRQNVMWXASS-UHFFFAOYSA-N 0.000 description 4
- DTLBKXRFWUERQN-UHFFFAOYSA-N 3,5-dibromopyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Br DTLBKXRFWUERQN-UHFFFAOYSA-N 0.000 description 4
- YWLUQJOZTNNPPH-UHFFFAOYSA-N 3-(1-methylindol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5C=CN(C)C5=CC=4)C(=O)NC3=NC=2)=C1 YWLUQJOZTNNPPH-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- CPRJNAUANBWOEN-UHFFFAOYSA-N 5-bromo-1-(2-trimethylsilylethoxymethyl)-3h-pyrrolo[2,3-b]pyridin-2-one Chemical compound BrC1=CN=C2N(COCC[Si](C)(C)C)C(=O)CC2=C1 CPRJNAUANBWOEN-UHFFFAOYSA-N 0.000 description 4
- SQZXFMCDIDWEGL-UHFFFAOYSA-N 5-bromo-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C2NC=CC2=CC(N2C(=O)NC3=NC=C(N=C32)Br)=C1 SQZXFMCDIDWEGL-UHFFFAOYSA-N 0.000 description 4
- RNPRNNYUHMYADJ-UHFFFAOYSA-N 5-bromo-3-iodo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(Br)C=C2C(I)=C1 RNPRNNYUHMYADJ-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229960004979 fampridine Drugs 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- QPYOLSJFOCIOHK-UHFFFAOYSA-N tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 QPYOLSJFOCIOHK-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- FVEOJPCOQYXPSY-UHFFFAOYSA-N 1-[4-[3-(1h-indol-5-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]phenyl]-n,n-dimethylmethanamine Chemical compound C1=CC(CN(C)C)=CC=C1C1=CN=C(NC=C2C=3C=C4C=CNC4=CC=3)C2=C1 FVEOJPCOQYXPSY-UHFFFAOYSA-N 0.000 description 3
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 3
- ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 description 3
- VHADYSUJZAPXOW-UHFFFAOYSA-N 1h-indol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2NC=CC2=C1 VHADYSUJZAPXOW-UHFFFAOYSA-N 0.000 description 3
- XPNPPOQHYUISHS-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-(1h-indol-5-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC=C2C=3C=C4C=CNC4=CC=3)C2=N1 XPNPPOQHYUISHS-UHFFFAOYSA-N 0.000 description 3
- MLPIPCKQZXPCSX-UHFFFAOYSA-N 2-[4-[3-(1h-indol-5-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-2-methoxyphenoxy]-n,n-dimethylethanamine Chemical compound C1=C(OCCN(C)C)C(OC)=CC(C=2C=C3C(C=4C=C5C=CNC5=CC=4)=CNC3=NC=2)=C1 MLPIPCKQZXPCSX-UHFFFAOYSA-N 0.000 description 3
- KVZBCDAJVSPXSP-UHFFFAOYSA-N 2-bromo-7-(1h-indol-5-yl)-5-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyrazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(Br)N=C2C(C=2C=C3C=CNC3=CC=2)=C1 KVZBCDAJVSPXSP-UHFFFAOYSA-N 0.000 description 3
- QONWBLJGJMTBKI-UHFFFAOYSA-N 2-bromo-7-iodo-5-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyrazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(Br)N=C2C(I)=C1 QONWBLJGJMTBKI-UHFFFAOYSA-N 0.000 description 3
- OFDLUROFHFYRIA-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)imidazo[4,5-b]pyrazine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C=NC3=NC=2)=C1 OFDLUROFHFYRIA-UHFFFAOYSA-N 0.000 description 3
- OYJKFLWAPGZMKO-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-pyridin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2N(C=3C=C4C=CNC4=CC=3)C(=O)NC2=NC=C1C1=CC=NC=C1 OYJKFLWAPGZMKO-UHFFFAOYSA-N 0.000 description 3
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 3
- VQIIIUZXKBIBAJ-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazine-2-thione Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(CC4CC4)C(=S)NC3=NC=2)=C1 VQIIIUZXKBIBAJ-UHFFFAOYSA-N 0.000 description 3
- ANQUZKPKKVNPTD-UHFFFAOYSA-N 4-[3-(1h-indol-5-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-5-yl]benzaldehyde Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(C=3C=CC(C=O)=CC=3)C=C2C(C=2C=C3C=CNC3=CC=2)=C1 ANQUZKPKKVNPTD-UHFFFAOYSA-N 0.000 description 3
- RRUKYRBIYOLONU-UHFFFAOYSA-N 4-[5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CNC3=NC=2)C=C1 RRUKYRBIYOLONU-UHFFFAOYSA-N 0.000 description 3
- VUISIWLXFTZVKU-UHFFFAOYSA-N 4-[[2-oxo-5-(3,4,5-trimethoxyphenyl)-1,3-dihydropyrrolo[2,3-b]pyridin-3-yl]methyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(CC=4C=CC(=CC=4)C(N)=O)C(=O)NC3=NC=2)=C1 VUISIWLXFTZVKU-UHFFFAOYSA-N 0.000 description 3
- RPXBKGNKBJMYOG-UHFFFAOYSA-N 5-(3,4,5-trimethoxyphenyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3CC(=O)NC3=NC=2)=C1 RPXBKGNKBJMYOG-UHFFFAOYSA-N 0.000 description 3
- QGRWEFHVAHCGQH-UHFFFAOYSA-N 5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C=CNC3=NC=2)=C1 QGRWEFHVAHCGQH-UHFFFAOYSA-N 0.000 description 3
- GQPZZEHVDIALIE-UHFFFAOYSA-N 5-(3,5-dimethylphenyl)-3-(1-methylindol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC1=CC(C)=CC(C=2N=C3N(C=4C=C5C=CN(C)C5=CC=4)C(=O)NC3=NC=2)=C1 GQPZZEHVDIALIE-UHFFFAOYSA-N 0.000 description 3
- VNTBQJJEQLEAJY-UHFFFAOYSA-N 5-[3-(1h-indol-5-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-n-(2-pyrrolidin-1-ylethyl)pyridin-2-amine Chemical compound C=1C=C(C=2C=C3C(C=4C=C5C=CNC5=CC=4)=CNC3=NC=2)C=NC=1NCCN1CCCC1 VNTBQJJEQLEAJY-UHFFFAOYSA-N 0.000 description 3
- QITXIHCDCBZEMF-UHFFFAOYSA-N 5-bromo-3-(1-methylindol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C1=CC=C2N(C)C=CC2=C1 QITXIHCDCBZEMF-UHFFFAOYSA-N 0.000 description 3
- SEJWVDCVNSZQJS-UHFFFAOYSA-N 5-bromo-3-n-(1h-indol-5-yl)pyrazine-2,3-diamine Chemical compound NC1=NC=C(Br)N=C1NC1=CC=C(NC=C2)C2=C1 SEJWVDCVNSZQJS-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 229910020008 S(O) Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- BJLLVMRHGCCXOV-UHFFFAOYSA-N n-[5-bromo-3-(2-trimethylsilylethynyl)pyrazin-2-yl]acetamide Chemical compound CC(=O)NC1=NC=C(Br)N=C1C#C[Si](C)(C)C BJLLVMRHGCCXOV-UHFFFAOYSA-N 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- TXWQPIPDZDRBOV-UHFFFAOYSA-N tert-butyl 4-[3-[3-(4-carbamoylphenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC=CC(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CNC3=NC=2)=C1 TXWQPIPDZDRBOV-UHFFFAOYSA-N 0.000 description 3
- SRQMKJGIFHMHKI-UHFFFAOYSA-N tert-butyl 4-[4-[3-(4-carbamoylphenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC=C(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CNC3=NC=2)C=C1 SRQMKJGIFHMHKI-UHFFFAOYSA-N 0.000 description 3
- 125000004149 thio group Chemical group *S* 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FQWUBDDFDBNOPL-CAOOACKPSA-N (3e)-3-(pyridin-4-ylmethylidene)-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=C\C=4C=CN=CC=4)/C(=O)NC3=NC=2)=C1 FQWUBDDFDBNOPL-CAOOACKPSA-N 0.000 description 2
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 2
- IYZNLFXYLPTBST-UHFFFAOYSA-N 1-(1h-indol-5-yl)-6-(3,4,5-trimethoxyphenyl)-3h-imidazo[4,5-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 IYZNLFXYLPTBST-UHFFFAOYSA-N 0.000 description 2
- QYOUKJJGIFHFJD-UHFFFAOYSA-N 1-[2-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethyl]piperazine Chemical compound COC1=CC(B2OC(C)(C)C(C)(C)O2)=CC=C1OCCN1CCNCC1 QYOUKJJGIFHFJD-UHFFFAOYSA-N 0.000 description 2
- ZUWGSRAZBKRISU-UHFFFAOYSA-N 1-[4-[4-[3-(1h-indol-5-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]benzoyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C3C(C=4C=C5C=CNC5=CC=4)=CNC3=NC=2)C=C1 ZUWGSRAZBKRISU-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- CYEYLYGHCOHIDC-UHFFFAOYSA-N 1-methyl-4-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]piperazine Chemical compound C1CN(C)CCN1CC1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 CYEYLYGHCOHIDC-UHFFFAOYSA-N 0.000 description 2
- PGTSGPCXPIFQEL-UHFFFAOYSA-N 1-methylindol-5-amine Chemical group NC1=CC=C2N(C)C=CC2=C1 PGTSGPCXPIFQEL-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- ABLIMXXAJWRGPB-UHFFFAOYSA-N 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1h-imidazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C=2NC=CN=2)C=C1 ABLIMXXAJWRGPB-UHFFFAOYSA-N 0.000 description 2
- KTKMLXBEBKGQGL-UHFFFAOYSA-N 2-bromo-5h-pyrrolo[2,3-b]pyrazine Chemical compound BrC1=CN=C2NC=CC2=N1 KTKMLXBEBKGQGL-UHFFFAOYSA-N 0.000 description 2
- ULGMTONBTOMHOK-UHFFFAOYSA-N 2-bromo-7-iodo-5h-pyrrolo[2,3-b]pyrazine Chemical compound BrC1=CN=C2NC=C(I)C2=N1 ULGMTONBTOMHOK-UHFFFAOYSA-N 0.000 description 2
- JIZQQDVOJUWOEI-UHFFFAOYSA-N 3,3-dimethyl-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(C)(C)C(=O)NC3=NC=2)=C1 JIZQQDVOJUWOEI-UHFFFAOYSA-N 0.000 description 2
- MDSLQWWZRJAELV-UHFFFAOYSA-N 3-(1,3-benzothiazol-5-yl)-5-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2N(C=3C=C4N=CSC4=CC=3)C(=O)NC2=NC=C1C(C=C1)=CC=C1N1CCOCC1 MDSLQWWZRJAELV-UHFFFAOYSA-N 0.000 description 2
- NMMATNQHSAAIGY-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 NMMATNQHSAAIGY-UHFFFAOYSA-N 0.000 description 2
- UQHKXSZPEUNUDH-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(C=4C=C5C=CNC5=CC=4)=CNC3=NC=2)=C1 UQHKXSZPEUNUDH-UHFFFAOYSA-N 0.000 description 2
- BDKQHXVYBFXYNY-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-[3-methoxy-4-(2-piperazin-1-ylethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC(C=2C=C3C(C=4C=C5C=CNC5=CC=4)=CNC3=NC=2)=CC=C1OCCN1CCNCC1 BDKQHXVYBFXYNY-UHFFFAOYSA-N 0.000 description 2
- QKKIWEILHCXECO-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CN(C)CCN1CC1=CC=C(C=2C=C3C(C=4C=C5C=CNC5=CC=4)=CNC3=NC=2)C=C1 QKKIWEILHCXECO-UHFFFAOYSA-N 0.000 description 2
- PRVHCAKGSNTBLW-UHFFFAOYSA-N 3-(2,3-dihydro-1h-inden-2-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C4CC5=CC=CC=C5C4)C(=O)NC3=NC=2)=C1 PRVHCAKGSNTBLW-UHFFFAOYSA-N 0.000 description 2
- BBUAHHOMTDMBPX-UHFFFAOYSA-N 3-benzylidene-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=CC=4C=CC=CC=4)C(=O)NC3=NC=2)=C1 BBUAHHOMTDMBPX-UHFFFAOYSA-N 0.000 description 2
- JYRONAVVWQIHMW-UHFFFAOYSA-N 3-cyclopentyl-5-(3,4-dimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C3CCCC3)C2=N1 JYRONAVVWQIHMW-UHFFFAOYSA-N 0.000 description 2
- LEYAMEZHQDXXQV-UHFFFAOYSA-N 4-[3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C=2C3=CC(=CN=C3NC=2)C=2C=CC(=CC=2)C(N)=O)C=C1 LEYAMEZHQDXXQV-UHFFFAOYSA-N 0.000 description 2
- AJUHCVAZMDGWQB-UHFFFAOYSA-N 4-[5-[3-(4-acetylpiperazine-1-carbonyl)phenyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=CC(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CNC3=NC=2)=C1 AJUHCVAZMDGWQB-UHFFFAOYSA-N 0.000 description 2
- PRGMHVZMKYMIJG-UHFFFAOYSA-N 4-[5-[3-(piperazine-1-carbonyl)phenyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CNC2=NC=C(C=3C=C(C=CC=3)C(=O)N3CCNCC3)C=C12 PRGMHVZMKYMIJG-UHFFFAOYSA-N 0.000 description 2
- NDQATEXYJSNSRD-UHFFFAOYSA-N 4-[5-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1CN(C)CCN1CC1=CC=CC(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CNC3=NC=2)=C1 NDQATEXYJSNSRD-UHFFFAOYSA-N 0.000 description 2
- YAEZGCXSMFMCKO-UHFFFAOYSA-N 4-[5-[4-[(4-acetylpiperazin-1-yl)methyl]phenyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1CN(C(=O)C)CCN1CC1=CC=C(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CNC3=NC=2)C=C1 YAEZGCXSMFMCKO-UHFFFAOYSA-N 0.000 description 2
- CGBCMHRCPRQCCE-UHFFFAOYSA-N 4-[5-bromo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-3-yl]-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=CN(S(=O)(=O)C=2C=CC(C)=CC=2)C2=NC=C(Br)C=C12 CGBCMHRCPRQCCE-UHFFFAOYSA-N 0.000 description 2
- KFTJBEFBDJHDKY-UHFFFAOYSA-N 4-[5-bromo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(Br)C=C2C(C=2C=CC(=CC=2)C(N)=O)=C1 KFTJBEFBDJHDKY-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- NQUBJOHNOXIWBP-UHFFFAOYSA-N 4-[[4-[3-(1h-indol-5-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]phenyl]methyl]-1-methylpiperazin-2-one Chemical compound C1C(=O)N(C)CCN1CC1=CC=C(C=2C=C3C(C=4C=C5C=CNC5=CC=4)=CNC3=NC=2)C=C1 NQUBJOHNOXIWBP-UHFFFAOYSA-N 0.000 description 2
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 2
- NAVNICSNKNRXON-UHFFFAOYSA-N 5-(3,4,5-trimethoxyphenyl)spiro[1h-pyrrolo[2,3-b]pyridine-3,1'-cyclopentane]-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C4(CCCC4)C(=O)NC3=NC=2)=C1 NAVNICSNKNRXON-UHFFFAOYSA-N 0.000 description 2
- ZUMBBARLJHSZAM-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-(1-methylindol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1C=C2N(C)C=CC2=CC=1N(C(NC1=NC=2)=O)C1=NC=2C1=CC=C(O)C=C1 ZUMBBARLJHSZAM-UHFFFAOYSA-N 0.000 description 2
- VUBQVBUEXKMCQU-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-(1H-indazol-6-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4NN=CC4=CC=3)C2=N1 VUBQVBUEXKMCQU-UHFFFAOYSA-N 0.000 description 2
- OJHBNLICKNDDHL-UHFFFAOYSA-N 5-bromo-1-(4-methylphenyl)sulfonyl-3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-b]pyridine Chemical compound C1CN(C)CCN1CC1=CC=C(C=2C3=CC(Br)=CN=C3N(C=2)S(=O)(=O)C=2C=CC(C)=CC=2)C=C1 OJHBNLICKNDDHL-UHFFFAOYSA-N 0.000 description 2
- LQJGZEFWBXJKJI-UHFFFAOYSA-N 5-bromo-3-(2-trimethylsilylethynyl)pyrazin-2-amine Chemical compound C[Si](C)(C)C#CC1=NC(Br)=CN=C1N LQJGZEFWBXJKJI-UHFFFAOYSA-N 0.000 description 2
- RAAKRWOQXGMFBM-UHFFFAOYSA-N 5-bromo-3-(4-fluorophenyl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(Br)C=C2C(C=2C=CC(F)=CC=2)=C1 RAAKRWOQXGMFBM-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical group CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000006003 dichloroethyl group Chemical group 0.000 description 2
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- 125000006001 difluoroethyl group Chemical group 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical class [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- KUCQMLFHLSDMKS-UHFFFAOYSA-N n-methyl-4-[5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=CNC2=NC=C(C=3C=CC(CN4CCN(C)CC4)=CC=3)C=C12 KUCQMLFHLSDMKS-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N p-hydroxyphenylamine Natural products NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 102000030769 platelet activating factor receptor Human genes 0.000 description 2
- 125000006684 polyhaloalkyl group Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- JYIGYTWAYATZEO-UHFFFAOYSA-N trimethyl-[2-(pyrrolo[2,3-b]pyridin-1-ylmethoxy)ethyl]silane Chemical compound C1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1 JYIGYTWAYATZEO-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical group COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- DJGHSJBYKIQHIK-UHFFFAOYSA-N (3,5-dimethylphenyl)boronic acid Chemical group CC1=CC(C)=CC(B(O)O)=C1 DJGHSJBYKIQHIK-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- FQWUBDDFDBNOPL-IUXPMGMMSA-N (3z)-3-(pyridin-4-ylmethylidene)-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=C/C=4C=CN=CC=4)/C(=O)NC3=NC=2)=C1 FQWUBDDFDBNOPL-IUXPMGMMSA-N 0.000 description 1
- BBUAHHOMTDMBPX-NVMNQCDNSA-N (3z)-3-benzylidene-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=C/C=4C=CC=CC=4)/C(=O)NC3=NC=2)=C1 BBUAHHOMTDMBPX-NVMNQCDNSA-N 0.000 description 1
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- POPHMOPNVVKGRW-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydronaphthalene Chemical compound C1CCC2CCCCC2=C1 POPHMOPNVVKGRW-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ROUYUBHVBIKMQO-UHFFFAOYSA-N 1,4-diiodobutane Chemical compound ICCCCI ROUYUBHVBIKMQO-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- XRYFFCUHEFROCI-UHFFFAOYSA-N 1-(cyclopropylmethyl)-6-(3,4,5-trimethoxyphenyl)-3h-imidazo[4,5-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3N(CC4CC4)C(=O)NC3=NC=2)=C1 XRYFFCUHEFROCI-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- DSWNHJFNMZVIRL-UHFFFAOYSA-N 1-[4-[[3-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]methyl]piperazin-1-yl]ethanone Chemical compound CC(=O)N1CCN(Cc2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1 DSWNHJFNMZVIRL-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- PESZAXRJFGLGTR-UHFFFAOYSA-N 1-methyl-4-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]piperazine Chemical compound C1CN(C)CCN1CC1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 PESZAXRJFGLGTR-UHFFFAOYSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- KJCIMSSFGUGTGA-UHFFFAOYSA-N 1-methylpiperazin-2-one Chemical compound CN1CCNCC1=O KJCIMSSFGUGTGA-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- ZVMHOIWRCCZGPZ-UHFFFAOYSA-N 1h-indol-6-ylboronic acid Chemical compound OB(O)C1=CC=C2C=CNC2=C1 ZVMHOIWRCCZGPZ-UHFFFAOYSA-N 0.000 description 1
- KCHKRCSVKZQYCA-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-5-ylboronic acid Chemical compound OB(O)C1=CN=C2NC=CC2=C1 KCHKRCSVKZQYCA-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- CBUOGMOTDGNEAW-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CBr)C=C1 CBUOGMOTDGNEAW-UHFFFAOYSA-N 0.000 description 1
- PELIJVQFPYPWOG-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid;magnesium Chemical compound [Mg].OOC(=O)C1=CC=CC=C1C(O)=O PELIJVQFPYPWOG-UHFFFAOYSA-N 0.000 description 1
- WFSJROCEOJANPD-UHFFFAOYSA-N 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound C1=C(O)C(OC)=CC(B2OC(C)(C)C(C)(C)O2)=C1 WFSJROCEOJANPD-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical group NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- PXEBCKJMBGGJJQ-UHFFFAOYSA-N 3,3-bis(cyclopropylmethyl)-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(CC4CC4)(CC4CC4)C(=O)NC3=NC=2)=C1 PXEBCKJMBGGJJQ-UHFFFAOYSA-N 0.000 description 1
- BEXIBVAXBFVLJP-UHFFFAOYSA-N 3,3-dibenzyl-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(CC=4C=CC=CC=4)(CC=4C=CC=CC=4)C(=O)NC3=NC=2)=C1 BEXIBVAXBFVLJP-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- KMOICDJWYSOXRT-UHFFFAOYSA-N 3,5-dibromo-6-chloropyrazin-2-amine Chemical compound NC1=NC(Cl)=C(Br)N=C1Br KMOICDJWYSOXRT-UHFFFAOYSA-N 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- USCMOXDGABWNQM-UHFFFAOYSA-N 3-(1,3-benzothiazol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5N=CSC5=CC=4)C(=O)NC3=NC=2)=C1 USCMOXDGABWNQM-UHFFFAOYSA-N 0.000 description 1
- RWJBLAAOZHZBOY-UHFFFAOYSA-N 3-(1,3-benzothiazol-5-yl)-5-(3,5-dimethylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC1=CC(C)=CC(C=2N=C3N(C=4C=C5N=CSC5=CC=4)C(=O)NC3=NC=2)=C1 RWJBLAAOZHZBOY-UHFFFAOYSA-N 0.000 description 1
- ZKLJEIQXSVXKEU-UHFFFAOYSA-N 3-(1,3-benzothiazol-5-yl)-5-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4N=CSC4=CC=3)C2=N1 ZKLJEIQXSVXKEU-UHFFFAOYSA-N 0.000 description 1
- KYGJJWVMSCHXRX-UHFFFAOYSA-N 3-(1,3-benzothiazol-5-yl)-5-pyridin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2N(C=3C=C4N=CSC4=CC=3)C(=O)NC2=NC=C1C1=CC=NC=C1 KYGJJWVMSCHXRX-UHFFFAOYSA-N 0.000 description 1
- KTHTTXMEVKWOID-UHFFFAOYSA-N 3-(1h-indazol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5C=NNC5=CC=4)C(=O)NC3=NC=2)=C1 KTHTTXMEVKWOID-UHFFFAOYSA-N 0.000 description 1
- JNPHUKPIKKTLLN-UHFFFAOYSA-N 3-(1h-indazol-5-yl)-5-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2N(C=3C=C4C=NNC4=CC=3)C(=O)NC2=NC=C1C(C=C1)=CC=C1N1CCOCC1 JNPHUKPIKKTLLN-UHFFFAOYSA-N 0.000 description 1
- IAIVCTUREHZOKA-UHFFFAOYSA-N 3-(1h-indazol-5-yl)-5-pyridin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2N(C=3C=C4C=NNC4=CC=3)C(=O)NC2=NC=C1C1=CC=NC=C1 IAIVCTUREHZOKA-UHFFFAOYSA-N 0.000 description 1
- BNETYKOYOKDQQO-UHFFFAOYSA-N 3-(1h-indazol-6-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5NN=CC5=CC=4)C(=O)NC3=NC=2)=C1 BNETYKOYOKDQQO-UHFFFAOYSA-N 0.000 description 1
- RQKAHLCVSUGEJV-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-(1h-indol-6-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C2C=CNC2=CC(C2=CN=C3NC(N(C3=N2)C=2C=C3C=CNC3=CC=2)=O)=C1 RQKAHLCVSUGEJV-UHFFFAOYSA-N 0.000 description 1
- YCABYMCMFCOHHV-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-(4-methoxy-3,5-dimethylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(C)C(OC)=C(C)C=C1C1=CN=C(NC(=O)N2C=3C=C4C=CNC4=CC=3)C2=N1 YCABYMCMFCOHHV-UHFFFAOYSA-N 0.000 description 1
- ZQTJWMUYDNXFHK-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2N(C=3C=C4C=CNC4=CC=3)C(=O)NC2=NC=C1C(C=C1)=CC=C1N1CCOCC1 ZQTJWMUYDNXFHK-UHFFFAOYSA-N 0.000 description 1
- YIUDJPYFKOHYHD-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1CN(C)CCN1C1=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=CC=N1 YIUDJPYFKOHYHD-UHFFFAOYSA-N 0.000 description 1
- OEPUFOSHPKWEQH-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=CC=C1OCCN1CCOCC1 OEPUFOSHPKWEQH-UHFFFAOYSA-N 0.000 description 1
- PJUPILHXIIQHAO-UHFFFAOYSA-N 3-(1h-indol-5-yl)-5-[3-methoxy-4-(2-piperazin-1-ylethoxy)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=CC=C1OCCN1CCNCC1 PJUPILHXIIQHAO-UHFFFAOYSA-N 0.000 description 1
- KLVOADXGXPXFNG-UHFFFAOYSA-N 3-(1h-indol-6-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5NC=CC5=CC=4)C(=O)NC3=NC=2)=C1 KLVOADXGXPXFNG-UHFFFAOYSA-N 0.000 description 1
- RFDMUMKIWCFUBN-UHFFFAOYSA-N 3-(1h-pyrrolo[2,3-b]pyridin-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5C=CNC5=NC=4)C(=O)NC3=NC=2)=C1 RFDMUMKIWCFUBN-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- XVUHGDPGFVEOSM-UHFFFAOYSA-N 3-(2-methyl-1h-indol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5C=C(C)NC5=CC=4)C(=O)NC3=NC=2)=C1 XVUHGDPGFVEOSM-UHFFFAOYSA-N 0.000 description 1
- WNUHBYJRRWMHCA-UHFFFAOYSA-N 3-(3h-benzimidazol-5-yl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=C5N=CNC5=CC=4)C(=O)NC3=NC=2)=C1 WNUHBYJRRWMHCA-UHFFFAOYSA-N 0.000 description 1
- BYMJNYSJVSZIPF-UHFFFAOYSA-N 3-(3h-benzimidazol-5-yl)-5-(3,4-dimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4N=CNC4=CC=3)C2=N1 BYMJNYSJVSZIPF-UHFFFAOYSA-N 0.000 description 1
- DPSOLRXJTWBTBL-UHFFFAOYSA-N 3-(3h-benzimidazol-5-yl)-5-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2N(C=3C=C4N=CNC4=CC=3)C(=O)NC2=NC=C1C(C=C1)=CC=C1N1CCOCC1 DPSOLRXJTWBTBL-UHFFFAOYSA-N 0.000 description 1
- GBGHIXSGNRBTGM-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C=4C=CC(O)=CC=4)C(=O)NC3=NC=2)=C1 GBGHIXSGNRBTGM-UHFFFAOYSA-N 0.000 description 1
- HLJRUTAPZCPDBA-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-5-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(O)=CC=C1N1C(=O)NC2=NC=C(C=3C=CC(=CC=3)N3CCOCC3)N=C21 HLJRUTAPZCPDBA-UHFFFAOYSA-N 0.000 description 1
- IXOSDXVNAIFVQU-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)NC2=NC=C(C=3C=C(OC)C(OC)=C(OC)C=3)N=C21 IXOSDXVNAIFVQU-UHFFFAOYSA-N 0.000 description 1
- VCYMMUBTGFAREH-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-pyridin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)NC2=NC=C(C=3C=CN=CC=3)N=C21 VCYMMUBTGFAREH-UHFFFAOYSA-N 0.000 description 1
- KDUPSKIOLZENPU-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(3,4,5-trimethoxyphenyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(CC4CC4)C(=O)NC3=NC=2)=C1 KDUPSKIOLZENPU-UHFFFAOYSA-N 0.000 description 1
- PYIRTMIDJWSUCG-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(CC4CC4)C(=O)NC3=NC=2)=C1 PYIRTMIDJWSUCG-UHFFFAOYSA-N 0.000 description 1
- WIZPOOKPFGKRAN-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(3,4-dimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2CC3CC3)C2=N1 WIZPOOKPFGKRAN-UHFFFAOYSA-N 0.000 description 1
- AFVQPMFFJNEQOI-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(3,5-dichlorophenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound ClC1=CC(Cl)=CC(C=2N=C3N(CC4CC4)C(=O)NC3=NC=2)=C1 AFVQPMFFJNEQOI-UHFFFAOYSA-N 0.000 description 1
- MXFTYWSDJVSPSC-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2CC3CC3)C2=N1 MXFTYWSDJVSPSC-UHFFFAOYSA-N 0.000 description 1
- WFDZNULNKMHQMR-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CC(=CC=3)N3CCOCC3)N=C2N1CC1CC1 WFDZNULNKMHQMR-UHFFFAOYSA-N 0.000 description 1
- HSGLINFFVMZJMY-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC(C=2N=C3N(CC4CC4)C(=O)NC3=NC=2)=CC=C1OCCN1CCOCC1 HSGLINFFVMZJMY-UHFFFAOYSA-N 0.000 description 1
- ZSXTYGXIGWXIBC-UHFFFAOYSA-N 3-(cyclopropylmethyl)-5-pyridin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=C(C=3C=CN=CC=3)N=C2N1CC1CC1 ZSXTYGXIGWXIBC-UHFFFAOYSA-N 0.000 description 1
- FKXOORRMAHPCMI-UHFFFAOYSA-N 3-(pyridin-3-ylmethyl)-5-(3,4,5-trimethoxyphenyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(CC=4C=NC=CC=4)C(=O)NC3=NC=2)=C1 FKXOORRMAHPCMI-UHFFFAOYSA-N 0.000 description 1
- SJQKLWBZTHZVPG-UHFFFAOYSA-N 3-(pyridin-3-ylmethylidene)-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=CC=4C=NC=CC=4)C(=O)NC3=NC=2)=C1 SJQKLWBZTHZVPG-UHFFFAOYSA-N 0.000 description 1
- LDTTYRLLPSXUQB-UHFFFAOYSA-N 3-(pyridin-4-ylmethyl)-5-(3,4,5-trimethoxyphenyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(CC=4C=CN=CC=4)C(=O)NC3=NC=2)=C1 LDTTYRLLPSXUQB-UHFFFAOYSA-N 0.000 description 1
- FQWUBDDFDBNOPL-UHFFFAOYSA-N 3-(pyridin-4-ylmethylidene)-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=CC=4C=CN=CC=4)C(=O)NC3=NC=2)=C1 FQWUBDDFDBNOPL-UHFFFAOYSA-N 0.000 description 1
- CSDCPKXPWNJTLY-UFWORHAWSA-N 3-[(E)-[2-oxo-5-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]benzonitrile Chemical compound C1=C(C=C(C=C1)/C=C/1\C2=CC(=CN=C2NC\1=O)C1=CC(=C(C(=C1)OC)OC)OC)C#N CSDCPKXPWNJTLY-UFWORHAWSA-N 0.000 description 1
- BODYCSYFOVDCON-LSCVHKIXSA-N 3-[(z)-[2-oxo-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=C/C=4C=C(C=CC=4)C(N)=O)/C(=O)NC3=NC=2)=C1 BODYCSYFOVDCON-LSCVHKIXSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- FQKKTEOYMUTPDC-UHFFFAOYSA-N 3-[4-(1h-imidazol-2-yl)phenyl]-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(C=4C=CC(=CC=4)C=4NC=CN=4)=CNC3=NC=2)=C1 FQKKTEOYMUTPDC-UHFFFAOYSA-N 0.000 description 1
- CSDCPKXPWNJTLY-UHFFFAOYSA-N 3-[[2-oxo-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]benzonitrile Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=CC=4C=C(C=CC=4)C#N)C(=O)NC3=NC=2)=C1 CSDCPKXPWNJTLY-UHFFFAOYSA-N 0.000 description 1
- WVNHJGNBMUWNDT-UHFFFAOYSA-N 3-benzyl-5-(3,4,5-trimethoxyphenyl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(CC=4C=CC=CC=4)C(=O)NC3=NC=2)=C1 WVNHJGNBMUWNDT-UHFFFAOYSA-N 0.000 description 1
- XUSYHDVYYMXQGN-UHFFFAOYSA-N 3-cyclopentyl-5-(2,4,6-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC(OC)=CC(OC)=C1C1=CN=C(NC(=O)N2C3CCCC3)C2=N1 XUSYHDVYYMXQGN-UHFFFAOYSA-N 0.000 description 1
- KNRLKUIJPKWHSL-UHFFFAOYSA-N 3-cyclopentyl-5-(3,4,5-trimethoxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C3N(C4CCCC4)C(=O)NC3=NC=2)=C1 KNRLKUIJPKWHSL-UHFFFAOYSA-N 0.000 description 1
- ICFDZIRYJSCARC-UHFFFAOYSA-N 3-cyclopentyl-5-(4-hydroxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(O)=CC=C1C1=CN=C(NC(=O)N2C3CCCC3)C2=N1 ICFDZIRYJSCARC-UHFFFAOYSA-N 0.000 description 1
- WGKQLBNOEWDFME-UHFFFAOYSA-N 3-cyclopentyl-5-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC(C=2N=C3N(C4CCCC4)C(=O)NC3=NC=2)=CC=C1OCCN1CCOCC1 WGKQLBNOEWDFME-UHFFFAOYSA-N 0.000 description 1
- AYYCJLDODRZCOB-UHFFFAOYSA-N 3-formylbenzamide Chemical compound NC(=O)C1=CC=CC(C=O)=C1 AYYCJLDODRZCOB-UHFFFAOYSA-N 0.000 description 1
- HGZJJKZPPMFIBU-UHFFFAOYSA-N 3-formylbenzonitrile Chemical compound O=CC1=CC=CC(C#N)=C1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- SJYRAFSTKJKANU-UHFFFAOYSA-N 3-iodo-1-(4-methylphenyl)sulfonyl-5-(3,4,5-trimethoxyphenyl)pyrrolo[2,3-b]pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(I)=CN(C3=NC=2)S(=O)(=O)C=2C=CC(C)=CC=2)=C1 SJYRAFSTKJKANU-UHFFFAOYSA-N 0.000 description 1
- BNUYPQOBSWQDMG-UHFFFAOYSA-N 3-iodo-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(I)=CNC3=NC=2)=C1 BNUYPQOBSWQDMG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IPKZJXIJURRFII-LSCVHKIXSA-N 4-[(z)-[2-oxo-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=C/C=4C=CC(=CC=4)C(N)=O)/C(=O)NC3=NC=2)=C1 IPKZJXIJURRFII-LSCVHKIXSA-N 0.000 description 1
- KFPRSPRIHQMUJC-UHFFFAOYSA-N 4-[5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CNC3=NC=2)=C1 KFPRSPRIHQMUJC-UHFFFAOYSA-N 0.000 description 1
- PRGMHVZMKYMIJG-UHFFFAOYSA-O 4-[5-[3-(piperazin-4-ium-1-carbonyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound O=C(C1=CC=C(C=C1)C=1C2=CC(C3=CC=CC(C(=O)N4CC[NH2+]CC4)=C3)=CN=C2NC=1)N PRGMHVZMKYMIJG-UHFFFAOYSA-O 0.000 description 1
- KGRHWBRNFKQGRZ-UHFFFAOYSA-O 4-[5-[4-(piperazin-4-ium-1-carbonyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound O=C(C1=CC=C(C=2C3=CC(C4=CC=C(C(=O)N5CC[NH2+]CC5)C=C4)=CN=C3NC=2)C=C1)N KGRHWBRNFKQGRZ-UHFFFAOYSA-O 0.000 description 1
- LFINTRBQKKMTFW-UHFFFAOYSA-N 4-[5-[4-(piperazine-1-carbonyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]benzamide hydrochloride Chemical group Cl.NC(=O)c1ccc(cc1)-c1c[nH]c2ncc(cc12)-c1ccc(cc1)C(=O)N1CCNCC1 LFINTRBQKKMTFW-UHFFFAOYSA-N 0.000 description 1
- WCXQFXJVCJRVLE-UHFFFAOYSA-N 4-[[2-oxo-5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]benzonitrile Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(=CC=4C=CC(=CC=4)C#N)C(=O)NC3=NC=2)=C1 WCXQFXJVCJRVLE-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- QWDCXCRLPNMJIH-UHFFFAOYSA-N 4-formylbenzamide Chemical compound NC(=O)C1=CC=C(C=O)C=C1 QWDCXCRLPNMJIH-UHFFFAOYSA-N 0.000 description 1
- IRYXPYKCDKUXHO-UHFFFAOYSA-N 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O1CCOC2=CC(C3=CN=C4NC(N(C4=N3)C=3C=C4C=CNC4=CC=3)=O)=CC=C21 IRYXPYKCDKUXHO-UHFFFAOYSA-N 0.000 description 1
- FIKBCKXJPBKDAT-UHFFFAOYSA-N 5-(2,5-difluoro-4-hydroxyphenyl)-3-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(F)C(O)=CC(F)=C1C1=CN=C(NC(=O)N2C=3C=C4C=CNC4=CC=3)C2=N1 FIKBCKXJPBKDAT-UHFFFAOYSA-N 0.000 description 1
- RCBYBBXDHYEVQH-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-(1h-indazol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4C=NNC4=CC=3)C2=N1 RCBYBBXDHYEVQH-UHFFFAOYSA-N 0.000 description 1
- CTUYZCLRYRRZIZ-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-(1h-indazol-6-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4NN=CC4=CC=3)C2=N1 CTUYZCLRYRRZIZ-UHFFFAOYSA-N 0.000 description 1
- AZMSXFAWGPPNIE-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4C=CNC4=CC=3)C2=N1 AZMSXFAWGPPNIE-UHFFFAOYSA-N 0.000 description 1
- MNDWDBWIHDIYCI-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-(1h-indol-5-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC=C2C=3C=C4C=CNC4=CC=3)C2=C1 MNDWDBWIHDIYCI-UHFFFAOYSA-N 0.000 description 1
- RGOZMRBEVXKQOD-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-(1h-pyrrolo[2,3-b]pyridin-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4C=CNC4=NC=3)C2=N1 RGOZMRBEVXKQOD-UHFFFAOYSA-N 0.000 description 1
- IQTSDRLTGSAEHK-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-(4-hydroxyphenyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=CC(O)=CC=3)C2=N1 IQTSDRLTGSAEHK-UHFFFAOYSA-N 0.000 description 1
- GSNXUTWHLHKWSI-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-3-phenyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=CC=CC=3)C2=N1 GSNXUTWHLHKWSI-UHFFFAOYSA-N 0.000 description 1
- YIRDNPKYRANUCH-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound ClC1=CC(Cl)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 YIRDNPKYRANUCH-UHFFFAOYSA-N 0.000 description 1
- LYDQJFHXSJTXFI-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)-3-(2-methyl-1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1C=C2NC(C)=CC2=CC=1N(C(NC1=NC=2)=O)C1=NC=2C1=CC(Cl)=CC(Cl)=C1 LYDQJFHXSJTXFI-UHFFFAOYSA-N 0.000 description 1
- LULIHHPLZQJUBM-UHFFFAOYSA-N 5-(3,5-difluoro-4-hydroxyphenyl)-3-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(F)C(O)=C(F)C=C1C1=CN=C(NC(=O)N2C=3C=C4C=CNC4=CC=3)C2=N1 LULIHHPLZQJUBM-UHFFFAOYSA-N 0.000 description 1
- OUUGFNCJIIIHNG-UHFFFAOYSA-N 5-(3,5-dimethoxyphenyl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=CC(OC)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 OUUGFNCJIIIHNG-UHFFFAOYSA-N 0.000 description 1
- XBHKOWKHISOMIL-UHFFFAOYSA-N 5-(3,5-dimethylphenyl)-3-(1h-indazol-6-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC1=CC(C)=CC(C=2N=C3N(C=4C=C5NN=CC5=CC=4)C(=O)NC3=NC=2)=C1 XBHKOWKHISOMIL-UHFFFAOYSA-N 0.000 description 1
- VUFXQMOECSSWIT-UHFFFAOYSA-N 5-(3-amino-4-methoxyphenyl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(N)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4C=CNC4=CC=3)C2=N1 VUFXQMOECSSWIT-UHFFFAOYSA-N 0.000 description 1
- WPWYJWOYQYVGKN-UHFFFAOYSA-N 5-(3-fluoro-4-methoxyphenyl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(F)C(OC)=CC=C1C1=CN=C(NC(=O)N2C=3C=C4C=CNC4=CC=3)C2=N1 WPWYJWOYQYVGKN-UHFFFAOYSA-N 0.000 description 1
- KHPQEDSQFJNEMB-UHFFFAOYSA-N 5-(3-hydroxyphenyl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=CC=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 KHPQEDSQFJNEMB-UHFFFAOYSA-N 0.000 description 1
- IJMBLAWBIHCSHO-UHFFFAOYSA-N 5-(4-amino-3-methoxyphenyl)-3-(1h-indol-5-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(N)C(OC)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 IJMBLAWBIHCSHO-UHFFFAOYSA-N 0.000 description 1
- HIELPDVRCJWXGZ-UHFFFAOYSA-N 5-(4-hydroxy-3,5-dimethoxyphenyl)-3-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(O)C(OC)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 HIELPDVRCJWXGZ-UHFFFAOYSA-N 0.000 description 1
- FUCAJAKLSZBROV-UHFFFAOYSA-N 5-(4-hydroxy-3,5-dimethylphenyl)-3-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound CC1=C(O)C(C)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 FUCAJAKLSZBROV-UHFFFAOYSA-N 0.000 description 1
- FULJPSJYUGLLHI-UHFFFAOYSA-N 5-(4-hydroxy-3-methoxyphenyl)-3-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(O)C(OC)=CC(C=2N=C3N(C=4C=C5C=CNC5=CC=4)C(=O)NC3=NC=2)=C1 FULJPSJYUGLLHI-UHFFFAOYSA-N 0.000 description 1
- CMAOZSCSXFTWNO-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-(2-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1C=C2NC(C)=CC2=CC=1N(C(NC1=NC=2)=O)C1=NC=2C1=CC=C(O)C=C1 CMAOZSCSXFTWNO-UHFFFAOYSA-N 0.000 description 1
- IWUITKREYZIEDR-UHFFFAOYSA-N 5-(4-hydroxyphenyl)-3-(4-methoxyphenyl)-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)NC2=NC=C(C=3C=CC(O)=CC=3)N=C21 IWUITKREYZIEDR-UHFFFAOYSA-N 0.000 description 1
- QAYATWJCROUOHW-UHFFFAOYSA-N 5-(6-amino-5-methoxypyridin-3-yl)-3-cyclopentyl-1H-imidazo[4,5-b]pyrazin-2-one Chemical compound COc1cc(cnc1N)-c1cnc2[nH]c(=O)n(C3CCCC3)c2n1 QAYATWJCROUOHW-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- DHPKTHROZFIEJK-UHFFFAOYSA-N 5-bromo-1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound BrC1=CN=C2NC(=O)CC2=C1 DHPKTHROZFIEJK-UHFFFAOYSA-N 0.000 description 1
- LPTVWZSQAIDCEB-UHFFFAOYSA-N 5-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CN=C2NC=CC2=C1 LPTVWZSQAIDCEB-UHFFFAOYSA-N 0.000 description 1
- INZKTAOMHJCPFQ-UHFFFAOYSA-N 5-bromo-3-(1h-indol-5-yl)imidazo[4,5-b]pyrazine Chemical compound C1=C2NC=CC2=CC(N2C=NC3=NC=C(N=C32)Br)=C1 INZKTAOMHJCPFQ-UHFFFAOYSA-N 0.000 description 1
- GIPGJYARDOQGDJ-UHFFFAOYSA-N 5-bromo-3-iodo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CN=C2NC=C(I)C2=C1 GIPGJYARDOQGDJ-UHFFFAOYSA-N 0.000 description 1
- YRGMYJUKFJPNPD-UHFFFAOYSA-N 5-bromopyridine-2,3-diamine Chemical compound NC1=CC(Br)=CN=C1N YRGMYJUKFJPNPD-UHFFFAOYSA-N 0.000 description 1
- RKUCGDPUOWGALR-UHFFFAOYSA-N 5-chloro-1-(cyclopropylmethyl)-6-(3,4,5-trimethoxyphenyl)-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=3NC(=O)N(CC4CC4)C=3N=2)Cl)=C1 RKUCGDPUOWGALR-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- VHCRLTJPUNUZRN-UHFFFAOYSA-N 6-bromo-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound BrC1=CN=C2NC(=O)NC2=C1 VHCRLTJPUNUZRN-UHFFFAOYSA-N 0.000 description 1
- XWRILMUJKQUVDH-UHFFFAOYSA-N 6-bromo-1-(1h-indol-5-yl)-3h-imidazo[4,5-b]pyridin-2-one Chemical compound C1=C2NC=CC2=CC(N2C(=O)NC3=NC=C(C=C32)Br)=C1 XWRILMUJKQUVDH-UHFFFAOYSA-N 0.000 description 1
- JYVRKTJNPZAMNN-UHFFFAOYSA-N 6-bromo-1-(cyclopropylmethyl)-3h-imidazo[4,5-b]pyridin-2-one Chemical compound C12=CC(Br)=CN=C2NC(=O)N1CC1CC1 JYVRKTJNPZAMNN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- CFQRWYFZRXOVJC-UHFFFAOYSA-N B.CC1=CC=C(S(=O)(=O)N2C=C(C3=C/C=C4\NC=C\C4=C\3)C3=CC(Br)=CN=C32)C=C1.CN1CCN(C(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)CC1.CN1CCN(C(=O)C2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1.CN1CCNCC1.O=C=O.[H]C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 Chemical compound B.CC1=CC=C(S(=O)(=O)N2C=C(C3=C/C=C4\NC=C\C4=C\3)C3=CC(Br)=CN=C32)C=C1.CN1CCN(C(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)CC1.CN1CCN(C(=O)C2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1.CN1CCNCC1.O=C=O.[H]C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 CFQRWYFZRXOVJC-UHFFFAOYSA-N 0.000 description 1
- ALUUJEVDBCKXET-UHFFFAOYSA-N B.COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC.[NaH] Chemical compound B.COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC.[NaH] ALUUJEVDBCKXET-UHFFFAOYSA-N 0.000 description 1
- JCEUGMPVCRZFSR-UHFFFAOYSA-N B=N.BC.B[K].C.C.C1=CN=C2CC=CC2=C1.CC(=O)O.CI.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3C(=C2)CC(=O)N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(C)(C)C3=C2)=CC(OC)=C1OC.C[Si](C)(C)CCOCCl.C[Si](C)(C)CCOCN1C(=O)C(Br)(Br)C2=CC(Br)=CN=C21.C[Si](C)(C)CCOCN1C(=O)CC2=CC(Br)=CN=C21.C[Si](C)(C)CCOCN1C=CC2=CC=CN=C21.O Chemical compound B=N.BC.B[K].C.C.C1=CN=C2CC=CC2=C1.CC(=O)O.CI.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3C(=C2)CC(=O)N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(C)(C)C3=C2)=CC(OC)=C1OC.C[Si](C)(C)CCOCCl.C[Si](C)(C)CCOCN1C(=O)C(Br)(Br)C2=CC(Br)=CN=C21.C[Si](C)(C)CCOCN1C(=O)CC2=CC(Br)=CN=C21.C[Si](C)(C)CCOCN1C=CC2=CC=CN=C21.O JCEUGMPVCRZFSR-UHFFFAOYSA-N 0.000 description 1
- HWMKLAYTEBNXDU-UHFFFAOYSA-N B=N.BP.COC1=CC(C2=CN=C3C(=C2)CC(=O)=N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C4(CCCC4)C3=C2)=CC(OC)=C1OC Chemical compound B=N.BP.COC1=CC(C2=CN=C3C(=C2)CC(=O)=N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C4(CCCC4)C3=C2)=CC(OC)=C1OC HWMKLAYTEBNXDU-UHFFFAOYSA-N 0.000 description 1
- TVFQNKCMZHNAAD-UHFFFAOYSA-N B=N.BrCC1CC1.COC1=CC(C2=CN=C3C(=C2)CC(=O)N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)(CC4CC4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)C3=C2)=CC(OC)=C1OC Chemical compound B=N.BrCC1CC1.COC1=CC(C2=CN=C3C(=C2)CC(=O)N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)(CC4CC4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)C3=C2)=CC(OC)=C1OC TVFQNKCMZHNAAD-UHFFFAOYSA-N 0.000 description 1
- MYQULKGUISPRBG-UHFFFAOYSA-N B=N.COC1=CC(C2=CN=C3C(=C2)CC(=O)=N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(=CC4=CN=CC=C4)C3=C2)=CC(OC)=C1OC.O=CC1=CN=CC=C1 Chemical compound B=N.COC1=CC(C2=CN=C3C(=C2)CC(=O)=N3COCC[Si](C)(C)C)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(=CC4=CN=CC=C4)C3=C2)=CC(OC)=C1OC.O=CC1=CN=CC=C1 MYQULKGUISPRBG-UHFFFAOYSA-N 0.000 description 1
- ZKMRNYWTYTXAPP-UHFFFAOYSA-N B=S.CC(C)(C)OC(=O)N1C(=O)N(C2=CC=C3NC=CC3=C2)C2=CC(Br)=CN=C21.CCOC(=O)N1C(=O)CC2=NC=C(Br)C=C21.CCOC(=O)N1C(=O)N(C(=O)OC(C)(C)C)C2=NC=C(Br)C=C21.CCOC(=O)OC1=CC=CC=N1.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=C2)=CC(OC)=C1OC.NC1=CC(Br)=CN=C1N.OB(O)C1=CC=C2NC=CC2=C1 Chemical compound B=S.CC(C)(C)OC(=O)N1C(=O)N(C2=CC=C3NC=CC3=C2)C2=CC(Br)=CN=C21.CCOC(=O)N1C(=O)CC2=NC=C(Br)C=C21.CCOC(=O)N1C(=O)N(C(=O)OC(C)(C)C)C2=NC=C(Br)C=C21.CCOC(=O)OC1=CC=CC=N1.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=C2)=CC(OC)=C1OC.NC1=CC(Br)=CN=C1N.OB(O)C1=CC=C2NC=CC2=C1 ZKMRNYWTYTXAPP-UHFFFAOYSA-N 0.000 description 1
- AQUPDWQHRMVLDU-VZXDIZMMSA-N BB.BC.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC.NC1=CC=C2NC=CC2=C1.NC1=NC=C(Br)N=C1Br.NC1=NC=C(Br)N=C1NC1=CC=C2NC=CC2=C1.NC1=NC=CN=C1.O=C1CC2=NC=C(Br)N=C2N1C1=CC=C2NC=CC2=C1.O=C1CCC(=O)N1Br.[2H]B Chemical compound BB.BC.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC.NC1=CC=C2NC=CC2=C1.NC1=NC=C(Br)N=C1Br.NC1=NC=C(Br)N=C1NC1=CC=C2NC=CC2=C1.NC1=NC=CN=C1.O=C1CC2=NC=C(Br)N=C2N1C1=CC=C2NC=CC2=C1.O=C1CCC(=O)N1Br.[2H]B AQUPDWQHRMVLDU-VZXDIZMMSA-N 0.000 description 1
- NXNHJAXLMJLADJ-UHFFFAOYSA-N BC.C#C.CC(=O)NCC1=CC=C(C2=CN(S(=O)(=O)C3=CC=C(C)C=C3)C3=NC=C(Br)C=C23)C=C1.CC(=O)OC(C)=O.CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(CN)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CCN(CC)CC.COC1=CC(B(O)O)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(C)=O)C=C4)C3=C2)=CC(C)=C1C.NCC1=CC=C(B(O)O)C=C1 Chemical compound BC.C#C.CC(=O)NCC1=CC=C(C2=CN(S(=O)(=O)C3=CC=C(C)C=C3)C3=NC=C(Br)C=C23)C=C1.CC(=O)OC(C)=O.CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(CN)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CCN(CC)CC.COC1=CC(B(O)O)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(C)=O)C=C4)C3=C2)=CC(C)=C1C.NCC1=CC=C(B(O)O)C=C1 NXNHJAXLMJLADJ-UHFFFAOYSA-N 0.000 description 1
- YOHIWCTYUCBDFG-VOEPQHRLSA-N B[W].BrC1=CN=C2N=CN(C3=CC=C4NC=CC4=C3)C2=N1.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3N=CN(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC.NC1=NC=C(Br)N=C1NC1=CC=C2NC=CC2=C1.[2H]CF Chemical compound B[W].BrC1=CN=C2N=CN(C3=CC=C4NC=CC4=C3)C2=N1.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3N=CN(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC.NC1=NC=C(Br)N=C1NC1=CC=C2NC=CC2=C1.[2H]CF YOHIWCTYUCBDFG-VOEPQHRLSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GIAFZEDDZXPDAL-UHFFFAOYSA-N BrC1=CC=C(C2=NC=CN2)C=C1.BrC1=CN=C2CC=CC2=C1.C.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(C2=CC=C(C3=NC=CN3)C=C2)OC1(C)C.CC1=CC=C(S(=O)(=O)Cl)C=C1.CI.COC1=CC(B(O)O)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(I)C3=C2)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=CC3=C2)=CC(C)=C1C.SN=[IH].[NaH] Chemical compound BrC1=CC=C(C2=NC=CN2)C=C1.BrC1=CN=C2CC=CC2=C1.C.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1(C)OB(C2=CC=C(C3=NC=CN3)C=C2)OC1(C)C.CC1=CC=C(S(=O)(=O)Cl)C=C1.CI.COC1=CC(B(O)O)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(I)C3=C2)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=CC3=C2)=CC(C)=C1C.SN=[IH].[NaH] GIAFZEDDZXPDAL-UHFFFAOYSA-N 0.000 description 1
- WZDWMWKRDBDBOX-UHFFFAOYSA-N BrC1=CN=C2CC=C(I)C2=N1 Chemical compound BrC1=CN=C2CC=C(I)C2=N1 WZDWMWKRDBDBOX-UHFFFAOYSA-N 0.000 description 1
- WYONSPGONYYYJE-UHFFFAOYSA-N BrC1=CN=C2CC=CC2=N1 Chemical compound BrC1=CN=C2CC=CC2=N1 WYONSPGONYYYJE-UHFFFAOYSA-N 0.000 description 1
- MZLLDDDHGDTDGX-UHFFFAOYSA-N BrCC1=CC=CC=C1.COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=CC=C4)(CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)CC3=C2)=CC(OC)=C1OC Chemical compound BrCC1=CC=CC=C1.COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=CC=C4)(CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)CC3=C2)=CC(OC)=C1OC MZLLDDDHGDTDGX-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- ZFBQQDWHAAXLIY-UHFFFAOYSA-N C1=CC2=CC(C3=CCC4=C3C=C(C3=CC=C(NCCN5CCCC5)N=C3)C=N4)=CC=C2N1 Chemical compound C1=CC2=CC(C3=CCC4=C3C=C(C3=CC=C(NCCN5CCCC5)N=C3)C=N4)=CC=C2N1 ZFBQQDWHAAXLIY-UHFFFAOYSA-N 0.000 description 1
- CBSYOFJPBIJYOL-UHFFFAOYSA-N C1=CC2=CC(C3=CCC4=NC=C(C5=CC=C(CN6CCCCC6)C=C5)C=C34)=CC=C2N1 Chemical compound C1=CC2=CC(C3=CCC4=NC=C(C5=CC=C(CN6CCCCC6)C=C5)C=C34)=CC=C2N1 CBSYOFJPBIJYOL-UHFFFAOYSA-N 0.000 description 1
- PESGFUWLZSOUBD-UHFFFAOYSA-N C1=CC2=CC(C3=CCC4=NC=C(C5=CC=C(N6CCNCC6)N=C5)C=C34)=CC=C2N1 Chemical compound C1=CC2=CC(C3=CCC4=NC=C(C5=CC=C(N6CCNCC6)N=C5)C=C34)=CC=C2N1 PESGFUWLZSOUBD-UHFFFAOYSA-N 0.000 description 1
- FNSZADULMAXTNN-UHFFFAOYSA-N C1=CC2=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=CC=C2N1 Chemical compound C1=CC2=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=CC=C2N1 FNSZADULMAXTNN-UHFFFAOYSA-N 0.000 description 1
- DBEXGTFCHROBBB-UHFFFAOYSA-N C1=CC=C(C2=CC3=C(CC=C3C3=CC=C4NC=CC4=C3)N=C2)C=C1 Chemical compound C1=CC=C(C2=CC3=C(CC=C3C3=CC=C4NC=CC4=C3)N=C2)C=C1 DBEXGTFCHROBBB-UHFFFAOYSA-N 0.000 description 1
- NLGRQFRTRZTETD-UHFFFAOYSA-L C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)CC3=C2)=CC(OC)=C1OC.Cl[Pd]Cl.O=C1CC2=CC(Br)=CN=C2C1.[C-]#[N+]C1=CC=C(C=C2C(=O)CC3=NC=C(C4=CC(OC)=C(OC)C(OC)=C4)C=C23)C=C1.[C-]#[N+]C1=CC=C(C=O)C=C1 Chemical compound C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.COC1=CC(B(O)O)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)CC3=C2)=CC(OC)=C1OC.Cl[Pd]Cl.O=C1CC2=CC(Br)=CN=C2C1.[C-]#[N+]C1=CC=C(C=C2C(=O)CC3=NC=C(C4=CC(OC)=C(OC)C(OC)=C4)C=C23)C=C1.[C-]#[N+]C1=CC=C(C=O)C=C1 NLGRQFRTRZTETD-UHFFFAOYSA-L 0.000 description 1
- RDLNJHJOSSVAJC-UHFFFAOYSA-N CC(=O)C1=CC=C(B(O)O)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CNC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C)=C(C)C(OC)=C4)C=C23)C=C1.CNC(=O)C1=CC=C(C2=CN(S(=O)(=O)C3=CC=C(C)C=C3)C3=NC=C(Br)C=C23)C=C1.COC1=CC(B(O)O)=CC(C)=C1C Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CNC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C)=C(C)C(OC)=C4)C=C23)C=C1.CNC(=O)C1=CC=C(C2=CN(S(=O)(=O)C3=CC=C(C)C=C3)C3=NC=C(Br)C=C23)C=C1.COC1=CC(B(O)O)=CC(C)=C1C RDLNJHJOSSVAJC-UHFFFAOYSA-N 0.000 description 1
- UITACJRJMGGFHE-UHFFFAOYSA-O CC(=O)N1CCN(C(=O)C2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1.CC(=O)OC(C)=O.NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CC[NH2+]CC5)C=C4)C=C23)C=C1.[Cl-] Chemical compound CC(=O)N1CCN(C(=O)C2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1.CC(=O)OC(C)=O.NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CC[NH2+]CC5)C=C4)C=C23)C=C1.[Cl-] UITACJRJMGGFHE-UHFFFAOYSA-O 0.000 description 1
- XVRGPKBHYNNTOW-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)C2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1 Chemical compound CC(=O)N1CCN(C(=O)C2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1 XVRGPKBHYNNTOW-UHFFFAOYSA-N 0.000 description 1
- JTGNWJHPJNEHCT-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)C2=CC=CC(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)=C2)CC1 Chemical compound CC(=O)N1CCN(C(=O)C2=CC=CC(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)=C2)CC1 JTGNWJHPJNEHCT-UHFFFAOYSA-N 0.000 description 1
- DTUXWMUPHISFAK-UHFFFAOYSA-N CC(=O)N1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1 Chemical compound CC(=O)N1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1 DTUXWMUPHISFAK-UHFFFAOYSA-N 0.000 description 1
- BFCIXBWINNUWFZ-UHFFFAOYSA-N CC(=O)NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 Chemical compound CC(=O)NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 BFCIXBWINNUWFZ-UHFFFAOYSA-N 0.000 description 1
- BXSBJHWESFZRKY-UHFFFAOYSA-N CC(=O)NCC1=CC=C(C2=CN(S(=O)(=O)C3=CC=C(C)C=C3)C3=NC=C(Br)C=C23)C=C1 Chemical compound CC(=O)NCC1=CC=C(C2=CN(S(=O)(=O)C3=CC=C(C)C=C3)C3=NC=C(Br)C=C23)C=C1 BXSBJHWESFZRKY-UHFFFAOYSA-N 0.000 description 1
- PDWUUABUBVMQMP-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)N3CCCCC3)C=C2)OC1(C)C.CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(C(N)=O)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CCCCC5)C=C4)C=C23)C=C1.NC(=O)C1=CC=C(OBO)C=C1 Chemical compound CC1(C)OB(C2=CC=C(C(=O)N3CCCCC3)C=C2)OC1(C)C.CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(C(N)=O)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CCCCC5)C=C4)C=C23)C=C1.NC(=O)C1=CC=C(OBO)C=C1 PDWUUABUBVMQMP-UHFFFAOYSA-N 0.000 description 1
- DDXMFQCQSQJQKG-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C3=NC=CN3)C=C2)OC1(C)C.COC1=CC(C2=CN=C3C(=C2)C(I)=CN3S(=O)(=O)C2=CC=C(C)C=C2)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(C4=CC=C(C5=NC=CN5)C=C4)C3=C2)=CC(C)=C1C Chemical compound CC1(C)OB(C2=CC=C(C3=NC=CN3)C=C2)OC1(C)C.COC1=CC(C2=CN=C3C(=C2)C(I)=CN3S(=O)(=O)C2=CC=C(C)C=C2)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(C4=CC=C(C5=NC=CN5)C=C4)C3=C2)=CC(C)=C1C DDXMFQCQSQJQKG-UHFFFAOYSA-N 0.000 description 1
- OLDJKBMYATVPQY-UHFFFAOYSA-N CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=C/C=C5\NC=C\C5=C\4)C3=N2)=C1 Chemical compound CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=C/C=C5\NC=C\C5=C\4)C3=N2)=C1 OLDJKBMYATVPQY-UHFFFAOYSA-N 0.000 description 1
- FPTIPLOXVRQZQU-UHFFFAOYSA-N CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=CC5=C(C=C4)C=NN5)C3=N2)=C1 Chemical compound CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=CC5=C(C=C4)C=NN5)C3=N2)=C1 FPTIPLOXVRQZQU-UHFFFAOYSA-N 0.000 description 1
- RSHULQBHKNMAKO-UHFFFAOYSA-N CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=CC=C5C(=C4)C=CN5C)C3=N2)=C1 Chemical compound CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=CC=C5C(=C4)C=CN5C)C3=N2)=C1 RSHULQBHKNMAKO-UHFFFAOYSA-N 0.000 description 1
- UUMHCJFYZKJWNT-UHFFFAOYSA-N CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=CC=C5SC=NC5=C4)C3=N2)=C1 Chemical compound CC1=CC(C)=CC(C2=CN=C3CC(=O)N(C4=CC=C5SC=NC5=C4)C3=N2)=C1 UUMHCJFYZKJWNT-UHFFFAOYSA-N 0.000 description 1
- XJTDKZZNXVABDX-UHFFFAOYSA-N CC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(C)=C1O Chemical compound CC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(C)=C1O XJTDKZZNXVABDX-UHFFFAOYSA-N 0.000 description 1
- QNJJJTXKWRTQMT-UHFFFAOYSA-N CC1=CC2=CC(N3C(=O)CC4=NC=C(C5=CC(Cl)=CC(Cl)=C5)N=C43)=CC=C2N1 Chemical compound CC1=CC2=CC(N3C(=O)CC4=NC=C(C5=CC(Cl)=CC(Cl)=C5)N=C43)=CC=C2N1 QNJJJTXKWRTQMT-UHFFFAOYSA-N 0.000 description 1
- MTYLBGDJVRFFBW-UHFFFAOYSA-N CC1=CC2=CC(N3C(=O)CC4=NC=C(C5=CC=C(O)C=C5)N=C43)=CC=C2N1 Chemical compound CC1=CC2=CC(N3C(=O)CC4=NC=C(C5=CC=C(O)C=C5)N=C43)=CC=C2N1 MTYLBGDJVRFFBW-UHFFFAOYSA-N 0.000 description 1
- DGKDDYRXBIMOMI-UHFFFAOYSA-N CC1=CC2=CC(N3C(=O)CC4=NC=C(C5=CC=NC=C5)N=C43)=CC=C2N1 Chemical compound CC1=CC2=CC(N3C(=O)CC4=NC=C(C5=CC=NC=C5)N=C43)=CC=C2N1 DGKDDYRXBIMOMI-UHFFFAOYSA-N 0.000 description 1
- ICGMEEUGNYXHBU-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(CN)C=C3)C3=CC(Br)=CN=C32)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(CN)C=C3)C3=CC(Br)=CN=C32)C=C1 ICGMEEUGNYXHBU-UHFFFAOYSA-N 0.000 description 1
- GNSSBHQJBSKIAL-WTMQMJMGSA-N CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(CN4CCN(C)CC4)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CN1CCN(CC2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)CC1.CN1CCN(CC2=CC=C(C3=CCC4=NC=C(C5=CC=C(C(N)=O)C=C5)C=C34)C=C2)CC1.NC(=O)C1=CC=C(B(O)O)C=C1.[2H]C Chemical compound CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(CN4CCN(C)CC4)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CN1CCN(CC2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)CC1.CN1CCN(CC2=CC=C(C3=CCC4=NC=C(C5=CC=C(C(N)=O)C=C5)C=C34)C=C2)CC1.NC(=O)C1=CC=C(B(O)O)C=C1.[2H]C GNSSBHQJBSKIAL-WTMQMJMGSA-N 0.000 description 1
- ZISBYLTVQHNTIK-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(F)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CF.COC1=CC(B(O)O)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(C4=CC=C(F)C=C4)C3=C2)=CC(C)=C1C.OB(O)C1=CC=C(F)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)N2C=C(C3=CC=C(F)C=C3)C3=CC(Br)=CN=C32)C=C1.CC1=CC=C(S(=O)(=O)N2C=C(I)C3=CC(Br)=CN=C32)C=C1.CF.COC1=CC(B(O)O)=CC(C)=C1C.COC1=CC(C2=CN=C3CC=C(C4=CC=C(F)C=C4)C3=C2)=CC(C)=C1C.OB(O)C1=CC=C(F)C=C1 ZISBYLTVQHNTIK-UHFFFAOYSA-N 0.000 description 1
- IPMMMCIUXOIWSB-UHFFFAOYSA-N CN(C)C1=CC=C(C2=CN=C3CC=C(C4=CC=C(F)C(Cl)=C4)C3=C2)C=N1 Chemical compound CN(C)C1=CC=C(C2=CN=C3CC=C(C4=CC=C(F)C(Cl)=C4)C3=C2)C=N1 IPMMMCIUXOIWSB-UHFFFAOYSA-N 0.000 description 1
- QBDMQBPZWHRZGG-UHFFFAOYSA-N CN(C)C1=CC=C(C2=CN=C3CC=C(C4=CC=C(N(C)C)N=C4)C3=C2)C=N1 Chemical compound CN(C)C1=CC=C(C2=CN=C3CC=C(C4=CC=C(N(C)C)N=C4)C3=C2)C=N1 QBDMQBPZWHRZGG-UHFFFAOYSA-N 0.000 description 1
- MKCUHQHRSZGPIS-UHFFFAOYSA-N CN(C)C1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 Chemical compound CN(C)C1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 MKCUHQHRSZGPIS-UHFFFAOYSA-N 0.000 description 1
- OJGUABDEIJFXFW-UHFFFAOYSA-N CN(C)CC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 Chemical compound CN(C)CC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 OJGUABDEIJFXFW-UHFFFAOYSA-N 0.000 description 1
- UQMOWLZREZXRAC-UHFFFAOYSA-N CN1C=CC2=CC(N3C(=O)CC4=NC=C(C5=CC=C(O)C=C5)N=C43)=CC=C21 Chemical compound CN1C=CC2=CC(N3C(=O)CC4=NC=C(C5=CC=C(O)C=C5)N=C43)=CC=C21 UQMOWLZREZXRAC-UHFFFAOYSA-N 0.000 description 1
- PWHUOFYLEWLJTK-UHFFFAOYSA-N CN1CCN(C(=O)C2=CC=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=C2)CC1 Chemical compound CN1CCN(C(=O)C2=CC=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=C2)CC1 PWHUOFYLEWLJTK-UHFFFAOYSA-N 0.000 description 1
- JVQMZIDNYPQKAH-UHFFFAOYSA-N CN1CCN(C2=NC=CC(C3=CN=C4CC(=O)N(C5=CC=C6NC=CC6=C5)C4=N3)=C2)CC1 Chemical compound CN1CCN(C2=NC=CC(C3=CN=C4CC(=O)N(C5=CC=C6NC=CC6=C5)C4=N3)=C2)CC1 JVQMZIDNYPQKAH-UHFFFAOYSA-N 0.000 description 1
- VBIJLZAJMFIQGW-UHFFFAOYSA-N CN1CCN(C2=NC=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=C2)CC1 Chemical compound CN1CCN(C2=NC=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=C2)CC1 VBIJLZAJMFIQGW-UHFFFAOYSA-N 0.000 description 1
- XXYYBCWYDMFIBD-UHFFFAOYSA-N CN1CCN(CC2=CC=C(C3=CCC4=NC=C(C5=CC6=C(C=C5)NC=C6)C=C34)C=C2)CC1 Chemical compound CN1CCN(CC2=CC=C(C3=CCC4=NC=C(C5=CC6=C(C=C5)NC=C6)C=C34)C=C2)CC1 XXYYBCWYDMFIBD-UHFFFAOYSA-N 0.000 description 1
- PCRNZXJHQUABJZ-UHFFFAOYSA-N CN1CCN(CC2=CC=C(C3=CCC4=NC=C(C5=CC=C(C(N)=O)C=C5)C=C34)C=C2)CC1 Chemical compound CN1CCN(CC2=CC=C(C3=CCC4=NC=C(C5=CC=C(C(N)=O)C=C5)C=C34)C=C2)CC1 PCRNZXJHQUABJZ-UHFFFAOYSA-N 0.000 description 1
- NHFNSJOBLVYZTN-UHFFFAOYSA-N CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1 Chemical compound CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1 NHFNSJOBLVYZTN-UHFFFAOYSA-N 0.000 description 1
- SRWYZUDXQDZBBF-UHFFFAOYSA-N CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1=O Chemical compound CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)C=C2)CC1=O SRWYZUDXQDZBBF-UHFFFAOYSA-N 0.000 description 1
- GJHNQAYPYGGQDK-UHFFFAOYSA-N CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1 Chemical compound CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1 GJHNQAYPYGGQDK-UHFFFAOYSA-N 0.000 description 1
- XJQDTYMTPWDONM-UHFFFAOYSA-N CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1=O Chemical compound CN1CCN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CC1=O XJQDTYMTPWDONM-UHFFFAOYSA-N 0.000 description 1
- MSNDTADKEXOWOT-UHFFFAOYSA-N CN1CCN(CC2=CC=CC(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)=C2)CC1 Chemical compound CN1CCN(CC2=CC=CC(C3=CN=C4CC=C(C5=CC=C(C(N)=O)C=C5)C4=C3)=C2)CC1 MSNDTADKEXOWOT-UHFFFAOYSA-N 0.000 description 1
- OIXNQOJWQJDMBJ-UHFFFAOYSA-N CN1CCN(CC2=CC=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=C2)CC1=O Chemical compound CN1CCN(CC2=CC=CC(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)=C2)CC1=O OIXNQOJWQJDMBJ-UHFFFAOYSA-N 0.000 description 1
- QYZRFGNLSZYAOQ-UHFFFAOYSA-N CN1CCN(Cc(cc2)ccc2-c(c2c3)c[nH]c2ncc3-c2ccc3[nH]ccc3c2)CC1 Chemical compound CN1CCN(Cc(cc2)ccc2-c(c2c3)c[nH]c2ncc3-c2ccc3[nH]ccc3c2)CC1 QYZRFGNLSZYAOQ-UHFFFAOYSA-N 0.000 description 1
- BMXPOQBRMFCCGB-UHFFFAOYSA-N CNC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C)=C(C)C(OC)=C4)C=C23)C=C1 Chemical compound CNC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C)=C(C)C(OC)=C4)C=C23)C=C1 BMXPOQBRMFCCGB-UHFFFAOYSA-N 0.000 description 1
- FDMZCSKJPNXIEX-UHFFFAOYSA-N CNC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(CN5CCN(C)CC5)C=C4)C=C23)C=C1 Chemical compound CNC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(CN5CCN(C)CC5)C=C4)C=C23)C=C1 FDMZCSKJPNXIEX-UHFFFAOYSA-N 0.000 description 1
- CFWQVNCFKPRFJJ-UHFFFAOYSA-N CNC1=CC=C(C2=CC3=C(CC=C3C3=CC=C4NC=CC4=C3)N=C2)C=N1 Chemical compound CNC1=CC=C(C2=CC3=C(CC=C3C3=CC=C4NC=CC4=C3)N=C2)C=N1 CFWQVNCFKPRFJJ-UHFFFAOYSA-N 0.000 description 1
- MHFIICZNQJLWAL-UHFFFAOYSA-N COC1=C(C)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1C Chemical compound COC1=C(C)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1C MHFIICZNQJLWAL-UHFFFAOYSA-N 0.000 description 1
- MLSIEVZLURHGMA-UHFFFAOYSA-N COC1=C(F)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 Chemical compound COC1=C(F)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 MLSIEVZLURHGMA-UHFFFAOYSA-N 0.000 description 1
- LYRCXZNGOPNOCQ-UHFFFAOYSA-N COC1=C(N)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 Chemical compound COC1=C(N)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 LYRCXZNGOPNOCQ-UHFFFAOYSA-N 0.000 description 1
- NAIXHJMCKWUVJS-UHFFFAOYSA-N COC1=C(N)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 Chemical compound COC1=C(N)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 NAIXHJMCKWUVJS-UHFFFAOYSA-N 0.000 description 1
- JZBHILNFIXVJOI-UHFFFAOYSA-N COC1=C(N)C=CC(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=C1 Chemical compound COC1=C(N)C=CC(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=C1 JZBHILNFIXVJOI-UHFFFAOYSA-N 0.000 description 1
- KPOXIHVDQVXPKT-UHFFFAOYSA-N COC1=C(N)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)=C1 Chemical compound COC1=C(N)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)=C1 KPOXIHVDQVXPKT-UHFFFAOYSA-N 0.000 description 1
- POENXZCZUMRDEP-UHFFFAOYSA-N COC1=C(N)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)=C1 Chemical compound COC1=C(N)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)=C1 POENXZCZUMRDEP-UHFFFAOYSA-N 0.000 description 1
- KQSKYTDCBPGJLT-UHFFFAOYSA-N COC1=C(N)C=CC(C2=NC3=C(CC(=O)N3C3CCCC3)N=C2)=C1 Chemical compound COC1=C(N)C=CC(C2=NC3=C(CC(=O)N3C3CCCC3)N=C2)=C1 KQSKYTDCBPGJLT-UHFFFAOYSA-N 0.000 description 1
- PJYUUCNXGGMJLG-UHFFFAOYSA-N COC1=C(O)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 Chemical compound COC1=C(O)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 PJYUUCNXGGMJLG-UHFFFAOYSA-N 0.000 description 1
- HHBAYPCXATXKFD-UHFFFAOYSA-N COC1=C(OC)C(OC)=CC(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CN=C3N(O)C=2)=C1 Chemical compound COC1=C(OC)C(OC)=CC(C=2C=C3C(C=4C=CC(=CC=4)C(N)=O)=CN=C3N(O)C=2)=C1 HHBAYPCXATXKFD-UHFFFAOYSA-N 0.000 description 1
- OGSNQRWNFOBTJZ-UHFFFAOYSA-N COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CC=C(O)C=C4)C3=N2)C=C1 Chemical compound COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CC=C(O)C=C4)C3=N2)C=C1 OGSNQRWNFOBTJZ-UHFFFAOYSA-N 0.000 description 1
- OYKMIJHYWQJNLR-UHFFFAOYSA-N COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 Chemical compound COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 OYKMIJHYWQJNLR-UHFFFAOYSA-N 0.000 description 1
- DBUHEFMIXMJSFF-UHFFFAOYSA-N COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=NC5=C4)C3=N2)C=C1 Chemical compound COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CC=C5NC=NC5=C4)C3=N2)C=C1 DBUHEFMIXMJSFF-UHFFFAOYSA-N 0.000 description 1
- GTGNHVHHCPXOLN-UHFFFAOYSA-N COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CN=C5NC=CC5=C4)C3=N2)C=C1 Chemical compound COC1=C(OC)C=C(C2=CN=C3CC(=O)N(C4=CN=C5NC=CC5=C4)C3=N2)C=C1 GTGNHVHHCPXOLN-UHFFFAOYSA-N 0.000 description 1
- VXCZNBYARSHFAW-UHFFFAOYSA-N COC1=C(OC)C=C(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)C=C1 Chemical compound COC1=C(OC)C=C(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)C=C1 VXCZNBYARSHFAW-UHFFFAOYSA-N 0.000 description 1
- AMHUTSKMGAIOIX-UHFFFAOYSA-N COC1=C(OC)C=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 Chemical compound COC1=C(OC)C=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 AMHUTSKMGAIOIX-UHFFFAOYSA-N 0.000 description 1
- ASBYDHNNHKVSKO-UHFFFAOYSA-N COC1=C(OC)C=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 Chemical compound COC1=C(OC)C=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)C=C1 ASBYDHNNHKVSKO-UHFFFAOYSA-N 0.000 description 1
- WVLHPEUOYWAPGL-UHFFFAOYSA-N COC1=C(OCCN(C)C)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)=C1 Chemical compound COC1=C(OCCN(C)C)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)=C1 WVLHPEUOYWAPGL-UHFFFAOYSA-N 0.000 description 1
- DFBNGRDJKKANFO-UHFFFAOYSA-N COC1=C(OCCN2CCNCC2)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 Chemical compound COC1=C(OCCN2CCNCC2)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 DFBNGRDJKKANFO-UHFFFAOYSA-N 0.000 description 1
- XQEBSAIPDJRMKZ-UHFFFAOYSA-N COC1=C(OCCN2CCNCC2)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)=C1 Chemical compound COC1=C(OCCN2CCNCC2)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)=C1 XQEBSAIPDJRMKZ-UHFFFAOYSA-N 0.000 description 1
- NDPDYSKLVDAPEU-UHFFFAOYSA-N COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 Chemical compound COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 NDPDYSKLVDAPEU-UHFFFAOYSA-N 0.000 description 1
- CFQUYDUUJBAMLJ-UHFFFAOYSA-N COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)=C1 Chemical compound COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)=C1 CFQUYDUUJBAMLJ-UHFFFAOYSA-N 0.000 description 1
- SOWWCXMRESCKDI-UHFFFAOYSA-N COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC(=O)N(CC4CC4)C3=N2)=C1 Chemical compound COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC(=O)N(CC4CC4)C3=N2)=C1 SOWWCXMRESCKDI-UHFFFAOYSA-N 0.000 description 1
- GVKFAGFFWCLPGO-UHFFFAOYSA-N COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)=C1 Chemical compound COC1=C(OCCN2CCOCC2)C=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)=C1 GVKFAGFFWCLPGO-UHFFFAOYSA-N 0.000 description 1
- HVAQCESAECHXIN-UHFFFAOYSA-N COC1=CC(C2=C(Cl)N=C3CC(=O)N(CC4CC4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=C(Cl)N=C3CC(=O)N(CC4CC4)C3=N2)=CC(OC)=C1OC HVAQCESAECHXIN-UHFFFAOYSA-N 0.000 description 1
- XDIAMDVXYBNQLX-UHFFFAOYSA-N COC1=CC(C2=CC3=C(CC=C3C3=CC=C4NC=CC4=C3)N=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CC3=C(CC=C3C3=CC=C4NC=CC4=C3)N=C2)=CC(OC)=C1OC XDIAMDVXYBNQLX-UHFFFAOYSA-N 0.000 description 1
- QMQUCIYZWKAPIR-UHFFFAOYSA-N COC1=CC(C2=CN=C3C(=C2)C(I)=CN3S(=O)(=O)C2=CC=C(C)C=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3C(=C2)C(I)=CN3S(=O)(=O)C2=CC=C(C)C=C2)=CC(C)=C1C QMQUCIYZWKAPIR-UHFFFAOYSA-N 0.000 description 1
- QTWQZYDLEQTSBY-IAQXMGSRSA-N COC1=CC(C2=CN=C3CC(=O)/C(=C/C4=CC=NC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)/C(=C\C4=CC=NC=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)/C(=C/C4=CC=NC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)/C(=C\C4=CC=NC=C4)C3=C2)=CC(OC)=C1OC QTWQZYDLEQTSBY-IAQXMGSRSA-N 0.000 description 1
- VZARBTKVUZCFTP-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=C(C(N)=O)C=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=C(C(N)=O)C=C4)C3=C2)=CC(OC)=C1OC VZARBTKVUZCFTP-UHFFFAOYSA-N 0.000 description 1
- NPMKNCIYZSZHNY-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC(C#N)=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC(C#N)=C4)C3=C2)=CC(OC)=C1OC NPMKNCIYZSZHNY-UHFFFAOYSA-N 0.000 description 1
- DVOBFEAUYFUQGF-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC(C(N)=O)=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC(C(N)=O)=C4)C3=C2)=CC(OC)=C1OC DVOBFEAUYFUQGF-UHFFFAOYSA-N 0.000 description 1
- POBLUTNLVQAWQB-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(=CC4=CC=CC=C4)C3=C2)=CC(OC)=C1OC POBLUTNLVQAWQB-UHFFFAOYSA-N 0.000 description 1
- FGLUXNCGPJNPAS-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(=CC4=CN=CC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4=CN=CC=C4)C3=C2)=CC(OC)=C1OC.N.O=CO Chemical compound COC1=CC(C2=CN=C3CC(=O)C(=CC4=CN=CC=C4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4=CN=CC=C4)C3=C2)=CC(OC)=C1OC.N.O=CO FGLUXNCGPJNPAS-UHFFFAOYSA-N 0.000 description 1
- HBIMBWZAPAZBRW-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(C)(C)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(C)(C)C3=C2)=CC(OC)=C1OC HBIMBWZAPAZBRW-UHFFFAOYSA-N 0.000 description 1
- RHESHHFXEXJVPT-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=C(C(N)=O)C=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=C(C(N)=O)C=C4)C3=C2)=CC(OC)=C1OC RHESHHFXEXJVPT-UHFFFAOYSA-N 0.000 description 1
- DJFFBCQHERUPFB-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=NC=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(CC4=CC=NC=C4)C3=C2)=CC(OC)=C1OC DJFFBCQHERUPFB-UHFFFAOYSA-N 0.000 description 1
- CAPBTBVZPSKIKL-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)(CC4CC4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)(CC4CC4)C3=C2)=CC(OC)=C1OC.COC1=CC(C2=CN=C3CC(=O)C(CC4CC4)C3=C2)=CC(OC)=C1OC CAPBTBVZPSKIKL-UHFFFAOYSA-N 0.000 description 1
- NOMGZZDLJUOLOX-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)C4(CCCC4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)C4(CCCC4)C3=C2)=CC(OC)=C1OC NOMGZZDLJUOLOX-UHFFFAOYSA-N 0.000 description 1
- MTPSNPVRHQPKTQ-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)CC3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)CC3=C2)=CC(OC)=C1OC MTPSNPVRHQPKTQ-UHFFFAOYSA-N 0.000 description 1
- GXMRYGSXYJGPNV-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC5=C(C=C4)C=NN5)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC5=C(C=C4)C=NN5)C3=N2)=CC(OC)=C1OC GXMRYGSXYJGPNV-UHFFFAOYSA-N 0.000 description 1
- AYTJQBXJORWGKB-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C(O)C=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C(O)C=C4)C3=N2)=CC(OC)=C1OC AYTJQBXJORWGKB-UHFFFAOYSA-N 0.000 description 1
- NWISSGMAFJDZQI-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5C(=C4)C=CN5C)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5C(=C4)C=CN5C)C3=N2)=CC(OC)=C1OC NWISSGMAFJDZQI-UHFFFAOYSA-N 0.000 description 1
- RPRYYUCTJCAIOU-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC(C)=CC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC(C)=CC5=C4)C3=N2)=CC(OC)=C1OC RPRYYUCTJCAIOU-UHFFFAOYSA-N 0.000 description 1
- RFMDKJXGPJIMNK-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1O Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1O RFMDKJXGPJIMNK-UHFFFAOYSA-N 0.000 description 1
- TXIYBOYZHMHCLH-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC TXIYBOYZHMHCLH-UHFFFAOYSA-N 0.000 description 1
- OLJPGPADVFQHOC-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=NC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=NC5=C4)C3=N2)=CC(OC)=C1OC OLJPGPADVFQHOC-UHFFFAOYSA-N 0.000 description 1
- ZHVXNYLTJXYVRT-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NN=CC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5NN=CC5=C4)C3=N2)=CC(OC)=C1OC ZHVXNYLTJXYVRT-UHFFFAOYSA-N 0.000 description 1
- DKSBVTIGQGHDQC-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5SC=NC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=C5SC=NC5=C4)C3=N2)=CC(OC)=C1OC DKSBVTIGQGHDQC-UHFFFAOYSA-N 0.000 description 1
- RXKPHWFRYRVGDK-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CC=CC=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CC=CC=C4)C3=N2)=CC(OC)=C1OC RXKPHWFRYRVGDK-UHFFFAOYSA-N 0.000 description 1
- KQXFPEFCIODICO-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CN=C5C=CNC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CN=C5C=CNC5=C4)C3=N2)=CC(OC)=C1OC KQXFPEFCIODICO-UHFFFAOYSA-N 0.000 description 1
- YHBLKZSHJHMBBL-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4=CN=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4=CN=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC YHBLKZSHJHMBBL-UHFFFAOYSA-N 0.000 description 1
- XYVSOQJRSFIEKQ-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4CCC5=C4C=CC=C5)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4CCC5=C4C=CC=C5)C3=N2)=CC(OC)=C1OC XYVSOQJRSFIEKQ-UHFFFAOYSA-N 0.000 description 1
- INRRTIOTHZZLDQ-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)=CC(OC)=C1OC INRRTIOTHZZLDQ-UHFFFAOYSA-N 0.000 description 1
- WHRZHQFLJIRQON-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(CC4CC4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(CC4CC4)C3=C2)=CC(OC)=C1OC WHRZHQFLJIRQON-UHFFFAOYSA-N 0.000 description 1
- WNLLXENOZGIHTB-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=O)N(CC4CC4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=O)N(CC4CC4)C3=N2)=CC(OC)=C1OC WNLLXENOZGIHTB-UHFFFAOYSA-N 0.000 description 1
- UVDDOUSOBRHOTO-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC(=S)N(CC4CC4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC(=S)N(CC4CC4)C3=N2)=CC(OC)=C1OC UVDDOUSOBRHOTO-UHFFFAOYSA-N 0.000 description 1
- PCWVPKBFFGSPMM-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=CC(C)=C1C.COC1=CC(C2=C[N+]([O-])=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=CC(C)=C1C.COC1=CC(C2=C[N+]([O-])=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=CC(C)=C1C PCWVPKBFFGSPMM-UHFFFAOYSA-N 0.000 description 1
- MAUKLCMMMHLZOP-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(C(N)=O)C=C4)C3=C2)=CC(OC)=C1OC MAUKLCMMMHLZOP-UHFFFAOYSA-N 0.000 description 1
- QNUQRIGZMLIZBL-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(C5=NC=CN5)C=C4)C3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(C5=NC=CN5)C=C4)C3=C2)=CC(C)=C1C QNUQRIGZMLIZBL-UHFFFAOYSA-N 0.000 description 1
- DTJCDWUGSBVFDD-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(=O)CC5=CC=CC=C5)C=C4)C3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(=O)CC5=CC=CC=C5)C=C4)C3=C2)=CC(C)=C1C DTJCDWUGSBVFDD-UHFFFAOYSA-N 0.000 description 1
- WKKCJUZKHQIJDA-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(=O)CCC5=CC=CC=C5)C=C4)C3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(=O)CCC5=CC=CC=C5)C=C4)C3=C2)=CC(C)=C1C WKKCJUZKHQIJDA-UHFFFAOYSA-N 0.000 description 1
- WGJSNNHDWXLZCD-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(C)=O)C=C4)C3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(CNC(C)=O)C=C4)C3=C2)=CC(C)=C1C WGJSNNHDWXLZCD-UHFFFAOYSA-N 0.000 description 1
- IERRRFQWABQWHI-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(F)C=C4)C3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(F)C=C4)C3=C2)=CC(C)=C1C IERRRFQWABQWHI-UHFFFAOYSA-N 0.000 description 1
- CUUNENROCSEWDO-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(N(C)C)N=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(N(C)C)N=C4)C3=C2)=CC(OC)=C1OC CUUNENROCSEWDO-UHFFFAOYSA-N 0.000 description 1
- WEQPUCSWCFTWKK-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(N)C=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(N)C=C4)C3=C2)=CC(OC)=C1OC WEQPUCSWCFTWKK-UHFFFAOYSA-N 0.000 description 1
- YNDZPPHHFLHOHK-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(N)N=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(N)N=C4)C3=C2)=CC(OC)=C1OC YNDZPPHHFLHOHK-UHFFFAOYSA-N 0.000 description 1
- ZEUCMSBFWRNOLL-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C(NC(C)=O)C=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C(NC(C)=O)C=C4)C3=C2)=CC(OC)=C1OC ZEUCMSBFWRNOLL-UHFFFAOYSA-N 0.000 description 1
- JXUCEULXNHDXHF-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C5C(=C4)C=CN5C)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C5C(=C4)C=CN5C)C3=C2)=CC(OC)=C1OC JXUCEULXNHDXHF-UHFFFAOYSA-N 0.000 description 1
- UIXLZKGWQQVUKA-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=N2)=CC(OC)=C1OC UIXLZKGWQQVUKA-UHFFFAOYSA-N 0.000 description 1
- LQIZTLMPQAFLNN-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(C4=CN=C(N)N=C4)C3=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=CN=C3CC=C(C4=CN=C(N)N=C4)C3=C2)=CC(OC)=C1OC LQIZTLMPQAFLNN-UHFFFAOYSA-N 0.000 description 1
- LFQHKWUHZIHIDV-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=C(I)C3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=C(I)C3=C2)=CC(C)=C1C LFQHKWUHZIHIDV-UHFFFAOYSA-N 0.000 description 1
- KMZLQXNYCQCNHU-UHFFFAOYSA-N COC1=CC(C2=CN=C3CC=CC3=C2)=CC(C)=C1C Chemical compound COC1=CC(C2=CN=C3CC=CC3=C2)=CC(C)=C1C KMZLQXNYCQCNHU-UHFFFAOYSA-N 0.000 description 1
- QSZJUGCPZBTOPL-UHFFFAOYSA-N COC1=CC(C2=NC3=C(CC(=O)N3C3=CC=C(N4CCOCC4)N=C3)N=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=NC3=C(CC(=O)N3C3=CC=C(N4CCOCC4)N=C3)N=C2)=CC(OC)=C1OC QSZJUGCPZBTOPL-UHFFFAOYSA-N 0.000 description 1
- MMBMUQDNFVPQQT-UHFFFAOYSA-N COC1=CC(C2=NC3=C(CC(=O)N3C3CC4=C(C=CC=C4)C3)N=C2)=CC(OC)=C1OC Chemical compound COC1=CC(C2=NC3=C(CC(=O)N3C3CC4=C(C=CC=C4)C3)N=C2)=CC(OC)=C1OC MMBMUQDNFVPQQT-UHFFFAOYSA-N 0.000 description 1
- QABQYHJSVJBVKE-UHFFFAOYSA-N COC1=CC(OC)=C(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)C(OC)=C1 Chemical compound COC1=CC(OC)=C(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)C(OC)=C1 QABQYHJSVJBVKE-UHFFFAOYSA-N 0.000 description 1
- QJANXXQVZPPXSB-UHFFFAOYSA-N COC1=CC(OC)=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 Chemical compound COC1=CC(OC)=CC(C2=CN=C3CC(=O)N(C4=CC=C5NC=CC5=C4)C3=N2)=C1 QJANXXQVZPPXSB-UHFFFAOYSA-N 0.000 description 1
- YXCDIVWSNOAVDA-UHFFFAOYSA-N COC1=CC=C(C2=CN=C3CC(=O)N(C4=CC5=C(C=C4)C=NN5)C3=N2)C=C1OC Chemical compound COC1=CC=C(C2=CN=C3CC(=O)N(C4=CC5=C(C=C4)C=NN5)C3=N2)C=C1OC YXCDIVWSNOAVDA-UHFFFAOYSA-N 0.000 description 1
- NMSSQXGXYBFUNC-UHFFFAOYSA-N COC1=CC=C(C2=CN=C3CC(=O)N(C4=CC=C5NN=CC5=C4)C3=N2)C=C1OC Chemical compound COC1=CC=C(C2=CN=C3CC(=O)N(C4=CC=C5NN=CC5=C4)C3=N2)C=C1OC NMSSQXGXYBFUNC-UHFFFAOYSA-N 0.000 description 1
- OXHKWKALNWOPAY-UHFFFAOYSA-N COC1=CC=C(C2=CN=C3CC(=O)N(C4=CC=CC=C4)C3=N2)C=C1OC Chemical compound COC1=CC=C(C2=CN=C3CC(=O)N(C4=CC=CC=C4)C3=N2)C=C1OC OXHKWKALNWOPAY-UHFFFAOYSA-N 0.000 description 1
- MMEVWFBRMWRLOR-UHFFFAOYSA-N COC1=CC=C(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)C=C1OC Chemical compound COC1=CC=C(C2=CN=C3CC(=O)N(C4CCCC4)C3=N2)C=C1OC MMEVWFBRMWRLOR-UHFFFAOYSA-N 0.000 description 1
- DSYQCEZKEPPKOA-UHFFFAOYSA-N COC1=CC=C(C2=CN=C3CC(=O)N(CC4CC4)C3=N2)C=C1OC Chemical compound COC1=CC=C(C2=CN=C3CC(=O)N(CC4CC4)C3=N2)C=C1OC DSYQCEZKEPPKOA-UHFFFAOYSA-N 0.000 description 1
- YCBYCZWVHUKNLV-UHFFFAOYSA-N COC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 Chemical compound COC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 YCBYCZWVHUKNLV-UHFFFAOYSA-N 0.000 description 1
- SAOGPZRUQHLTKV-UHFFFAOYSA-N COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC(OC)=C(OC)C(OC)=C4)N=C32)C=C1 Chemical compound COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC(OC)=C(OC)C(OC)=C4)N=C32)C=C1 SAOGPZRUQHLTKV-UHFFFAOYSA-N 0.000 description 1
- MFTDDQMWKPDBHJ-UHFFFAOYSA-N COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC=C(O)C=C4)N=C32)C=C1 Chemical compound COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC=C(O)C=C4)N=C32)C=C1 MFTDDQMWKPDBHJ-UHFFFAOYSA-N 0.000 description 1
- XHPDYTWWARYIHP-UHFFFAOYSA-N COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC=C(OC)C(OC)=C4)N=C32)C=C1 Chemical compound COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC=C(OC)C(OC)=C4)N=C32)C=C1 XHPDYTWWARYIHP-UHFFFAOYSA-N 0.000 description 1
- SNSVDGPJEFVVLV-UHFFFAOYSA-N COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC=NC=C4)N=C32)C=C1 Chemical compound COC1=CC=C(N2C(=O)CC3=NC=C(C4=CC=NC=C4)N=C32)C=C1 SNSVDGPJEFVVLV-UHFFFAOYSA-N 0.000 description 1
- REIDEDZRSLSTAE-UHFFFAOYSA-N COc(cc(cc1OC)-c(nc2N3c4cnc(cc[nH]5)c5c4)cnc2NC3=O)c1OC Chemical compound COc(cc(cc1OC)-c(nc2N3c4cnc(cc[nH]5)c5c4)cnc2NC3=O)c1OC REIDEDZRSLSTAE-UHFFFAOYSA-N 0.000 description 1
- ATSCJCUPDYRKFE-UHFFFAOYSA-N COc1cc(-c(cc2C3)cnc2N(COCC[S+](C)C)C3=O)cc(OC)c1OC Chemical compound COc1cc(-c(cc2C3)cnc2N(COCC[S+](C)C)C3=O)cc(OC)c1OC ATSCJCUPDYRKFE-UHFFFAOYSA-N 0.000 description 1
- XGRSJZJWKCUJEQ-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 Chemical compound CS(=O)(=O)NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 XGRSJZJWKCUJEQ-UHFFFAOYSA-N 0.000 description 1
- STMXEJSZVUOWSO-UHFFFAOYSA-N C[S+](C)CCOCN(C(Cc1c2)=O)c1ncc2Br Chemical compound C[S+](C)CCOCN(C(Cc1c2)=O)c1ncc2Br STMXEJSZVUOWSO-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- IDDMQFIMAPLOGU-UHFFFAOYSA-N C[n](cc1)c(cc2)c1cc2-c(c1c2)c[nH]c1ncc2-c(cc1OC)cc(OC)c1OC Chemical compound C[n](cc1)c(cc2)c1cc2-c(c1c2)c[nH]c1ncc2-c(cc1OC)cc(OC)c1OC IDDMQFIMAPLOGU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DBDKPUREOHXHQA-UHFFFAOYSA-N Cc1cc(C)cc(-c(nc2N3c(cc4)cc5c4[nH]cc5)cnc2NC3=O)c1 Chemical compound Cc1cc(C)cc(-c(nc2N3c(cc4)cc5c4[nH]cc5)cnc2NC3=O)c1 DBDKPUREOHXHQA-UHFFFAOYSA-N 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 108050001278 Cdc42 Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 description 1
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 239000012825 JNK inhibitor Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 1
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 125000005855 N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- FRQJWQDPDMKFSE-UHFFFAOYSA-N N1C=CC2=CC(=CC=C12)N1C(NC=2C1=NC(=CN2)C=2C=C1C=CNC1=CC2)=O.N2C=CC1=CC(=CC=C21)B(O)O Chemical compound N1C=CC2=CC(=CC=C12)N1C(NC=2C1=NC(=CN2)C=2C=C1C=CNC1=CC2)=O.N2C=CC1=CC(=CC=C21)B(O)O FRQJWQDPDMKFSE-UHFFFAOYSA-N 0.000 description 1
- ZZEHXPGXZZUZJS-UHFFFAOYSA-N NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C(=O)N5CCCCC5)=CC=C4)C=C23)C=C1 Chemical compound NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C(=O)N5CCCCC5)=CC=C4)C=C23)C=C1 ZZEHXPGXZZUZJS-UHFFFAOYSA-N 0.000 description 1
- KINVHJFKPWPECA-UHFFFAOYSA-O NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C(=O)N5CC[NH2+]CC5)=CC=C4)C=C23)C=C1.[Cl-] Chemical compound NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC(C(=O)N5CC[NH2+]CC5)=CC=C4)C=C23)C=C1.[Cl-] KINVHJFKPWPECA-UHFFFAOYSA-O 0.000 description 1
- STFGAVRGWRISPS-UHFFFAOYSA-N NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CCCCC5)C=C4)C=C23)C=C1 Chemical compound NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CCCCC5)C=C4)C=C23)C=C1 STFGAVRGWRISPS-UHFFFAOYSA-N 0.000 description 1
- OMOFOSYPABHBNY-UHFFFAOYSA-O NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CCCCC5)C=C4)C=C23)C=C1.NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CC[NH2+]CC5)C=C4)C=C23)C=C1.[Cl-] Chemical compound NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CCCCC5)C=C4)C=C23)C=C1.NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(C(=O)N5CC[NH2+]CC5)C=C4)C=C23)C=C1.[Cl-] OMOFOSYPABHBNY-UHFFFAOYSA-O 0.000 description 1
- PWXGXCRBIRWTGE-UHFFFAOYSA-N NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(N)N=C4)C=C23)C=C1 Chemical compound NC(=O)C1=CC=C(C2=CCC3=NC=C(C4=CC=C(N)N=C4)C=C23)C=C1 PWXGXCRBIRWTGE-UHFFFAOYSA-N 0.000 description 1
- JNAMZRHONDDOAK-UHFFFAOYSA-N NC.OBO Chemical compound NC.OBO JNAMZRHONDDOAK-UHFFFAOYSA-N 0.000 description 1
- WDIOWMRGCZAXIM-UHFFFAOYSA-N NC1=CC=C(C2=CCC3=NC=C(C4=CC=C(N)N=C4)C=C23)C=C1 Chemical compound NC1=CC=C(C2=CCC3=NC=C(C4=CC=C(N)N=C4)C=C23)C=C1 WDIOWMRGCZAXIM-UHFFFAOYSA-N 0.000 description 1
- SGQMZFUCTHOVFV-UHFFFAOYSA-N NC1=CC=C(C2=CN=C3CC=C(C4=CC=C(F)C(Cl)=C4)C3=C2)C=N1 Chemical compound NC1=CC=C(C2=CN=C3CC=C(C4=CC=C(F)C(Cl)=C4)C3=C2)C=N1 SGQMZFUCTHOVFV-UHFFFAOYSA-N 0.000 description 1
- MPPNSWYGJFWMRK-UHFFFAOYSA-N NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 Chemical compound NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=C1 MPPNSWYGJFWMRK-UHFFFAOYSA-N 0.000 description 1
- GNDPVIOVULHVNG-UHFFFAOYSA-N NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 Chemical compound NC1=CC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 GNDPVIOVULHVNG-UHFFFAOYSA-N 0.000 description 1
- RQVXDURTBVEFTC-UHFFFAOYSA-N NC1=CC=C(C2=NC3=C(CC(=O)N3C3CCCC3)N=C2)C=N1 Chemical compound NC1=CC=C(C2=NC3=C(CC(=O)N3C3CCCC3)N=C2)C=N1 RQVXDURTBVEFTC-UHFFFAOYSA-N 0.000 description 1
- GYGVYWUKQYASHR-UHFFFAOYSA-N NC1=NC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 Chemical compound NC1=NC=C(C2=CN=C3CC=C(C4=CC=C5NC=CC5=C4)C3=C2)C=N1 GYGVYWUKQYASHR-UHFFFAOYSA-N 0.000 description 1
- ZWEJISQTAWQDRY-UHFFFAOYSA-N NC1=NC=C(C2=CN=C3CC=C(C4=CN=C(N)N=C4)C3=C2)C=N1 Chemical compound NC1=NC=C(C2=CN=C3CC=C(C4=CN=C(N)N=C4)C3=C2)C=N1 ZWEJISQTAWQDRY-UHFFFAOYSA-N 0.000 description 1
- ZJKOOPMEEVIKBA-UHFFFAOYSA-N NC=1NC2=CC=CC=C2C1.B(O)O Chemical compound NC=1NC2=CC=CC=C2C1.B(O)O ZJKOOPMEEVIKBA-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- MPTRQLXNBJOFSI-UHFFFAOYSA-N Nc(nc1)ncc1-c(cc12)cnc1[nH]cc2-c(cc1)cc2c1[nH]cc2 Chemical compound Nc(nc1)ncc1-c(cc12)cnc1[nH]cc2-c(cc1)cc2c1[nH]cc2 MPTRQLXNBJOFSI-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- OVTNQQIJBYJCML-UHFFFAOYSA-N O=C1CC2=C(N=C(C3=C(F)C=C(O)C(F)=C3)C=N2)N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=C(N=C(C3=C(F)C=C(O)C(F)=C3)C=N2)N1C1=CC=C2NC=CC2=C1 OVTNQQIJBYJCML-UHFFFAOYSA-N 0.000 description 1
- HLXHZTZBRYXCQH-UHFFFAOYSA-N O=C1CC2=C(N=C(C3=CC(F)=C(O)C(F)=C3)C=N2)N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=C(N=C(C3=CC(F)=C(O)C(F)=C3)C=N2)N1C1=CC=C2NC=CC2=C1 HLXHZTZBRYXCQH-UHFFFAOYSA-N 0.000 description 1
- YJABZBINKYKPSL-UHFFFAOYSA-N O=C1CC2=NC=C(Br)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(Br)N=C2N1C1=CC=C2NC=CC2=C1 YJABZBINKYKPSL-UHFFFAOYSA-N 0.000 description 1
- BWWFGYSQLXJBSD-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC(Cl)=CC(Cl)=C3)N=C2N1CC1CC1 Chemical compound O=C1CC2=NC=C(C3=CC(Cl)=CC(Cl)=C3)N=C2N1CC1CC1 BWWFGYSQLXJBSD-UHFFFAOYSA-N 0.000 description 1
- DLZYBMSATGVJRE-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC(F)=CC(F)=C3)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC(F)=CC(F)=C3)N=C2N1C1=CC=C2NC=CC2=C1 DLZYBMSATGVJRE-UHFFFAOYSA-N 0.000 description 1
- XSKFENAUPDIKFA-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC4=C(C=C3)NC=C4)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC4=C(C=C3)NC=C4)N=C2N1C1=CC=C2NC=CC2=C1 XSKFENAUPDIKFA-UHFFFAOYSA-N 0.000 description 1
- AKHCYSMRWCGXBR-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC4=C(C=C3)OCCO4)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC4=C(C=C3)OCCO4)N=C2N1C1=CC=C2NC=CC2=C1 AKHCYSMRWCGXBR-UHFFFAOYSA-N 0.000 description 1
- WVCAHVVCNZMKKS-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C(O)C=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C(O)C=C1 WVCAHVVCNZMKKS-UHFFFAOYSA-N 0.000 description 1
- PIYOGSRNJVBWHF-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2NC=CC2=C1 PIYOGSRNJVBWHF-UHFFFAOYSA-N 0.000 description 1
- WGXZSWIIWKLKKO-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2NC=NC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2NC=NC2=C1 WGXZSWIIWKLKKO-UHFFFAOYSA-N 0.000 description 1
- NUWBSHKMUSGZID-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2NN=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2NN=CC2=C1 NUWBSHKMUSGZID-UHFFFAOYSA-N 0.000 description 1
- XKIIOODJITUYKZ-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2SC=NC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1C1=CC=C2SC=NC2=C1 XKIIOODJITUYKZ-UHFFFAOYSA-N 0.000 description 1
- GBYFWLDALNVQFF-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1CC1CC1 Chemical compound O=C1CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)N=C2N1CC1CC1 GBYFWLDALNVQFF-UHFFFAOYSA-N 0.000 description 1
- NGUAEIUZYLIGRI-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1=CC2=C(C=C1)C=NN2 Chemical compound O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1=CC2=C(C=C1)C=NN2 NGUAEIUZYLIGRI-UHFFFAOYSA-N 0.000 description 1
- TTWFQDRWMCDFSN-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1=CC=C2NC=CC2=C1 TTWFQDRWMCDFSN-UHFFFAOYSA-N 0.000 description 1
- IGHGPGKZQPPMPE-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1=CC=C2SC=NC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1=CC=C2SC=NC2=C1 IGHGPGKZQPPMPE-UHFFFAOYSA-N 0.000 description 1
- WCGCNSBEWFJQEE-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1CCCC1 Chemical compound O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1C1CCCC1 WCGCNSBEWFJQEE-UHFFFAOYSA-N 0.000 description 1
- ZQPHMGCCNHSNKS-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1CC1CC1 Chemical compound O=C1CC2=NC=C(C3=CC=C(O)C=C3)N=C2N1CC1CC1 ZQPHMGCCNHSNKS-UHFFFAOYSA-N 0.000 description 1
- PLVKWARDEHXETF-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=C4C=CNC4=C3)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=C4C=CNC4=C3)N=C2N1C1=CC=C2NC=CC2=C1 PLVKWARDEHXETF-UHFFFAOYSA-N 0.000 description 1
- HFTDFHXPBLAARC-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=CC(O)=C3)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=CC(O)=C3)N=C2N1C1=CC=C2NC=CC2=C1 HFTDFHXPBLAARC-UHFFFAOYSA-N 0.000 description 1
- GUNGWSSLXFFOEE-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC2=C(C=C1)C=NN2 Chemical compound O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC2=C(C=C1)C=NN2 GUNGWSSLXFFOEE-UHFFFAOYSA-N 0.000 description 1
- CKQAIDOKDDXDHQ-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC=C2NC=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC=C2NC=CC2=C1 CKQAIDOKDDXDHQ-UHFFFAOYSA-N 0.000 description 1
- OOHDBKGNNLNJFY-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC=C2NN=CC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC=C2NN=CC2=C1 OOHDBKGNNLNJFY-UHFFFAOYSA-N 0.000 description 1
- IABHPBFWDJROIO-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC=C2SC=NC2=C1 Chemical compound O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1=CC=C2SC=NC2=C1 IABHPBFWDJROIO-UHFFFAOYSA-N 0.000 description 1
- JCQOCNBWZMPPHD-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1CCCC1 Chemical compound O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1C1CCCC1 JCQOCNBWZMPPHD-UHFFFAOYSA-N 0.000 description 1
- FILWPZBUGKTIEY-UHFFFAOYSA-N O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1CC1CC1 Chemical compound O=C1CC2=NC=C(C3=CC=NC=C3)N=C2N1CC1CC1 FILWPZBUGKTIEY-UHFFFAOYSA-N 0.000 description 1
- XMEXPMPNEPJPQX-UHFFFAOYSA-N O=C1CN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CCN1 Chemical compound O=C1CN(CC2=CC=C(C3=CN=C4CC=C(C5=CC=C6NC=CC6=C5)C4=C3)C=C2)CCN1 XMEXPMPNEPJPQX-UHFFFAOYSA-N 0.000 description 1
- OSFPHMZQBQZLAY-UHFFFAOYSA-N OBO.NC1=CC=CC=C1 Chemical compound OBO.NC1=CC=CC=C1 OSFPHMZQBQZLAY-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical group CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 125000005631 S-sulfonamido group Chemical group 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 101000761953 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein kinase byr2 Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DISHMIITASECFQ-UHFFFAOYSA-N [C-]#[N+]C1=CC=C(C=C2C(=O)CC3=NC=C(C4=CC(OC)=C(OC)C(OC)=C4)C=C23)C=C1 Chemical compound [C-]#[N+]C1=CC=C(C=C2C(=O)CC3=NC=C(C4=CC(OC)=C(OC)C(OC)=C4)C=C23)C=C1 DISHMIITASECFQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 1
- 125000005012 alkyl thioether group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000005854 carbamoyl-(C1-C2)alkyl group Chemical group 0.000 description 1
- URQAFOVWPMQYCX-UHFFFAOYSA-N carbamoyloxy(phenyl)borinic acid Chemical compound NC(=O)OB(O)C1=CC=CC=C1 URQAFOVWPMQYCX-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000009226 cognitive therapy Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000005852 di-N,N—(C1-C2)alkylamino(C2-C3)alkyl group Chemical group 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 125000005911 methyl carbonate group Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 230000007388 microgliosis Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- UQEIFYRRSNJVDO-UHFFFAOYSA-N n,n-dibenzyl-2-phenylethanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CCC1=CC=CC=C1 UQEIFYRRSNJVDO-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUJGYWFWHBPESW-UHFFFAOYSA-N n-methyl-4-[5-(3,4,5-trimethoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=CNC2=NC=C(C=3C=C(OC)C(OC)=C(OC)C=3)C=C12 FUJGYWFWHBPESW-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 231100000199 ototoxic Toxicity 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 238000002732 pharmacokinetic assay Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- MHBAAGYJKTZUKJ-UHFFFAOYSA-N tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(=O)C1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 MHBAAGYJKTZUKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 125000005853 β-dimethylaminoethyl group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- Mammalian protein kinases are involved in the regulation of important cellular functions. Due to the fact that dysfunctions in protein kinase activity have been associated with several diseases and disorders, protein kinases are targets for drug development.
- MLKs Mixed lineage kinases
- MAPK kinase kinases that target JNK and p38 MAPK for activation in response to diverse stimuli that stress cells.
- MLKs regulate a broad range of cellular processes.
- MLK3 is the most widely expressed MLK family member and is present in neurons. It is activated by GTPases of the Ras superfamily, such as Cdc42 and Rac, which trigger protein dimerization via a leucine zipper interface, resulting in auto-phosphorylation at Thr277 and Ser281 within the protein activation loop and subsequent activation of the enzyme.
- CEP1347 Preclinical studies of the mixed lineage kinase (MLK) inhibitor CEP1347 have shown that this agent can protect neurons against a considerable range of insults, including exposure to the Alzheimer's peptide, A ⁇ .
- HAD HIV-associated dementia
- CEP1347 can protect primary rat hippocampal neurons as well as dorsal root ganglion neurons from the otherwise lethal effects of exposure to HIV-1 gp120. It has been determined that CEP1347 mediates this effect by inhibiting the activity of the mixed lineage kinase (MLK) family.
- MLK mixed lineage kinase
- Maggirwar et al. recently examined the effect of Tat and gp120 on MLK3. Tat and gp120 were shown to induce autophosphorylation of MLK3 in primary rat neurons and this was abolished by the addition of CEP1347. These studies suggest that the normal function of MLK3 is compromised by HIV-1 neurotoxins, resulting in the downstream signaling events that result in neuronal death and monocyte activation (with release of inflammatory cytokines). Most recently, Eggert et al. have demonstrated that CEP1347 is neuroprotective in an in vivo model of HIV-1 infection, reversing microglial activation and restoring normal synaptic architecture, as well as restoring macrophage secretory profiles to a trophic vs.
- MLK3 has been shown to drive the production of the HIV virus.
- CEP1347 does not have ideal pharmacokinetic properties, which could potentially affect its ability to gain entry to the CNS.
- Other small molecule MLK3 inhibitors are needed that have improved pharmacokinetic and brain penetrating properties.
- An inhibitor of MLK3 could also find use in the treatment of psychological disorders.
- Depression is a complex disease that has a multifactorial etiology. This may include genetic factors, changes in normal neuronal signaling, and reduced levels of certain neurotrophins (such as brain-derived neurotrophic factor, BDNF) within particular regions of the brain (Krishnan, V., and E. J. Nestler. 2008. Nature 455:894-902).
- Treatments for depression include drugs such as SSRIs, as well as cognitive and behavioral therapy (“talk therapy”) and other inventions such as exercise.
- SSRIs and exercise share the common property that they promote neurogenesis; this is thought to be related to their anti-depressive effects because of effects on neuronal plasticity and remodeling (Krishnan, supra).
- MLK3 mixed lineage kinase 3
- MLK3 inhibitors have also been shown to increase production of BDNF itself (Conforti, P. et al. 2008. Mol Cell Neurosci 39:1-7).
- Combined treatment with SSRIs and MLK3 inhibitors could result in the synergistic promotion of neurogenesis, due to the neurotrophin-sensitizing effects of MLK3 inhibitors and their ability to directly upregulate BDNF (Wang and Conforti, supra). Increase of the therapeutic effectiveness of SSRIs (and possibly talk therapy and exercise also) could also result if the compounds were coadministered.
- Exposure to MLK3 inhibitors may also compensate for lowered BDNF levels in hippocampus of persons with depression, thereby alleviating depression (based on the “BDNF hypothesis”) (Krishnan, supra).
- Disclosed herein are compounds having an inhibitory effect on MLK1, MLK2, and MLK3.
- compounds of Formula I as described below.
- novel compounds that can be used for therapeutic methods involving modulation of MLKs.
- the present invention provides for compounds of Formula I:
- dashed lines indicate that a second bond may alternatively be present or absent
- X 1 is chosen from CH and N;
- X 2 is chosen from C and N;
- Y 1 is —(CR 6a R 6b ) m —Z 1 —(CR 7a R 7b ) n —;
- Y 2 is —(CR 8a R 8b ) p —Z 2 —(CR 9a R 9b ) q —;
- Y 3 is —(CR 10a R 10b ) r —Z 3 —(CR 11a R 11b ) s —;
- Y 4 is —(CH 2 ) 1 —Z 4 —;
- Z 1 , Z 2 , and Z 3 are each independently chosen from a bond, O, S, S(O), S(O) 2 , N(R 12 ), C(O), C(O)N(R 12 ), N(R 12 )C(O), S(O) 2 N(R 12 ), and N(R 12 )S(O) 2 ;
- Z 4 is chosen from a bond, 0, and N;
- n, p, q, r, and s are each independently an integer from 0 to 6;
- t is an integer from 0 to 2;
- R 1 , R 2 , and R 3 are independently chosen from hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl, amido, amino, alkoxy, hydroxy, cyano, and nitro, any of which may be optionally substituted; or R 1 and R 2 may each additionally be heteroalkyl, and may be joined together such that R 1 and R 2 together form an alkylene, alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms, which may be optionally substituted;
- R 4 is chosen from hydrogen, (O), (S), halogen, hydroxy, cyano, nitro, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyloxy, lower thioalkoxy, lower heterocycloalkyl, aryl, lower aralkyl, lower heteroaryl, lower heteroaralkyl, amido, acyl, amino, and lower alkoxy, any of which may be optionally substituted; or R 3 and R 4 may each additionally be heteroalkyl, and may be joined together such that R 1 and R 2 together form an alkylene, alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms, which may be optionally substituted;
- R 5 and R 13 are each independently chosen from hydrogen, halogen, hydroxy, cyano, nitro, lower alkyl, lower alkene, lower alkyne, lower aryl, lower arylalkyl, lower cycloalkyl, lower cycloalkylalkyl, lower heteroaryl, lower heteroarylalkyl, lower heterocycloalkyl, lower heterocycloalkylalkyl, and lower alkoxy, any of which may be optionally substituted; and additionally, R 13 and R 3 may be joined together to form a lower spiro-cycloalkyl or spiro-phenyl comprising from 3 to 6 atoms, which may be optionally substituted;
- R 6a , R 6b , R 7a , R 7b , R 8a , R 8b , R 9a , R 9b , R 10a , R 10b , R 11a , R 11b , and R 12 are each independently chosen from a bond, hydrogen, halogen, hydroxy, C 1 -C 3 alkoxy and C 1 -C 3 alkyl; and
- R 14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- Y 1 is —(CR 6a R 6b ) m —Z 1 —(CR 7 R 7b ) n —, and m and n are both 0, and Z 1 is a bond
- Y 1 collapses to a direct bond linking the parent ring system with R 1 .
- Y 1 is —(CR 6a R 6b ) m —Z 1 —(CR 7a R 7b ) n —, the rightmost portion of Y 1 attaches to the parent molecule.
- Y 1 , Y 2 , Y 3 , and Y 4 are no more than 6 atoms in length.
- R 4 is chosen from hydrogen, (O), and (S).
- R 4 is (O)
- the second bond linking R 4 and the fused bicyclic core is present
- the second bond in the five-membered portion of the fused bicyclic core is absent.
- R 4 is hydrogen
- the second bond linking R 4 and the fused bicyclic core is absent
- the second bond in the five-membered portion of the fused bicyclic core is present.
- X 1 is CH
- X 2 is C.
- X 1 is N
- X 2 is N.
- X 1 is CH
- X 2 is N.
- X 1 is N
- X 2 is C.
- Z 1 is a bond
- R 1 and R 5 are both hydrogen.
- p and r are each independently an integer from 0 to 3;
- Z 2 and Z 3 are each independently chosen from a bond and 0.
- R 6a , R 6b , R 7a , R 7b , R 8a , R 8b , R 9a , R 9b , R 10a , R 10b , R 11a , R 11b , and R 12 are all hydrogen.
- compounds have structural Formula II
- dashed lines indicate that a second bond may alternatively be present or absent
- X 1 is chosen from CH and N;
- X 2 is chosen from C and N;
- Y 1 , Y 2 , and Y 3 are independently chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
- Y 4 is chosen from —(CH 2 ) m , C(O), —(CH 2 ) m O—, and —(CH 2 ) m N—;
- n is an integer from 0 to 2;
- R 1 , R 2 , and R 3 are independently chosen from lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl, amido, amino, alkoxy, hydroxy, cyano, and nitro, any of which may be optionally substituted; or R 1 and R 2 may each additionally be heteroalkyl, and may be joined together such that R 1 and R 2 together form an alkylene, alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms, which may be optionally substituted;
- R 4 is chosen from hydrogen, (O), and (S);
- R 5 is chosen from hydrogen, hydroxy, cyano, lower alkyl, lower cycloalkyl, and lower alkoxy, any of which may be optionally substituted;
- R 13 is chosen from hydrogen, halogen, hydroxy, cyano, nitro, lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower alkoxy, any of which may be optionally substituted; and additionally, R 13 and R 3 may be joined together to form a lower spiro-cycloalkyl or spiro-phenyl comprising from 3 to 6 atoms, which may be optionally substituted; and
- R 14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- compounds have structural Formula III
- dashed lines indicate that a second bond may alternatively be present or absent
- X 1 and X 2 are independently chosen from CH and N;
- Y 3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl
- Y 4 is chosen from C(O), —(CH 2 ) m —, —(CH 2 ) m O—, and —(CH 2 ) m N—;
- n is an integer from 0 to 1;
- R 2 and R 3 are independently chosen from lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl, any of which may be optionally substituted;
- R 4 is chosen from hydrogen, (O), and (S);
- R 13 is chosen from hydrogen, lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower alkoxy, any of which may be optionally substituted;
- R 14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- compounds have a structural Formula chosen from Formula IV and Formula V:
- X 1 and X 2 are independently chosen from CH and N;
- Y 3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl
- Y 4 is chosen from C(O), —(CH 2 ) m —, —(CH 2 ) m O—, and —(CH 2 ) m N—;
- n is an integer from 0 to 1;
- R 2 and R 3 are independently chosen from lower cycloalkyl, lower heterocycloalkyl, lower aryl, and lower heteroaryl, any of which may be optionally substituted;
- R 14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- compounds have a structural Formula chosen from Formula VI, Formula VII, Formula VIII, and Formula IX:
- Y 3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl
- Y 4 is chosen from C(O), —(CH 2 ) m —, —(CH 2 ) m O—, and —(CH 2 ) m N—;
- n is an integer from 0 to 1;
- R 2 is chosen from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused bicyclic heteroaryl, any of which may be optionally substituted;
- R 3 is chosen from lower cycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted;
- R 14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- R 2 and R 3 are each independently chosen from lower cycloalkyl, lower aryl, and monocyclic or bicyclic heteroaryl, any of which may be optionally substituted.
- R 2 is substituted with one or more substituents chosen from halogen, hydroxy, lower amino, C 1 -C 3 alkoxy and C 1 -C 3 alkyl.
- R 2 is chosen from phenyl and lower heteroaryl, any of which may be optionally substituted.
- R 2 is chosen from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused bicyclic heteroaryl, any of which may be optionally substituted.
- R 2 is chosen from phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally substituted.
- R 2 is substituted with one or more substituents chosen from fluorine, hydroxy, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , methoxy, and methyl.
- R 2 is optionally substituted phenyl.
- R 2 is chosen from
- u is an integer from 0 to 3;
- Y 4 is chosen from C(O), —(CH 2 ) m —, —(CH 2 ) m O—, and —(CH 2 ) m N—;
- n is an integer from 0 to 1;
- R 14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted;
- each R 15 is independently chosen from halogen, hydroxy, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, lower amino, lower amido, lower sulfonamido, and lower sulfonyl.
- R 14 is chosen from piperazinyl, pyrrolyl, and N(CH 3 ) 2 .
- each R 15 is independently chosen from R 15 is independently chosen from fluorine, hydroxy, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , NS(O) 2 CH 3 , methoxy, and methyl.
- Y 4 is —(CH 2 ) m —
- n 0;
- R 14 is null
- u is an integer from 0 to 3;
- R 15 is independently chosen from R 15 is independently chosen from fluorine, hydroxy, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , NS(O) 2 CH 3 , methoxy, and methyl.
- Y 4 is chosen from C(O), O, N, and —CH 2 —.
- Y 4 is —CH 2 —.
- Y 3 is chosen from a bond and lower alkyl.
- Y 3 is chosen from a bond and methyl.
- Y 3 is a bond
- R 3 is chosen from lower cycloalkyl, lower aryl, and monocyclic or bicyclic heteroaryl, any of which may be optionally substituted.
- R 3 is substituted with one or more substituents chosen from halogen, hydroxy, lower amino, lower amido, lower phenylamido, lower phenylalkylamido, lower heterocycloalkyl, lowerheterocycloalkyl, loweralkylheterocycloalkyl, C 1 -C 3 alkoxy and C 1 -C 3 alkyl.
- R 3 is chosen from benzothiazolyl, pyrrolopyridinyl, indanyl, cyclopropyl, cyclopentyl, phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally substituted.
- R 3 is substituted with one or more substituents chosen from fluorine, chlorine, hydroxy, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , C(O)NH 2 , C(O)NHCH 3 , morpholino, piperazinyl, methylpiperazinyl, acetamido, methylacetamido, methylpropionamido, phenylacetamidomethylene, benzamidomethylene, phenylpropanamidomethylene, methoxy and methyl.
- substituents chosen from fluorine, chlorine, hydroxy, NH 2 , NH(CH 3 ), N(CH 3 ) 2 , C(O)NH 2 , C(O)NHCH 3 , morpholino, piperazinyl, methylpiperazinyl, acetamido, methylacetamido, methylpropionamido, phenylacetamidomethylene, benzamidomethylene, phenylpropanamidom
- dashed lines indicate that a second bond may alternatively be present or absent
- X 1 and X 2 are independently chosen from CH and N;
- Y 3 is a bond
- Y 4 is chosen from C(O), CH 2 , CHF, and CF 2 ;
- R 2 is chosen from phenyl and 6-membered monocyclic heteroaryl, either of which may be optionally substituted;
- R 3 is optionally substituted bicyclic heteroaryl
- R 4 is chosen from hydrogen, (O), and (S);
- R 14 is optionally substituted monocyclic heterocycloalkyl.
- R 3 is an optionally substituted 5/6-fused bicyclic heteroaryl.
- R 14 is optionally substituted piperazinyl.
- R 2 is chosen from hydrogen, halo, hydroxy, C 1 -C 4 alkyl, C 3 -C 10 cycloalkyl, C 1 -C 4 alkyloxy, C 3 -C 10 cycloalkyloxy, aryl, cyano or nitro.
- R 1 and R 2 together form a butadienylene bridge.
- Z 1 is a bond
- R 1 , R 5 , and R 4 are hydrogen
- R 2 and R 3 are each independently chosen from aryl and heteroaryl, either of which may be optionally substituted.
- Z 1 is a bond
- R 1 , R 5 , and R 4 are hydrogen
- R 2 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted;
- R 3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine.
- n 0 or 1
- n 0:
- Z 1 is a bond
- R 1 , R 5 , and R 4 are hydrogen
- R 1 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine;
- R 2 is chosen from 5-substituted-1,2,3-trimethoxybenzene, 4-substituted-1,2-dimethoxyphenyl, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine
- R 1 , R 5 , and R 4 are hydrogen
- R 2 and R 3 are each independently chosen from aryl and heteroaryl, either of which may be optionally substituted.
- Z 1 is a bond
- R 1 , R 5 , and R 4 are hydrogen
- R 2 is chosen from aryl and heteroaryl, either of which may be optionally substituted;
- R 3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine, any of which may be optionally substituted.
- Z 1 is a bond
- R 1 , R 5 , and R 4 represent hydrogen
- R 3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine;
- R 2 is chosen from 5-substituted-1,2,3-trimethoxybenzene, 4-substituted-1,2-dimethoxybenzene, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine
- R 4 is (O), the second bond linking R 4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent;
- Z 1 is a bond
- R 1 and R 5 are each hydrogen
- R 2 and R 3 are each independently chosen from aryl and heteroaryl, either of which may be optionally substituted.
- R 4 is (O), the second bond linking R 4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent;
- Z 1 is a bond
- R 1 and R 5 are each hydrogen
- R 2 is chosen from aryl and heteroaryl, either of which may be optionally substituted;
- R 3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine.
- R 4 is (O), the second bond linking R 4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent;
- Z 1 is a bond
- R 1 and R 5 are each hydrogen
- R 3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, or 5-substituted pyrimidine-2-amine;
- R 4 is chosen from 5-substituted-1,2,3-trimethoxybenzene, 4-substituted-1,2-dimethoxybenzene, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine
- optionally substituted groups are substituted with one or more substituent chosen from halogen, hydroxy, C 1 -C 3 alkoxy and C 1 -C 3 alkyl.
- R 4 is mono- or poly-substituted with fluorine.
- R 5 is mono- or poly-substituted with fluorine.
- Also provided herein is a compound as disclosed herein for use as a medicament.
- Also provided herein is a compound as disclosed herein for use as a medicament for the treatment of an MLK-mediated disease.
- Also provided herein is the use of a compound as disclosed herein in the manufacture of a medicament for the treatment of an MLK-mediated disease.
- composition comprising a compound of Formula I together with a pharmaceutically acceptable carrier.
- composition comprising a compound chosen from Examples 1 to 167.
- Also provided herein is a method of inhibition of MLK comprising contacting MLK with a compound of Formula I.
- said MLK is MLK3.
- said inhibition is selective over other kinases.
- Also provided herein is a method of treatment of a MLK-mediated disease comprising the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
- said disease is an inflammatory disease or a metabolic disease.
- said disease is chosen from diabetes mellitus, hyperglycemia, retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, peripheral inflammation, and HIV dementia.
- Also provided herein is a method of treatment of a MLK-mediated disease comprising the administration of:
- said disorder a psychological disorder.
- said disease is chosen from depression, bipolar disorder, and post-traumatic stress disorder (PTSD).
- PTSD post-traumatic stress disorder
- said disorder is a traumatic brain injury.
- said traumatic brain injury is stroke.
- said disorder is chosen from Alzheimer's Disease (AD), Parkinson's Disease, HIV dementia and HIV associated neurocognitive disorder (HAND).
- AD Alzheimer's Disease
- Parkinson's Disease HIV dementia
- HAND HIV associated neurocognitive disorder
- said disorder is a neurologic disorder of hearing or vision.
- said disorder is chosen from ototoxicity, hearing loss, acute injury to the inner ear, acoustic trauma, and injury resulting from blast noise.
- the methods of treatment disclosed herein additionally comprise the administration of a second therapeutic agent, as part of a therapeutic regimen.
- the compounds may be delivered in the same dosage form or separately, and further may be taken concurrently or one subsequent to the other.
- said second therapeutic agent is a selective serotonin reuptake inhibitor (SSRI).
- SSRI selective serotonin reuptake inhibitor
- said second therapeutic agent is CEP1347.
- Also provided herein is a method of treatment of a MLK-mediated disease comprising the administration of:
- said second therapeutic agent is a selective serotonin reuptake inhibitor (SSRI).
- SSRI selective serotonin reuptake inhibitor
- said second therapeutic agent is CEP1347.
- Also provided herein is a method of achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as disclosed herein to a patient, wherein the effect is chosen from:
- the effect is chosen from:
- said immune cells are chosen from monocytes, macrophages and microglia.
- the effect is chosen from:
- said immune cells are chosen from monocytes, macrophages and microglia.
- the effect is chosen from:
- acyl refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon.
- An “acetyl” group refers to a —C(O)CH 3 group.
- An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.
- alkenyl refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms.
- alkenylene refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(—CH ⁇ CH—), (—C::C—)].
- alkenyl radicals examples include ethenyl, propenyl, 2-propenyl, 2-methylpropenyl, butenyl, isobutenyl, 1,4-butadienyl, isoprenyl, vinyl, and the like.
- alkenyl may include “alkenylene” groups.
- alkoxy refers to an alkyl ether radical, wherein the term alkyl is as defined below.
- suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.
- alkyl refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, said alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, said alkyl will comprise from 1 to 6 carbon atoms. Alkyl groups may be optionally substituted as defined herein. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, noyl and the like.
- alkylene refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH 2 —). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.
- alkylamino refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino and the like.
- alkylidene refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.
- alkylthio refers to an alkyl thioether (R—S—) radical wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized.
- suitable alkyl thioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.
- alkynyl refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms.
- alkynylene refers to a carbon-carbon triple bond attached at two positions such as ethynylene (—C:::C—, — ⁇ C—)
- alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, Butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like.
- alkynyl may include “alkynylene” groups.
- amido and “carbamoyl,” as used herein, alone or in combination, refer to an amino group as described below attached to the parent molecular moiety through a carbonyl group, or vice versa.
- C-amido refers to a —C(O)N(RR′) group with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- N-amido refers to a RC(O)N(R′)— group, with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- acylamino as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group.
- An example of an “acylamino” group is acetylamino (CH 3 C(O)NH—).
- amino refers to —NRR′, wherein R and R′ are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally. R and R′ may combine to form heterocycloalkyl, either of which may be optionally substituted.
- aryl as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together.
- aryl embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.
- arylalkenyl or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
- arylalkoxy or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
- arylalkyl or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.
- arylalkynyl or “aralkynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
- arylalkanoyl or “aralkanoyl” or “aroyl,” as used herein, alone or in combination, refers to an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.
- aryloxy refers to an aryl group attached to the parent molecular moiety through an oxy.
- carbamate refers to an ester of carbamic acid (—NRC(O)O—) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein.
- O-carbamyl refers to a —OC(O)NRR′ group
- N-carbamyl refers to a ROC(O)NR′— group.
- R and R′ are as defined herein, or as defined by the specifically enumerated “R” groups designated.
- carbonyl when alone includes formyl [—C(O)H] and in combination is a —C(O)— group.
- carboxyl or “carboxy.” as used herein, refers to —C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt.
- An “O-carboxy” group refers to a RC(O)O— group, where R is as defined herein.
- a “C-carboxy” group refers to a —C(O)OR groups where R is as defined herein.
- cyano as used herein, alone or in combination, refers to —CN.
- cycloalkyl or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein.
- said cycloalkyl will comprise from 5 to 7 carbon atoms.
- cycloalkyl groups examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl and the like.
- “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.
- esters refers to a carboxy group bridging two moieties linked at carbon atoms.
- ether refers to an oxy group bridging two moieties linked at carbon atoms.
- halo or halogen, as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.
- haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
- Haloalkoxy includes perhaloalkoxy.
- perhaloalkoxy refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
- An example of perhaloalkoxy is perfluoromethoxy.
- haloalkyl refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl, polyhaloalkyl, and perhaloalkyl radicals.
- a monohaloalkyl radical for one example, may have an iodo, bromo, chloro or fluoro atom within the radical.
- Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.
- haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
- Haloalkylene refers to a haloalkyl group attached at two or more positions.
- haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
- Haloalkylene refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (—CFH—), difluoromethylene (—CF 2 —), chloromethylene (—CHCl—) and the like.
- perhaloalkyl as used herein, alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms. Examples include perfluoromethyl.
- heteroalkyl refers to a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms chosen from O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, —CH 2 —NH—OCH 3 .
- heteroaryl refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from O, S, and N. Additionally, a heteroaryl may contain one or two C(O), S(O), or S(O) 2 groups as ring members. In certain embodiments, said heteroaryl will comprise from 5 to 10 atoms. In certain embodiments, said heteroaryl will comprise from 5 to 7 atoms. In certain embodiments, said heteroaryl will comprise from 1 to 4 heteroatoms as ring members.
- said heteroaryl will comprise from 1 to 2 heteroatoms as ring members.
- the term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings.
- heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, triazinyl, triazolyl, tetrazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazoly
- Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- heterocycloalkyl and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently chosen from N, O, and S. Additionally, a heterocycloalkyl may contain one or two C(O), S(O), or S(O) 2 groups as ring members. In certain embodiments, said hetercycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said hetercycloalkyl will comprise from 1 to 2 heteroatoms as ring members.
- said hetercycloalkyl will comprise from 3 to 8 ring members in each ring. In further embodiments, said hetercycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, said hetercycloalkyl will comprise from 5 to 6 ring members in each ring.
- “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group.
- heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihy-dropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like.
- the heterocycle groups may be optionally substituted unless specifically prohibited.
- lower means containing from 1 to and including 6 carbon atoms.
- lower alkyl as used herein, alone or in a combination, means C 1 -C 6 straight or branched chain alkyl.
- lower alkenyl means C 2 -C 6 straight or branched chain alkenyl.
- lower alkynyl means C 2 -C 6 straight or branched chain alkynyl.
- lower aryl as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as provided.
- lower heteroaryl means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four said members may be heteroatoms chosen from O, S, and N, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms chosen from O, S, and N.
- lower cycloalkyl means a monocyclic cycloalkyl having between three and six ring members. Lower cycloalkyls may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- lower heterocycloalkyl means a monocyclic heterocycloalkyl having between three and six ring members, of which between one and four may be heteroatoms chosen from O, S, and N.
- Examples of lower heterocycloalkyls include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl.
- Lower heterocycloalkyls may be unsaturated.
- lower amino refers to NRR′, wherein R and R′ are independently chosen from hydrogen, lower alkyl, and lower heteroalkyl, any of which may be optionally substituted. Additionally, the R and R′ of a lower amino group may combine to form a five- or six-membered heterocycloalkyl, either of which may be optionally substituted.
- nitro refers to —NO 2 .
- oxy or “oxa,” as used herein, alone or in combination, refer to —O—.
- perhaloalkoxy refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
- perhaloalkyl refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
- sulfonate “sulfonic acid,” and “sulfonic.” as used herein, alone or in combination, refer the —SO 3 H group and its anion as the sulfonic acid is used in salt formation.
- N-sulfonamido refers to a RS( ⁇ O) 2 NR′— group with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- S-sulfonamido refers to a —S( ⁇ O) 2 NRR′, group, with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- thia and thio refer to a —S— group or an ether wherein the oxygen is replaced with sulfur.
- the oxidized derivatives of the thio group namely sulfinyl and sulfonyl, are included in the definition of thia and thio.
- sulfanyl as used herein, alone or in combination, refers to —S—.
- sulfinyl as used herein, alone or in combination, refers to —S(O)—.
- sulfonyl as used herein, alone or in combination, refers to —S(O) 2 —.
- thiol as used herein, alone or in combination, refers to an —SH group.
- thiocarbonyl when alone includes thioformyl —C(S)H and in combination is a —C(S)— group.
- any definition herein may be used in combination with any other definition to describe a composite structural group.
- the trailing element of any such definition is that which attaches to the parent moiety.
- the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group
- the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.
- the term “optionally substituted” means the anteceding group may be substituted or unsubstituted.
- the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino
- Two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy.
- An optionally substituted group may be unsubstituted (e.g., —CH 2 CH 3 ), fully substituted (e.g., —CF 2 CF 3 ), monosubstituted (e.g., —CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., —CH 2 CF 3 ).
- R or the term R′ refers to a moiety chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted.
- aryl, heterocycle, R, etc. occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence.
- certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written.
- an unsymmetrical group such as —C(O)N(R)— may be attached to the parent moiety at either the carbon or the nitrogen.
- bonds refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.
- a bond may be single, double, or triple unless otherwise specified.
- a dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.
- treating refers to delaying the onset of, retarding or reversing the progress of, or alleviating or preventing either the disease or condition to which the term applies, or one or more symptoms of such disease or condition.
- patient means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits. Preferably, the patient is a human.
- disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one or more of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and/or causes the human or animal to have a reduced duration or quality of life.
- neuropsychiatric disorder includes, without limitation, psychological, psychiatric, and neurological disorders.
- HAND HIV associated neurocognitive disorder
- combination therapy means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
- administering means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
- Administration is by any route including parenteral, and transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal).
- Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
- Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like.
- prodrug refers to a precursor compound that, following administration, releases the biologically active compound in vivo via some chemical or physiological process (e.g., a prodrug on reaching physiological pH or through enzyme action is converted to the biologically active compound).
- controlled release sustained release
- extended release extended release
- timed release any drug-containing formulation in which release of the drug is not immediate, i.e., with a “controlled release” formulation, oral administration does not result in immediate release of the drug into an absorption pool.
- controlled release as defined in Remington: The Science and Practice of Pharmacy , 21 st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2003).
- immediate and nonimmediate release can be defined kinetically by reference to the following equation:
- the “absorption pool” represents a solution of the drug administered at a particular absorption site, and k r , k a and k e are first-order rate constants for (1) release of the drug from the formulation, (2) absorption, and (3) elimination, respectively.
- the rate constant for drug release k r is far greater than the absorption rate constant k a .
- the opposite is true, i.e., k r ⁇ k a , such that the rate of release of drug from the dosage form is the rate-limiting step in the delivery of the drug to the target area.
- sustained release and “extended release” are used in their conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, for example, 12 hours or more, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period.
- delayed release refers to a pharmaceutical preparation that passes through the stomach intact and dissolves in the small intestine.
- MLK3 inhibitor is used herein to refer to a compound that exhibits an IC 50 with respect to MLK3 activity of no more than about 100 ⁇ M and more typically not more than about 50 ⁇ M, as measured in the MLK3 (assay name) described generally hereinbelow.
- IC 50 is that concentration of inhibitor which reduces the activity and/or expression of an enzyme (e.g., MLK or MLK3) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit inhibition against MLK3.
- compounds will exhibit an IC50 with respect to MLK3 of no more than about 10 ⁇ M; in further embodiments, compounds will exhibit an IC 50 with respect to MLK3 of no more than about 5 ⁇ M; in yet further embodiments, compounds will exhibit an IC 50 with respect to MLK3 of not more than about 1 ⁇ M; in yet further embodiments, compounds will exhibit an IC 50 with respect to MLK3 of not more than about 200 nM, as measured in the MLK3 assay described herein.
- terapéuticaally effective is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder. This amount will achieve the goal of reducing or eliminating the said disease or disorder.
- terapéuticaally acceptable refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- prodrug refers to a compound that is made more active in vivo.
- Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003).
- Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound.
- prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
- a wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
- An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
- Prodrugs of compounds of Formula I are provided herein.
- Prodrugs of compounds provided herein include, but are not limited to, carboxylate esters, carbonate esters, hemi-esters, phosphorus esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo compounds, phosphamides, glycosides, ethers, acetals, and ketals.
- Prodrug esters and carbonates may be formed, for example, by reacting one or more hydroxyl groups of compounds of Formula I or Formula II with alkyl, alkoxy or aryl substituted acylating reagents using methods known to those of skill in the art to produce methyl carbonates, acetates, benzoates, pivalates and the like.
- prodrug esters of the compounds provided herein include, but are not limited to, compounds of Formula I having a carboxyl moiety wherein the free hydrogen is replaced by C 1 -C 4 alkyl, C 1 -C 7 alkanoyloxymethyl, 1-((C 1 -C 5 )alkanoyloxy)ethyl, 1-methyl-1-((C 1 -C 5 )alkanoyloxy)-ethyl, C 1 -C 5 alkoxycarbonyloxymethyl, 1-((C 1 -C 5 )alkoxycarbonyloxy)ethyl, 1-methyl-1-((C 1 -C 5 )alkoxycarbonyloxy)ethyl, N—((C 1 -C 5 )alkoxycarbonyl)aminomethyl, 1-(N—((C 1 -C 5 )alkoxycarbonyl)amino)ethyl, 3-phthalidyl, 4-crotonolactony
- Oligopeptide modifications and biodegradable polymer derivatives are within the scope of the present disclosure.
- Methods for selecting and preparing suitable prodrugs are provided, for example, in the following: T. Higuchi and V. Stella, “Prodrugs as Novel Delivery Systems,” Vol. 14, ACS Symposium Series, 1975; H. Bundgaard, “Design of Prodrugs,” Elsevier, 1985; and “Bioreversible Carriers in Drug Design,” ed. Edward Roche, American Pharmaceutical Association and Pergamon Press, 1987.
- the compounds disclosed herein can exist as therapeutically acceptable salts.
- the present invention includes compounds disclosed herein in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable.
- Pharmaceutical Salts Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
- terapéuticaally acceptable salt represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein.
- the salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid.
- Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenyl
- basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
- acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion.
- the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
- Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
- a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
- the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N-dibenzylethylenediamine.
- Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
- isotopically-substituted or -labeled compounds of Formula I wherein one or more atoms are replaced by one or more atoms having specific atomic mass or mass numbers.
- isotopes that can be incorporated into compounds disclosed herein include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 18 F, 35 S and 36 Cl).
- isotopically-labeled compounds of Formula I and prodrugs thereof, as well as isotopically-labeled, pharmaceutically acceptable salts of compounds of Formula I and prodrugs thereof, are herein disclosed.
- Isotopically-labeled compounds are useful in assays of the tissue distribution of the compounds and their prodrugs and metabolites; preferred isotopes for such assays include 3 H and 14 C.
- preferred isotopes for such assays include 3 H and 14 C.
- substitution with heavier isotopes, such as deuterium ( 2 H) can provide increased metabolic stability, which offers therapeutic advantages such as increased in vivo half-life or reduced dosage requirements.
- Isotopically-labeled compounds and prodrugs thereof can generally be prepared according to the methods described herein by substituting an isotopically-labeled reagent for a non-isotopically labeled reagent.
- the present invention provides methods of preparing compounds of Formula I, that are based on the synthetic protocols outlined in Schemes 1 through 21 as well as methods well known by persons skilled in the art, and the more detailed particular examples presented below in the experimental section describing the examples.
- the compounds can be readily prepared by the use of chemical reactions and procedures known to those of skill in the art.
- the variables e.g., R groups
- denoting groups in the general methods described below have the meanings as hereinbefore defined.
- compounds can be prepared from other compounds disclosed herein by elaboration, transformation, exchange and the like of the functional groups present.
- elaboration includes, but is not limited to, hydrolysis, reduction, oxidation, alkylation, acylation, esterification, amidation and dehydration.
- transformations can in some instances require the use of protecting groups by the methods disclosed in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis ; Wiley: New York, (1999), and incorporated herein by reference. Such methods would be initiated after synthesis of the desired compound or at another place in the synthetic route that would be readily apparent to one skilled in the art.
- compositions which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients.
- the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen.
- compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- a compound as provided herein can be incorporated into a variety of formulations for therapeutic administration, including solid, semi-solid, liquid or gaseous forms.
- the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
- these methods include the step of bringing into association a compound or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients.
- active ingredient a compound or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof
- the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- oral formulations in the form of powders and granules containing one or more compounds disclosed herein.
- the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
- sterile liquid carrier for example, saline or sterile pyrogen-free water
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner.
- Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
- systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
- Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
- the active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.
- compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray.
- Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the compounds may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
- the powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
- a compound is prepared for delivery in a sustained-release, controlled release, extended-release, timed-release or delayed-release formulation, for example, in semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
- sustained-release materials have been established and are well known by those skilled in the art.
- Current extended-release formulations include film-coated tablets, multiparticulate or pellet systems, matrix technologies using hydrophilic or lipophilic materials and wax-based tablets with pore-forming excipients (see, for example, Huang, et al. Drug Dev. Ind. Pharm. 29:79 (2003); Pearnchob, et al. Drug Dev. Ind. Pharm. 29:925 (2003); Maggi, et al.
- Sustained-release delivery systems can, depending on their design, release the compounds over the course of hours or days, for instance, over 4, 6, 8, 10, 12, 16, 20, 24 hours or more.
- sustained release formulations can be prepared using naturally-occurring or synthetic polymers, for instance, polymeric vinyl pyrrolidones, such as polyvinyl pyrrolidone (PVP); carboxyvinyl hydrophilic polymers; hydrophobic and/or hydrophilic hydrocolloids, such as methylcellulose, ethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose; and carboxypolymethylene.
- polymeric vinyl pyrrolidones such as polyvinyl pyrrolidone (PVP); carboxyvinyl hydrophilic polymers
- hydrophobic and/or hydrophilic hydrocolloids such as methylcellulose, ethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose
- carboxypolymethylene for instance, polymeric vinyl pyrrolidones, such as polyvinyl pyrrolidone (PVP); carboxyvinyl hydrophilic polymers; hydrophobic and/or hydrophilic hydrocolloids,
- the sustained or extended-release formulations can also be prepared using natural ingredients, such as minerals, including titanium dioxide, silicon dioxide, zinc oxide, and clay (see, U.S. Pat. No. 6,638,521, herein incorporated by reference).
- Exemplified extended release formulations that can be used in delivering a compound include those described in U.S. Pat. Nos. 6,635,680; 6,624,200; 6,613,361; 6,613,358, 6,596,308; 6,589,563; 6,562,375; 6,548,084; 6,541,020; 6,537,579; 6,528,080 and 6,524,621, each of which is hereby incorporated herein by reference.
- Controlled release formulations of particular interest include those described in U.S. Pat. Nos.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- the agents can be formulated into ointments, creams, salves, powders or gels.
- the transdermal delivery agent can be DMSO.
- Transdermal delivery systems can include, e.g., patches.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Exemplified transdermal delivery formulations that can find use with the compounds disclosed herein include those described in U.S. Pat. Nos. 6,589,549; 6,544,548; 6,517,864; 6,512,010; 6,465,006; 6,379,696; 6,312,717 and 6,310,177, each of which are hereby incorporated herein by reference.
- the precise amount of compound administered to a patient will be the responsibility of the attendant physician.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity.
- the dosage can be increased or decreased over time, as required by an individual patient. A patient initially may be given a low dose, which is then increased to an efficacious dosage tolerable to the patient. Typically, a useful dosage for adults may be from 5 to 2000 mg, but have been known to range from 0.1 to 500 mg/kg per day.
- a dose may range from 1 to 200 mg, when administered by oral route; or from 0.1 to 100 mg or, in certain embodiments, 1 to 30 mg, when administered by intravenous route; in each case administered, for example, from 1 to 4 times per day.
- a useful dosage of the combination partner may be from 20% to 100% of the normally recommended dose, since, as discussed below, even doses of a given drug which would be subtherapeutic if administered on its own may be therapeutic when used in combination with another agent.
- Dosage amount and interval can be adjusted individually to provide plasma levels of the active compounds which are sufficient to maintain therapeutic effect.
- therapeutically effective serum levels will be achieved by administering single daily doses, but efficacious multiple daily dose schedules may be used as well.
- the effective local concentration of the drug may not be related to plasma concentration.
- the compounds described herein may be administered in combination with another therapeutic agent.
- another therapeutic agent such as a pharmaceutically acceptable salt, ester, or prodrug thereof.
- the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
- the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
- another therapeutic agent which also includes a therapeutic regimen
- increased therapeutic benefit may result by also providing the patient with another therapeutic agent for dementia or inflammation.
- the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
- combination therapies include use of certain compounds disclosed herein with compounds used for treating diseases and conditions which can be affected by SGLT inhibition, such as antidiabetic agents, lipid-lowering/lipid-modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure, atherosclerosis or related disorders.
- diseases and conditions which can be affected by SGLT inhibition, such as antidiabetic agents, lipid-lowering/lipid-modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure, atherosclerosis or related disorders.
- the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.
- agents to be used in combination with compounds disclosed herein include lithium, valproate and other agents used in neuroprotection, PAF receptor antagonists, antioxidants including mitochondrially-targeted antioxidants, activators of SIRTI and other sirtuins, inhibitors of indoleamine 2,3 dehydrogenase (IDO), agents which enhance trans-blood brain bather (BBB) uptake of drugs, including compounds that inhibit drug pumps at the BBB such as, for example, ritonavir; HAART drugs and other agents for use in HIV treatment; agents for the treatment of cardiovascular, heart, and metabolic disorders, such as HMG-CoA reductase inhibitors including statins, insulin and insulin mimetics, and glycogen synthase kinase-3 beta (GSK3 ⁇ ) inhibitors; agents which “normalize” mitochondrial function; antiinflammatory agents including PAF receptor antagonists or PAF acetylhydrolase, cyclooxygenase inhibitors (including COX-2 selective and nonselective) such as
- agents for neuroprotection and/or neurogenesis include selective serotonin reuptake inhibitors SSRIs and small molecule agonists of neurotrophin receptors.
- Any of the aforementioned agents may be combined with viral vectors that express genes intended to induce neural progenitor cells, as well.
- Treatment with the compounds disclosed here in may also be effective when delivered along with deep-brain stimulation, such as in Parkinsonism and HIV-associated dementia/HIV-associated neurocognitive disorder.
- certain embodiments provide methods for treating MLK3-mediated disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, in combination with at least one additional agent for the treatment of said disorder that is known in the art.
- certain embodiments provide therapeutic compositions comprising at least one compound disclosed herein in combination with one or more additional agents for the treatment of MLK3-mediated disorders.
- Specific diseases to be treated by the compounds, compositions, and methods disclosed herein include: metabolic diseases such as type 1 and type 2 diabetes mellitus, hyperglycemia, diabetic complications (such as retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease), insulin resistance, metabolic syndrome (Syndrome X), hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, hepatic steatosis, non-alcoholic steatohepatitis (NASH), chronic heart failure, and atherosclerosis.
- metabolic diseases such as type 1 and type 2 diabetes mellitus, hyperglycemia, diabetic complications (such as retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease), insulin resistance, metabolic syndrome (Syndrome X), hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia
- Compounds disclosed herein may also be useful for the treatment of inflammatory diseases such as bacterial sepsis, otitis media, endotoxemia, mucosal hyperplasia, inflammatory bowel disease, Crohn's disease, irritable bowel syndrome, and ulcerative colitis; and respiratory diseases and conditions such as asthma, chronic obstructive pulmonary disease (COPD), and acute inhalation-induced lung injury.
- inflammatory diseases such as bacterial sepsis, otitis media, endotoxemia, mucosal hyperplasia, inflammatory bowel disease, Crohn's disease, irritable bowel syndrome, and ulcerative colitis
- respiratory diseases and conditions such as asthma, chronic obstructive pulmonary disease (COPD), and acute inhalation-induced lung injury.
- COPD chronic obstructive pulmonary disease
- Compounds disclosed herein may also be useful for the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, lupus and Crohn's disease.
- Compounds disclosed herein may also be useful for the treatment of proliferative disorders including cancers such as liver cancer. Furthermore, Compounds disclosed herein may also be useful for the treatment of hepatitis, including viral hepatitis, and non-alcoholic steatohepatitis (NASH).
- hepatitis including viral hepatitis, and non-alcoholic steatohepatitis (NASH).
- NASH non-alcoholic steatohepatitis
- Compounds disclosed herein may also be useful for the treatment of ischemic injury, including stroke, cerebral ischemia/reperfusion, myocardial infarction, and ischemic heart disease.
- Compounds disclosed herein may also be useful for the treatment of diseases and disorders of the nervous system such as Alzheimer's Disease (AD), Parkinson's Disease, HIV dementia, HIV associated neurocognitive disorder (HAND), neuroinflammatory diseases, and neuropathies including drug-induced peripheral neuropathy, and diabetic neuropathy, and HIV-associated neuropathy, ototoxicity and hearing loss, acute insults to the inner ear, including acoustic trauma, blast noise (for example, as experienced by military personnel), exposure to ototoxic chemotherapeutic agents for cancer therapy (such as cisplatin) and treatment with aminoglycoside antibiotics.
- AD Alzheimer's Disease
- Parkinson's Disease HIV dementia
- neuroinflammatory diseases and neuropathies including drug-induced peripheral neuropathy, and diabetic neuropathy, and HIV-associated neuropathy, ototoxicity and hearing loss
- acute insults to the inner ear including acoustic trauma, blast noise (for example, as experienced by military personnel), exposure to ototoxic chemotherapeutic agents for cancer
- Compounds disclosed herein may also be useful for the treatment of pain including inflammatory pain, neuropathic pain, back pain including discogenic pain, the pain of arthritis and autoimmune disorders such as rheumatoid arthritis, and cancer pain including pain due to bone metastasis.
- Compounds disclosed herein may also be useful for the treatment of psychological disorders including depression or major depressive disorder (MDD), bipolar disorder, and post-traumatic stress disorder.
- MDD major depressive disorder
- bipolar disorder bipolar disorder
- post-traumatic stress disorder a disorder that is characterized by depression or major depressive disorder (MDD), bipolar disorder, and post-traumatic stress disorder.
- Compounds disclosed herein may also be useful for enhancement of stem-cell based therapies in the central nervous system (CNS).
- CNS central nervous system
- LC-MS/UV/ELS analysis was performed on instrumentation consisting of Shimadzu LC-LOAD vp series HPLC pumps and dual wavelength IJV detector, a Gilson 215 autosampler, a Sedex 75c evaporative light scattering (ELS) detector, and a PE/Sciex API 150EX mass spectrometer.
- the ELS detector was set to a temperature of 40° C., a gain setting of 7, and a N3 pressure of 3.3 atm.
- the Turbo IonSpray source was employed on the API 150 with an ion spray voltage of 5 kV, a temperature of 300° C., and orifice and ring voltages of 5 V and 175 V respectively. Positive ions were scanned in Q1 from 160 to 650 m/z. 5.0 ⁇ L injections were performed for each sample, on a Phenomenex Gemini 5 ⁇ m C18 column. Mobile phases consisted of 0.05% formic acid in both HPLC grade water (A) and HPLC grade acetonitrile (B).
- Compound F was prepared by a method analogous to that described in Example 1 by substituting 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B.
- Compound T was prepared by a method analogous to that described in Example 1 by substituting 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 1H-indol-5-ylboronic acid in the reaction with Intermediate A.
- Compound W was prepared by a method analogous to that described in Example 1 by substituting 2-aminopyrimidin-5-ylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 2-aminopyrimidin-5-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B.
- HPLC retention time 1.17 minutes.
- Compound X was prepared by a method analogous to that described in Example 1 by substituting 6-(dimethylamino)pyridin-3-ylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 6-(dimethylamino)pyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B.
- HPLC retention time 1.17 minutes.
- Compound Z was prepared by a method analogous to that described in Example 1 by substituting 4-aminophenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 6-aminopyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 0.68 minutes. MS ESI (m/z): 302.4 (M+H)+, talc. 301.
- Compound AC was prepared by a method analogous to that described in Example 1 by substituting 4-carbamoylphenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 3,4-dimethoxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B.
- HPLC retention time 1.60 minutes.
- Compound AD was prepared by a method analogous to that described in Example 1 by substituting 4-carbamoylphenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 4-amino-3-methoxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.46 minutes. MS ESI (m/z): 359.2 (M+H) + , calc. 358.
- Compound AE was prepared by a method analogous to that described in Example 1 by substituting 4-carbamoylphenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B.
- HPLC retention time 1.13 minutes.
- Compound AF was prepared by a method analogous to that described in Example 1 by substituting 3-chloro-4-fluorophenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.47 minutes. MS ESI (m/z): 339.4 (M+H) + , calc. 338.
- Compound AL was prepared by a method analogous to that described in Example 33 by substituting dimethylamine (2 M solution in THF) for 1-methylpiperazine in the reaction with intermediate T. HPLC retention time: 1.66 minutes. MS ESI (m/z): 367.4 (M+H) + , calc. 366.
- Compound AP was prepared by a method analogous to that described in Example 36 by substituting 2-(dimethylamino)ethanol for 2-(piperazin-1-yl)ethanol in the reaction with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol.
- HPLC retention time 1.20 minutes.
- Compound AZ was prepared by a method analogous to that described in Example 36 by substituting 4-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine for 1-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperazine and 2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine for intermediate B.
- HPLC retention time 1.59 minutes.
- N-bromosuccinimide (32.3 g, 181 mmol) in portions over a six hour period, during which time the temperature of the reaction was kept below 0° C.
- the resulting mixture was stored at 4° C. overnight, after which it was stirred vigorously and quenched with H 2 O (100 mL).
- Compound BE was prepared by a method analogous to that described in Example 1 by substituting 1-methyl-1H-indol-5-amine for 1H-indol-5-amine in the reaction with Intermediate BA to prepare 6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one.
- Compound BG was prepared by a method analogous to that described in Example 3 by substituting 3,5-dimethylphenylboronic acid for 4-hydroxyphenylboronic acid in the reaction with 6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one. 1.6 mg recovered. HPLC retention time: 3.04 minutes MS ESI (m/z): 370.2 (M+H) + , calc. 369.
- Compound BH was prepared by a method analogous to that described in Example 1 by substituting pyridin-4-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Compound BC. 1.6 mg recovered. HPLC retention time: 1.10 minutes. MS ESI (m/z): 329.4 (M+H) + , calc. 328.
- Examples 47-119 shown in Table 3 below, were synthesized in parallel according to procedures given below in Schemes 7 and 8, using the reagents in Tables 1 and 2.
- Examples 47-118 were physically characterized by electrospray ionization mass spectrometry. Structures and molecular masses are given below in Table 3.
- Example 119 was prepared by a method analogous to that described in Examples 68-118 by substituting 6 chloro-3,5-dibromopyrazin-2-amine for 3,5-dibromopyrazin-2-amine in the reaction with aminomethylcyclopropane. MS ESI (m/z): 390.83 calc
- intermediate 6 was coupled to indole-5-boronic acid using copper acetate in a mixture of DCM/pyridine, after which it was deprotected using TFA/CH 2 Cl 2 .
- 3-Pyridin-4-ylmethyl-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one was prepared by a method analogous to that described in Example 135.
- the title compound (14 mg, 61%) was obtained after silica gel chromatography eluting with 0-8% MeOH:DCM.
- 4- ⁇ 3-[3-(4-Carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl ⁇ -piperazine-1-carboxylic acid tert-butyl ester was prepared by a method analogous to that described in Example 148 by substituting 4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-carboxylic acid tert-butyl ester for 4-[3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-carboxylic acid tert-butyl ester.
- hydrochloride salt of 4- ⁇ 5-[3-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl ⁇ -benzamide was prepared by a method analogous to that described in Example 149 by substituting 4- ⁇ 4-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl ⁇ -piperazine-1-carboxylic acid tert-butyl ester for 4- ⁇ 3-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl ⁇ -piperazine-1-carboxylic acid tert-butyl ester.
- N-Methyl-4- ⁇ 5-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl ⁇ -benzamide was prepared by a method analogous to that described in Example 164 by substituting 3,4,5-trimethoxyphenylboronic acid for 1-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-piperazine. Purification by precipitation from hot DCM yielded the title compound (46 mg, 51%).
- Compounds disclosed herein may be evaluated in pharmacokinetic assays and models to determine absorption, distribution, metabolism, and excretion parameters.
- the choice and tailoring of in vitro and ex vivo assays and in vivo models will vary according to the route of administration/formulation, indication under study, properties of test compounds, etc., as well as according to such factors as costs, availability of technology and resources, etc.
- Such parameters are well known in the fields of pharmacology and drug development. It is within the capacity of one skilled in the art to design and carry out, such work, or to outsource it to a capable third party.
- Compounds were administered via a single intravenous (IV) injection in CL57 BL/6 mice at 10 mg/kg in DMSO/PEG400 solution. Three mice in each group were used for blood and brain collection at each time point. Blood samples (300 ⁇ L) were collected via the retro-orbital vein predose and at 5 min, 0.25, 0.50, 1, 2, 4, 6, 8, and 24 hours postdose.
- Blood samples were placed into tubes containing sodium heparin and centrifuged under refrigerated conditions at 8000 rpm for 6 minutes to separate plasma from the samples.
- the brain of each animal was collected after the final blood collection.
- the whole tissue was harvested, excised and rinsed by saline, dried by filter paper, and then placed into one tube per tissue per animal. All samples were stored at ⁇ 20° C. until bioanalysis.
- HPLC/MS/MS high performance liquid chromatography/mass spectrometry
- AUC Plasma AUC Brain + indicates ⁇ 1500 + indicates ⁇ 500
- Ex. ⁇ indicates ⁇ 1500 ⁇ indicates ⁇ 500 1 + + 4 ⁇ ⁇ 9 + + 17 + ⁇ 18 + ⁇ 32 + + +
- CB-17/IcrCrl-SCIDbr CB17/SCID mice
- HIVE mice HIVE mice
- Vehicle only serves as the control.
- CB17/SCID mice receive intracranial (i.c.) injections of media (sham-operated) and serve as additional controls.
- Animals are treated with vehicle or test compound (i.e., a compound as disclosed herein) starting 1 d post-i.c, injection and for 7 d after MDM injections and test compound treatments. Dosing parameters, number per group, etc. may be varied as needed, and such variations are within the skill of one skilled in the art.
- Brain tissue is collected at necropsy, fixed in 4% phosphate-buffered paraformaldehyde, and embedded in paraffin. Paraffin blocks are cut until the injection site of the human MDM is identified. HIV-1 p24 Ag (cloneKal-1; Dako, Carpinteria, Calif.) is used to test for virus-infected human MDM. For each mouse. 30-100 serial (5-mm-thick) sections are cut from the injection site and three to seven sections (10 sections apart) analyzed. Abs to vimentin intermediate filaments (clone VIM 3B4; Boehringer Mannheim, Indianapolis, Ind.) are used for detection of human cells in mouse brains.
- Mouse microglia are detected by Abs to Iba-1 (WAKO, Osaka, Japan), and astrocytes are detected by Abs for glial fibrillaryacidic protein ([GFAP] Dako).
- GFAP glial fibrillaryacidic protein
- H chain (200 kDa) neurofilaments (Dako) are used for detection of neurons. All sections are counterstained with Mayer's hematoxylin. The numbers of human MDM and HIV-1 p24 Ag-positive cells are counted with a Nikon Microphot-FXA microscope. All obtained images are imported into Image-Pro Plus, v.
- MLK inhibitors will exhibit a dose-dependent reduction in microgliosis and restoration of normal synaptic architecture relative to control animals. Compounds disclosed herein can be tested according to this method and are expected to exhibit similar results.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
Description
- This application claims the benefit of U.S. Provisional Applications No. 61/117,950, filed Nov. 25, 2008, No. 61/148,755 filed Jan. 30, 2009, and No. 61/148,778 filed Jan. 30, 2009, all of which are incorporated by reference as if written herein in their entireties.
- This research has been funded in part by NIH Grant No: NIH P01 3MH64570.
- Mammalian protein kinases are involved in the regulation of important cellular functions. Due to the fact that dysfunctions in protein kinase activity have been associated with several diseases and disorders, protein kinases are targets for drug development.
- Mixed lineage kinases (MLKs) are MAPK kinase kinases that target JNK and p38 MAPK for activation in response to diverse stimuli that stress cells. As a result, the MLKs regulate a broad range of cellular processes. MLK3 is the most widely expressed MLK family member and is present in neurons. It is activated by GTPases of the Ras superfamily, such as Cdc42 and Rac, which trigger protein dimerization via a leucine zipper interface, resulting in auto-phosphorylation at Thr277 and Ser281 within the protein activation loop and subsequent activation of the enzyme.
- Preclinical studies of the mixed lineage kinase (MLK) inhibitor CEP1347 have shown that this agent can protect neurons against a considerable range of insults, including exposure to the Alzheimer's peptide, Aβ. Studies using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsonism have demonstrated the efficacy of CEP1347 in treating motor deficits and neuronal degeneration, and CEP1347-mediated neuroprotection has also been observed in an in vitro model for Parkinson's Disease, using methamphetamine-exposed human mesencephalic-derived neurons. This finding suggests that CEP1347 might also be protective in the context of neurologic complications such as HIV-associated dementia (HAD). In fact, Bodner et al. have shown that CEP1347 can protect primary rat hippocampal neurons as well as dorsal root ganglion neurons from the otherwise lethal effects of exposure to HIV-1 gp120. It has been determined that CEP1347 mediates this effect by inhibiting the activity of the mixed lineage kinase (MLK) family.
- Maggirwar et al. recently examined the effect of Tat and gp120 on MLK3. Tat and gp120 were shown to induce autophosphorylation of MLK3 in primary rat neurons and this was abolished by the addition of CEP1347. These studies suggest that the normal function of MLK3 is compromised by HIV-1 neurotoxins, resulting in the downstream signaling events that result in neuronal death and monocyte activation (with release of inflammatory cytokines). Most recently, Eggert et al. have demonstrated that CEP1347 is neuroprotective in an in vivo model of HIV-1 infection, reversing microglial activation and restoring normal synaptic architecture, as well as restoring macrophage secretory profiles to a trophic vs. toxic phenotype in response to HIV-1 infection. Eggert, D., Gorantla, S., Poluekova, L., Dou, H. Schifitto, G., Maggirwar, S. B., Dewhurst. S., Gelbard, H. A. and H. E. Gendelman: “Neuroprotective Activities of CEP-1347 in Models of HIV-1 Encephalitis,” J. Immunol. (in press).]
- Recently, MLK3 has been shown to drive the production of the HIV virus. As a result, several lines of evidence now support that an inhibitor of MLK3 could serve as a treatment for numerous neurological conditions, including neuroAIDS. CEP1347 does not have ideal pharmacokinetic properties, which could potentially affect its ability to gain entry to the CNS. Other small molecule MLK3 inhibitors are needed that have improved pharmacokinetic and brain penetrating properties.
- An inhibitor of MLK3 could also find use in the treatment of psychological disorders. Depression is a complex disease that has a multifactorial etiology. This may include genetic factors, changes in normal neuronal signaling, and reduced levels of certain neurotrophins (such as brain-derived neurotrophic factor, BDNF) within particular regions of the brain (Krishnan, V., and E. J. Nestler. 2008. Nature 455:894-902). Treatments for depression include drugs such as SSRIs, as well as cognitive and behavioral therapy (“talk therapy”) and other inventions such as exercise. Interestingly, SSRIs and exercise share the common property that they promote neurogenesis; this is thought to be related to their anti-depressive effects because of effects on neuronal plasticity and remodeling (Krishnan, supra).
- Pharmacologic blockade of mixed lineage kinase 3 (MLK3) has been shown to result in activation of neurotrophin-mediated signaling pathways, and increased expression of neurotrophin receptors—resulting in enhanced responsiveness to endogenous neurotrophins, including BDNF (Wang, L. H., A. J. Paden, and E. M. Johnson, Jr. 2005. J Pharmacol Exp Ther 312:1007-19). MLK3 inhibitors have also been shown to increase production of BDNF itself (Conforti, P. et al. 2008. Mol Cell Neurosci 39:1-7).
- Combined treatment with SSRIs and MLK3 inhibitors could result in the synergistic promotion of neurogenesis, due to the neurotrophin-sensitizing effects of MLK3 inhibitors and their ability to directly upregulate BDNF (Wang and Conforti, supra). Increase of the therapeutic effectiveness of SSRIs (and possibly talk therapy and exercise also) could also result if the compounds were coadministered.
- Exposure to MLK3 inhibitors may also compensate for lowered BDNF levels in hippocampus of persons with depression, thereby alleviating depression (based on the “BDNF hypothesis”) (Krishnan, supra).
- Disclosed herein are compounds having an inhibitory effect on MLK1, MLK2, and MLK3. In a related aspect, also disclosed herein are compounds of Formula I as described below. Thus, provided herein are novel compounds that can be used for therapeutic methods involving modulation of MLKs. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions affected by MLK inhibition.
- In one aspect, the present invention provides for compounds of Formula I:
- wherein:
- dashed lines indicate that a second bond may alternatively be present or absent;
- X1 is chosen from CH and N;
- X2 is chosen from C and N;
- Y1 is —(CR6aR6b)m—Z1—(CR7aR7b)n—;
- Y2 is —(CR8aR8b)p—Z2—(CR9aR9b)q—;
- Y3 is —(CR10aR10b)r—Z3—(CR11aR11b)s—;
- Y4 is —(CH2)1—Z4—;
- Z1, Z2, and Z3, are each independently chosen from a bond, O, S, S(O), S(O)2, N(R12), C(O), C(O)N(R12), N(R12)C(O), S(O)2N(R12), and N(R12)S(O)2;
- Z4 is chosen from a bond, 0, and N;
- m, n, p, q, r, and s are each independently an integer from 0 to 6;
- t is an integer from 0 to 2;
- R1, R2, and R3 are independently chosen from hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl, amido, amino, alkoxy, hydroxy, cyano, and nitro, any of which may be optionally substituted; or R1 and R2 may each additionally be heteroalkyl, and may be joined together such that R1 and R2 together form an alkylene, alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms, which may be optionally substituted;
- R4 is chosen from hydrogen, (O), (S), halogen, hydroxy, cyano, nitro, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyloxy, lower thioalkoxy, lower heterocycloalkyl, aryl, lower aralkyl, lower heteroaryl, lower heteroaralkyl, amido, acyl, amino, and lower alkoxy, any of which may be optionally substituted; or R3 and R4 may each additionally be heteroalkyl, and may be joined together such that R1 and R2 together form an alkylene, alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms, which may be optionally substituted;
- R5 and R13 are each independently chosen from hydrogen, halogen, hydroxy, cyano, nitro, lower alkyl, lower alkene, lower alkyne, lower aryl, lower arylalkyl, lower cycloalkyl, lower cycloalkylalkyl, lower heteroaryl, lower heteroarylalkyl, lower heterocycloalkyl, lower heterocycloalkylalkyl, and lower alkoxy, any of which may be optionally substituted; and additionally, R13 and R3 may be joined together to form a lower spiro-cycloalkyl or spiro-phenyl comprising from 3 to 6 atoms, which may be optionally substituted;
- R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, and R12 are each independently chosen from a bond, hydrogen, halogen, hydroxy, C1-C3 alkoxy and C1-C3 alkyl; and
- R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- When, for example, Y1 is —(CR6aR6b)m—Z1—(CR7R7b)n—, and m and n are both 0, and Z1 is a bond, then Y1 collapses to a direct bond linking the parent ring system with R1. This applies to all similar constructions used herein, including Y2 and Y3. Also, when for example Y1 is —(CR6aR6b)m—Z1—(CR7aR7b)n—, the rightmost portion of Y1 attaches to the parent molecule.
- In certain embodiments, Y1, Y2, Y3, and Y4 are no more than 6 atoms in length.
- In certain embodiments, R4 is chosen from hydrogen, (O), and (S).
- In certain embodiments, R4 is (O), the second bond linking R4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent.
- In certain embodiments, R4 is hydrogen, the second bond linking R4 and the fused bicyclic core is absent, and the second bond in the five-membered portion of the fused bicyclic core is present.
- In certain embodiments,
- X1 is CH; and
- X2 is C.
- In certain embodiments,
- X1 is N; and
- X2 is N.
- In certain embodiments,
- X1 is CH; and
- X2 is N.
- In certain embodiments,
- X1 is N; and
- X2 is C.
- In certain embodiments,
- m and n are both 0;
- Z1 is a bond; and
- R1 and R5 are both hydrogen.
- In certain embodiments,
- p and r are each independently an integer from 0 to 3;
- q and s are each 0; and
- Z2 and Z3 are each independently chosen from a bond and 0.
- In certain embodiments, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, and R12 are all hydrogen.
- In certain embodiments, compounds have structural Formula II
- wherein:
- dashed lines indicate that a second bond may alternatively be present or absent;
- X1 is chosen from CH and N;
- X2 is chosen from C and N;
- Y1, Y2, and Y3 are independently chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
- Y4 is chosen from —(CH2)m, C(O), —(CH2)mO—, and —(CH2)mN—;
- m is an integer from 0 to 2;
- R1, R2, and R3 are independently chosen from lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl, amido, amino, alkoxy, hydroxy, cyano, and nitro, any of which may be optionally substituted; or R1 and R2 may each additionally be heteroalkyl, and may be joined together such that R1 and R2 together form an alkylene, alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms, which may be optionally substituted;
- R4 is chosen from hydrogen, (O), and (S);
- R5 is chosen from hydrogen, hydroxy, cyano, lower alkyl, lower cycloalkyl, and lower alkoxy, any of which may be optionally substituted;
- R13 is chosen from hydrogen, halogen, hydroxy, cyano, nitro, lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower alkoxy, any of which may be optionally substituted; and additionally, R13 and R3 may be joined together to form a lower spiro-cycloalkyl or spiro-phenyl comprising from 3 to 6 atoms, which may be optionally substituted; and
- R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- In certain embodiments, compounds have structural Formula III
- wherein:
- dashed lines indicate that a second bond may alternatively be present or absent;
- X1 and X2 are independently chosen from CH and N;
- Y3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
- Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
- m is an integer from 0 to 1;
- R2 and R3 are independently chosen from lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl, any of which may be optionally substituted;
- R4 is chosen from hydrogen, (O), and (S);
- R13 is chosen from hydrogen, lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower alkoxy, any of which may be optionally substituted;
- R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- In certain embodiments, compounds have a structural Formula chosen from Formula IV and Formula V:
- wherein:
- X1 and X2 are independently chosen from CH and N;
- Y3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
- Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
- m is an integer from 0 to 1;
- R2 and R3 are independently chosen from lower cycloalkyl, lower heterocycloalkyl, lower aryl, and lower heteroaryl, any of which may be optionally substituted; and
- R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- In certain embodiments, compounds have a structural Formula chosen from Formula VI, Formula VII, Formula VIII, and Formula IX:
- wherein
- Y3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
- Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
- m is an integer from 0 to 1;
- R2 is chosen from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused bicyclic heteroaryl, any of which may be optionally substituted;
- R3 is chosen from lower cycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted;
- R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
- In certain embodiments, R2 and R3 are each independently chosen from lower cycloalkyl, lower aryl, and monocyclic or bicyclic heteroaryl, any of which may be optionally substituted.
- In certain embodiments, R2 is substituted with one or more substituents chosen from halogen, hydroxy, lower amino, C1-C3 alkoxy and C1-C3 alkyl.
- In further embodiments, R2 is chosen from phenyl and lower heteroaryl, any of which may be optionally substituted.
- In further embodiments, R2 is chosen from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused bicyclic heteroaryl, any of which may be optionally substituted.
- In further embodiments, R2 is chosen from phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally substituted.
- In further embodiments, R2 is substituted with one or more substituents chosen from fluorine, hydroxy, NH2, NH(CH3), N(CH3)2, methoxy, and methyl.
- In further embodiments, R2 is optionally substituted phenyl.
- In further embodiments, R2 is chosen from
- wherein
- u is an integer from 0 to 3;
- Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
- m is an integer from 0 to 1;
- R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted; and
- each R15 is independently chosen from halogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, lower amino, lower amido, lower sulfonamido, and lower sulfonyl.
- In certain embodiments, R14 is chosen from piperazinyl, pyrrolyl, and N(CH3)2.
- In certain embodiments, each R15 is independently chosen from R15 is independently chosen from fluorine, hydroxy, NH2, NH(CH3), N(CH3)2, NS(O)2CH3, methoxy, and methyl.
- In certain embodiments,
- Y4 is —(CH2)m—;
- m is 0;
- R14 is null;
- u is an integer from 0 to 3; and
- R15 is independently chosen from R15 is independently chosen from fluorine, hydroxy, NH2, NH(CH3), N(CH3)2, NS(O)2CH3, methoxy, and methyl.
- In certain embodiments, Y4 is chosen from C(O), O, N, and —CH2—.
- In certain embodiments, Y4 is —CH2—.
- In certain embodiments, Y3 is chosen from a bond and lower alkyl.
- In certain embodiments, Y3 is chosen from a bond and methyl.
- In certain embodiments, Y3 is a bond.
- In certain embodiments, R3 is chosen from lower cycloalkyl, lower aryl, and monocyclic or bicyclic heteroaryl, any of which may be optionally substituted.
- In certain embodiments, R3 is substituted with one or more substituents chosen from halogen, hydroxy, lower amino, lower amido, lower phenylamido, lower phenylalkylamido, lower heterocycloalkyl, lowerheterocycloalkyl, loweralkylheterocycloalkyl, C1-C3 alkoxy and C1-C3 alkyl.
- In certain embodiments, R3 is chosen from benzothiazolyl, pyrrolopyridinyl, indanyl, cyclopropyl, cyclopentyl, phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally substituted.
- In certain embodiments, R3 is substituted with one or more substituents chosen from fluorine, chlorine, hydroxy, NH2, NH(CH3), N(CH3)2, C(O)NH2, C(O)NHCH3, morpholino, piperazinyl, methylpiperazinyl, acetamido, methylacetamido, methylpropionamido, phenylacetamidomethylene, benzamidomethylene, phenylpropanamidomethylene, methoxy and methyl.
- In certain embodiments are provided a compound of structural Formula III
- or a salt thereof, wherein:
- dashed lines indicate that a second bond may alternatively be present or absent;
- X1 and X2 are independently chosen from CH and N;
- Y3 is a bond;
- Y4 is chosen from C(O), CH2, CHF, and CF2;
- R2 is chosen from phenyl and 6-membered monocyclic heteroaryl, either of which may be optionally substituted;
- R3 is optionally substituted bicyclic heteroaryl;
- R4 is chosen from hydrogen, (O), and (S);
- R14 is optionally substituted monocyclic heterocycloalkyl.
- In certain embodiments, R3 is an optionally substituted 5/6-fused bicyclic heteroaryl.
- In certain embodiments, wherein Y4 is CH2.
- In certain embodiments, R14 is optionally substituted piperazinyl.
- In certain embodiments, R2 is chosen from hydrogen, halo, hydroxy, C1-C4 alkyl, C3-C10 cycloalkyl, C1-C4 alkyloxy, C3-C10 cycloalkyloxy, aryl, cyano or nitro.
- In certain embodiments, R1 and R2 together form a butadienylene bridge.
- In certain embodiments,
- m and n are both 0;
- Z1 is a bond;
- R1, R5, and R4 are hydrogen; and
- R2 and R3 are each independently chosen from aryl and heteroaryl, either of which may be optionally substituted.
- In certain embodiments,
- m and n are both 0;
- Z1 is a bond;
- R1, R5, and R4 are hydrogen;
- R2 is selected from the group consisting of aryl and heteroaryl, either of which may be optionally substituted; and
- R3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine.
- In certain embodiments,
- m is 0 or 1
- n is 0:
- Z1 is a bond;
- R1, R5, and R4 are hydrogen; and
- R1 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine; and
- R2 is chosen from 5-substituted-1,2,3-trimethoxybenzene, 4-substituted-1,2-dimethoxyphenyl, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine
- In certain embodiments,
- R1, R5, and R4 are hydrogen; and
- R2 and R3 are each independently chosen from aryl and heteroaryl, either of which may be optionally substituted.
- In certain embodiments of Formula I,
- m and n are both 0;
- Z1 is a bond;
- R1, R5, and R4 are hydrogen,
- R2 is chosen from aryl and heteroaryl, either of which may be optionally substituted; and
- R3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine, any of which may be optionally substituted.
- In certain embodiments of Formula I,
- m and n are both 0;
- Z1 is a bond;
- R1, R5, and R4 represent hydrogen,
- R3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine; and
- R2 is chosen from 5-substituted-1,2,3-trimethoxybenzene, 4-substituted-1,2-dimethoxybenzene, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine
- In certain embodiments,
- R4 is (O), the second bond linking R4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent;
- m and n are both 0;
- Z1 is a bond;
- R1 and R5 are each hydrogen; and
- R2 and R3 are each independently chosen from aryl and heteroaryl, either of which may be optionally substituted.
- In certain embodiments,
- R4 is (O), the second bond linking R4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent;
- m and n are both 0;
- Z1 is a bond;
- R1 and R5 are each hydrogen; and
- R2 is chosen from aryl and heteroaryl, either of which may be optionally substituted; and
- R3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine.
- In certain embodiments,
- R4 is (O), the second bond linking R4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent;
- m and n are both 0;
- Z1 is a bond;
- R1 and R5 are each hydrogen;
- R3 is chosen from 5-substituted-1H-indole, 5-substituted pyridine-2-amine, or 5-substituted pyrimidine-2-amine; and
- R4 is chosen from 5-substituted-1,2,3-trimethoxybenzene, 4-substituted-1,2-dimethoxybenzene, 5-substituted pyridine-2-amine, and 5-substituted pyrimidine-2-amine
- In certain embodiments, optionally substituted groups are substituted with one or more substituent chosen from halogen, hydroxy, C1-C3 alkoxy and C1-C3 alkyl.
- In certain embodiments, R4 is mono- or poly-substituted with fluorine.
- In certain embodiments, R5 is mono- or poly-substituted with fluorine.
- In certain embodiments is provided a compound chosen from Examples 1 to 167.
- Also provided herein is a compound as disclosed herein for use as a medicament.
- Also provided herein is a compound as disclosed herein for use as a medicament for the treatment of an MLK-mediated disease.
- Also provided herein is the use of a compound as disclosed herein in the manufacture of a medicament for the treatment of an MLK-mediated disease.
- Also provided herein is a pharmaceutical composition comprising a compound of Formula I together with a pharmaceutically acceptable carrier.
- Also provided is a pharmaceutical composition comprising a compound chosen from Examples 1 to 167.
- Also provided herein is a method of inhibition of MLK comprising contacting MLK with a compound of Formula I.
- In certain embodiments, said MLK is MLK3.
- In certain embodiments, said inhibition is selective over other kinases.
- Also provided herein is a method of treatment of a MLK-mediated disease comprising the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
- In certain embodiments, said disease is an inflammatory disease or a metabolic disease.
- In certain embodiments, said disease is chosen from diabetes mellitus, hyperglycemia, retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, peripheral inflammation, and HIV dementia.
- Also provided herein is a method of treatment of a MLK-mediated disease comprising the administration of:
- a) a therapeutically effective amount of a compound of Formula I; and
- b) another therapeutic agent.
- In certain embodiments, said disorder a psychological disorder.
- In certain embodiments, said disease is chosen from depression, bipolar disorder, and post-traumatic stress disorder (PTSD).
- In certain embodiments, said disorder is a traumatic brain injury.
- In certain embodiments, said traumatic brain injury is stroke.
- In certain embodiments, said disorder is chosen from Alzheimer's Disease (AD), Parkinson's Disease, HIV dementia and HIV associated neurocognitive disorder (HAND).
- In certain embodiments, said disorder is a neurologic disorder of hearing or vision.
- In certain embodiments, said disorder is chosen from ototoxicity, hearing loss, acute injury to the inner ear, acoustic trauma, and injury resulting from blast noise.
- In certain embodiments the methods of treatment disclosed herein additionally comprise the administration of a second therapeutic agent, as part of a therapeutic regimen. The compounds may be delivered in the same dosage form or separately, and further may be taken concurrently or one subsequent to the other.
- In certain embodiments, said second therapeutic agent is a selective serotonin reuptake inhibitor (SSRI).
- In certain embodiments, said second therapeutic agent is CEP1347.
- Also provided herein is a method of treatment of a MLK-mediated disease comprising the administration of:
- a) a therapeutically effective amount of a an MKL inhibitor; and
- b) another therapeutic agent.
- In certain embodiments, said second therapeutic agent is a selective serotonin reuptake inhibitor (SSRI).
- In certain embodiments, said second therapeutic agent is CEP1347.
- Also provided herein is a method of achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as disclosed herein to a patient, wherein the effect is chosen from:
-
- increased survival of cells of the nervous system, cochlear cells, vestibular cells or retinal cells;
- increased survival of heart cells;
- promotion of neurogenesis;
- promotion of synaptogenesis;
- prevention or reduction of neuronal damage;
- restoration or improvement of neuronal function;
- suppression of neuroinflammation or peripheral inflammation;
- suppression of activation of immune cells;
- suppression of proliferation of hepatocytes following injury; and suppression of proliferation of cancer cells.
- In certain embodiments, the effect is chosen from:
-
- increased survival of heart cells;
- suppression of neuroinflammation or peripheral inflammation;
- suppression of activation of immune cells;
- suppression of proliferation of hepatocytes following injury; and
- suppression of proliferation of cancer cells.
- In certain embodiments, said immune cells are chosen from monocytes, macrophages and microglia.
- In certain embodiments, the effect is chosen from:
-
- increased survival of cells of the nervous system, cochlear cells, vestibular cells or retinal cells;
- increased survival of heart cells;
- promotion of neurogenesis;
- promotion of synaptogenesis;
- prevention or reduction of neuronal damage;
- restoration or improvement of neuronal function;
- suppression of neuroinflammation or peripheral inflammation;
- suppression of activation of immune cells;
- suppression of proliferation of hepatocytes following injury; and
- suppression of proliferation of cancer cells.
- In certain embodiments, said immune cells are chosen from monocytes, macrophages and microglia.
- In certain embodiments, the effect is chosen from:
-
- increased survival of cells of the nervous system, cochlear cells, vestibular cells or retinal cells;
- promotion of neurogenesis;
- promotion of synaptogenesis;
- prevention or reduction of neuronal damage; and
- restoration or improvement of neuronal function.
- As used herein, the terms below have the meanings indicated.
- When ranges of values are disclosed, and the notation “from n1 . . . to n2” is used, where n1 and n2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 μM (micromolar),” which is intended to include 1 μM 3 μM, and everything in between to any number of significant figures (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).
- The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant figures.
- The term “acyl,” as used herein, alone or in combination, refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon. An “acetyl” group refers to a —C(O)CH3 group. An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.
- The term “alkenyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms. The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(—CH═CH—), (—C::C—)]. Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-propenyl, 2-methylpropenyl, butenyl, isobutenyl, 1,4-butadienyl, isoprenyl, vinyl, and the like. Unless otherwise specified, the term “alkenyl” may include “alkenylene” groups.
- The term “alkoxy,” as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as defined below. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.
- The term “alkyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, said alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, said alkyl will comprise from 1 to 6 carbon atoms. Alkyl groups may be optionally substituted as defined herein. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, noyl and the like. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH2—). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.
- The term “alkylamino,” as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino and the like.
- The term “alkylidene,” as used herein, alone or in combination, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.
- The term “alkylthio,” as used herein, alone or in combination, refers to an alkyl thioether (R—S—) radical wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized. Examples of suitable alkyl thioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.
- The term “alkynyl,” as used herein, alone or in combination, refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms. The term “alkynylene” refers to a carbon-carbon triple bond attached at two positions such as ethynylene (—C:::C—, —≡C—) Examples of alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, Butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like. Unless otherwise specified, the term “alkynyl” may include “alkynylene” groups.
- The terms “amido” and “carbamoyl,” as used herein, alone or in combination, refer to an amino group as described below attached to the parent molecular moiety through a carbonyl group, or vice versa. The term “C-amido” as used herein, alone or in combination, refers to a —C(O)N(RR′) group with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “N-amido” as used herein, alone or in combination, refers to a RC(O)N(R′)— group, with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “acylamino” as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group. An example of an “acylamino” group is acetylamino (CH3C(O)NH—).
- The term “amino,” as used herein, alone or in combination, refers to —NRR′, wherein R and R′ are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally. R and R′ may combine to form heterocycloalkyl, either of which may be optionally substituted.
- The term “aryl,” as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together. The term “aryl” embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.
- The term “arylalkenyl” or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
- The term “arylalkoxy” or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
- The term “arylalkyl” or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.
- The term “arylalkynyl” or “aralkynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
- The term “arylalkanoyl” or “aralkanoyl” or “aroyl,” as used herein, alone or in combination, refers to an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, naphthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.
- The term aryloxy as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an oxy.
- The terms “benzo” and “benz,” as used herein, alone or in combination, refer to the divalent radical C6H4=derived from benzene. Examples include benzothiophene and benzimidazole.
- The term “carbamate,” as used herein, alone or in combination, refers to an ester of carbamic acid (—NRC(O)O—) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein. The term “O-carbamyl” as used herein, alone or in combination, refers to a —OC(O)NRR′ group; and the term “N-carbamyl” as used herein, alone or in combination, refers to a ROC(O)NR′— group. R and R′ are as defined herein, or as defined by the specifically enumerated “R” groups designated.
- The term “carbonyl,” as used herein, when alone includes formyl [—C(O)H] and in combination is a —C(O)— group.
- The term “carboxyl” or “carboxy.” as used herein, refers to —C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt. An “O-carboxy” group refers to a RC(O)O— group, where R is as defined herein. A “C-carboxy” group refers to a —C(O)OR groups where R is as defined herein.
- The term “cyano,” as used herein, alone or in combination, refers to —CN.
- The term “cycloalkyl,” or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein. In certain embodiments, said cycloalkyl will comprise from 5 to 7 carbon atoms. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl and the like. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.
- The term “ester,” as used herein, alone or in combination, refers to a carboxy group bridging two moieties linked at carbon atoms.
- The term “ether,” as used herein, alone or in combination, refers to an oxy group bridging two moieties linked at carbon atoms.
- The term “halo,” or “halogen,” as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.
- The term “haloalkoxy,” as used herein, alone or in combination, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom. Haloalkoxy includes perhaloalkoxy. The term “perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms. An example of perhaloalkoxy is perfluoromethoxy.
- The term “haloalkyl,” as used herein, alone or in combination, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl, polyhaloalkyl, and perhaloalkyl radicals. A monohaloalkyl radical, for one example, may have an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. “Haloalkylene” refers to a haloalkyl group attached at two or more positions. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. “Haloalkylene” refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (—CFH—), difluoromethylene (—CF2—), chloromethylene (—CHCl—) and the like. The term “perhaloalkyl” as used herein, alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms. Examples include perfluoromethyl.
- The term “heteroalkyl,” as used herein, alone or in combination, refers to a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms chosen from O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3.
- The term “heteroaryl,” as used herein, alone or in combination, refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from O, S, and N. Additionally, a heteroaryl may contain one or two C(O), S(O), or S(O)2 groups as ring members. In certain embodiments, said heteroaryl will comprise from 5 to 10 atoms. In certain embodiments, said heteroaryl will comprise from 5 to 7 atoms. In certain embodiments, said heteroaryl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said heteroaryl will comprise from 1 to 2 heteroatoms as ring members. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, triazinyl, triazolyl, tetrazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.
- The terms “heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently chosen from N, O, and S. Additionally, a heterocycloalkyl may contain one or two C(O), S(O), or S(O)2 groups as ring members. In certain embodiments, said hetercycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said hetercycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said hetercycloalkyl will comprise from 3 to 8 ring members in each ring. In further embodiments, said hetercycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, said hetercycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group. Examples of heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihy-dropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. The heterocycle groups may be optionally substituted unless specifically prohibited.
- The term “hydroxy,” as used herein, alone or in combination, refers to —OH.
- The term “lower,” as used herein, alone or in a combination, where not otherwise specifically defined, means containing from 1 to and including 6 carbon atoms.
- The term “lower alkyl,” as used herein, alone or in a combination, means C1-C6 straight or branched chain alkyl. The term “lower alkenyl” means C2-C6 straight or branched chain alkenyl. The term “lower alkynyl” means C2-C6 straight or branched chain alkynyl.
- The term “lower aryl,” as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as provided.
- The term “lower heteroaryl,” as used herein, alone or in combination, means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four said members may be heteroatoms chosen from O, S, and N, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms chosen from O, S, and N.
- The term “lower cycloalkyl,” as used herein, alone or in combination, means a monocyclic cycloalkyl having between three and six ring members. Lower cycloalkyls may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- The term “lower heterocycloalkyl,” as used herein, alone or in combination, means a monocyclic heterocycloalkyl having between three and six ring members, of which between one and four may be heteroatoms chosen from O, S, and N. Examples of lower heterocycloalkyls include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower heterocycloalkyls may be unsaturated.
- The term “lower amino,” as used herein, alone or in combination, refers to NRR′, wherein R and R′ are independently chosen from hydrogen, lower alkyl, and lower heteroalkyl, any of which may be optionally substituted. Additionally, the R and R′ of a lower amino group may combine to form a five- or six-membered heterocycloalkyl, either of which may be optionally substituted.
- The term “nitro,” as used herein, alone or in combination, refers to —NO2.
- The terms “oxy” or “oxa,” as used herein, alone or in combination, refer to —O—.
- The term “oxo,” as used herein, alone or in combination, refers to ═O.
- The term “perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
- The term “perhaloalkyl” as used herein, alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
- The terms “sulfonate.” “sulfonic acid,” and “sulfonic.” as used herein, alone or in combination, refer the —SO3H group and its anion as the sulfonic acid is used in salt formation.
- The term “N-sulfonamido” refers to a RS(═O)2NR′— group with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- The term “S-sulfonamido” refers to a —S(═O)2NRR′, group, with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated.
- The terms “thia” and “thio,” as used herein, alone or in combination, refer to a —S— group or an ether wherein the oxygen is replaced with sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included in the definition of thia and thio. The term “sulfanyl,” as used herein, alone or in combination, refers to —S—. The term “sulfinyl,” as used herein, alone or in combination, refers to —S(O)—. The term “sulfonyl,” as used herein, alone or in combination, refers to —S(O)2—.
- The term “thiol,” as used herein, alone or in combination, refers to an —SH group.
- The term “thiocarbonyl,” as used herein, when alone includes thioformyl —C(S)H and in combination is a —C(S)— group.
- Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.
- When a group is defined to be “null,” what is meant is that said group is absent.
- The term “optionally substituted” means the anteceding group may be substituted or unsubstituted. When substituted, the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N3, SH, SCH3, C(O)CH3, CO2CH3, CO2H, pyridinyl, thiophene, furanyl, lower carbamate, and lower urea. Two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy. An optionally substituted group may be unsubstituted (e.g., —CH2CH3), fully substituted (e.g., —CF2CF3), monosubstituted (e.g., —CH2CH2F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., —CH2CF3). Where substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particular moiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted with.”
- The term R or the term R′, appearing by itself and without a number designation, unless otherwise defined, refers to a moiety chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted. Such R and R′ groups should be understood to be optionally substituted as defined herein. Whether an R group has a number designation or not, every R group, including R, R′ and Rn where n=(1, 2, 3, . . . n), every substituent, and every term should be understood to be independent of every other in terms of selection from a group. Should any variable, substituent, or term (e.g. aryl, heterocycle, R, etc.) occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence. Those of skill in the art will further recognize that certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written. Thus, by way of example only, an unsymmetrical group such as —C(O)N(R)— may be attached to the parent moiety at either the carbon or the nitrogen.
- Asymmetric centers exist in the compounds disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Compounds can be prepared using diastereomers, enantiomers or racemic mixtures as starting materials. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Furthermore, diastereomer and enantiomer products can be separated by chromatography, fractional crystallization or other methods known to those of skill in the art. Additionally, the compounds disclosed herein may exist as geometric isomers. The present invention includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. Additionally, compounds may exist as tautomers; all tautomeric isomers are provided by this invention. Solvates, hydrates, isomorphs, polymorphs are also provided. Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms.
- The term “bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. A bond may be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position. When, for example, Y1 is —(CR6aR6b)m—Z1—(CR7aR7b)n—, and m and n are both 0, and Z1 is a bond, then Y1 collapses to a direct bond linking the parent ring system with R1. This applies to all similar constructions used herein, including Y2 and Y3. Or, for example, when either of R6a and R6b of (CR6aR6b)m are designated to be “a bond,” and m≧1, then an additional bond forms between a C of (CR6aR6b) and an adjacent atom. When m≧2, then (CR6aR6b)m may form an alkene (alkenylene) or alkyne (alkynylene).
- As used herein, the terms “treating” and “treatment” refer to delaying the onset of, retarding or reversing the progress of, or alleviating or preventing either the disease or condition to which the term applies, or one or more symptoms of such disease or condition.
- The term “patient” (and, equivalently, “subject”) means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits. Preferably, the patient is a human.
- The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one or more of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and/or causes the human or animal to have a reduced duration or quality of life.
- The term “neuropsychiatric disorder” includes, without limitation, psychological, psychiatric, and neurological disorders.
- The term “HIV associated neurocognitive disorder (HAND)” is related to, and is intended to be substantially synonymous with, the terms HIV dementia, AIDS dementia, HIV encephalopathy, and NeuroAIDS.
- The term “combination therapy” means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
- As used herein, the term “administering” means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route including parenteral, and transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like.
- As used herein, the term “prodrug” refers to a precursor compound that, following administration, releases the biologically active compound in vivo via some chemical or physiological process (e.g., a prodrug on reaching physiological pH or through enzyme action is converted to the biologically active compound).
- The terms “controlled release,” “sustained release,” “extended release,” and “timed release” are intended to refer interchangeably to any drug-containing formulation in which release of the drug is not immediate, i.e., with a “controlled release” formulation, oral administration does not result in immediate release of the drug into an absorption pool. The terms are used interchangeably with “nonimmediate release” as defined in Remington: The Science and Practice of Pharmacy, 21st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2003). As discussed therein, immediate and nonimmediate release can be defined kinetically by reference to the following equation:
-
- The “absorption pool” represents a solution of the drug administered at a particular absorption site, and kr, ka and ke are first-order rate constants for (1) release of the drug from the formulation, (2) absorption, and (3) elimination, respectively. For immediate release dosage forms, the rate constant for drug release kr is far greater than the absorption rate constant ka. For controlled release formulations, the opposite is true, i.e., kr<<ka, such that the rate of release of drug from the dosage form is the rate-limiting step in the delivery of the drug to the target area.
- The terms “sustained release” and “extended release” are used in their conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, for example, 12 hours or more, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period.
- As used herein, the term “delayed release” refers to a pharmaceutical preparation that passes through the stomach intact and dissolves in the small intestine.
- “MLK3 inhibitor” is used herein to refer to a compound that exhibits an IC50 with respect to MLK3 activity of no more than about 100 μM and more typically not more than about 50 μM, as measured in the MLK3 (assay name) described generally hereinbelow. “IC50” is that concentration of inhibitor which reduces the activity and/or expression of an enzyme (e.g., MLK or MLK3) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit inhibition against MLK3. In certain embodiments, compounds will exhibit an IC50 with respect to MLK3 of no more than about 10 μM; in further embodiments, compounds will exhibit an IC50 with respect to MLK3 of no more than about 5 μM; in yet further embodiments, compounds will exhibit an IC50 with respect to MLK3 of not more than about 1 μM; in yet further embodiments, compounds will exhibit an IC50 with respect to MLK3 of not more than about 200 nM, as measured in the MLK3 assay described herein.
- The phrase “therapeutically effective” is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder. This amount will achieve the goal of reducing or eliminating the said disease or disorder.
- The term “therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound. Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
- Prodrugs of compounds of Formula I are provided herein. Prodrugs of compounds provided herein include, but are not limited to, carboxylate esters, carbonate esters, hemi-esters, phosphorus esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo compounds, phosphamides, glycosides, ethers, acetals, and ketals. Prodrug esters and carbonates may be formed, for example, by reacting one or more hydroxyl groups of compounds of Formula I or Formula II with alkyl, alkoxy or aryl substituted acylating reagents using methods known to those of skill in the art to produce methyl carbonates, acetates, benzoates, pivalates and the like. Illustrative examples of prodrug esters of the compounds provided herein include, but are not limited to, compounds of Formula I having a carboxyl moiety wherein the free hydrogen is replaced by C1-C4 alkyl, C1-C7 alkanoyloxymethyl, 1-((C1-C5)alkanoyloxy)ethyl, 1-methyl-1-((C1-C5)alkanoyloxy)-ethyl, C1-C5 alkoxycarbonyloxymethyl, 1-((C1-C5)alkoxycarbonyloxy)ethyl, 1-methyl-1-((C1-C5)alkoxycarbonyloxy)ethyl, N—((C1-C5)alkoxycarbonyl)aminomethyl, 1-(N—((C1-C5)alkoxycarbonyl)amino)ethyl, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N—(C1-C2)alkylamino(C2-C3)alkyl (e.g., beta-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl. Oligopeptide modifications and biodegradable polymer derivatives (as described, for example, in Int. J. Pharm. 115, 61-67, 1995) are within the scope of the present disclosure. Methods for selecting and preparing suitable prodrugs are provided, for example, in the following: T. Higuchi and V. Stella, “Prodrugs as Novel Delivery Systems,” Vol. 14, ACS Symposium Series, 1975; H. Bundgaard, “Design of Prodrugs,” Elsevier, 1985; and “Bioreversible Carriers in Drug Design,” ed. Edward Roche, American Pharmaceutical Association and Pergamon Press, 1987.
- The compounds disclosed herein can exist as therapeutically acceptable salts. The present invention includes compounds disclosed herein in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
- The term “therapeutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
- Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
- Also provided herein are isotopically-substituted or -labeled compounds of Formula I, wherein one or more atoms are replaced by one or more atoms having specific atomic mass or mass numbers. Examples of isotopes that can be incorporated into compounds disclosed herein include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 18F, 35S and 36Cl). Isotopically-labeled compounds of Formula I and prodrugs thereof, as well as isotopically-labeled, pharmaceutically acceptable salts of compounds of Formula I and prodrugs thereof, are herein disclosed. Isotopically-labeled compounds are useful in assays of the tissue distribution of the compounds and their prodrugs and metabolites; preferred isotopes for such assays include 3H and 14C. In addition, in certain circumstances substitution with heavier isotopes, such as deuterium (2H), can provide increased metabolic stability, which offers therapeutic advantages such as increased in vivo half-life or reduced dosage requirements. Isotopically-labeled compounds and prodrugs thereof can generally be prepared according to the methods described herein by substituting an isotopically-labeled reagent for a non-isotopically labeled reagent.
- In other aspects, provided herein are intermediates and processes useful for preparing the intermediates below as well as the compounds of Formula I, and pharmaceutically acceptable salts and prodrugs thereof.
- In a similar manner, the present invention provides methods of preparing compounds of Formula I, that are based on the synthetic protocols outlined in Schemes 1 through 21 as well as methods well known by persons skilled in the art, and the more detailed particular examples presented below in the experimental section describing the examples. By following the general preparative methods discussed below, or employing variations or alternative methods, the compounds can be readily prepared by the use of chemical reactions and procedures known to those of skill in the art. Unless otherwise specified, the variables (e.g., R groups) denoting groups in the general methods described below have the meanings as hereinbefore defined.
- Those of skill in the art will recognize that compounds with each described functional group are generally prepared using slight variations of the below-listed general methods. Within the scope of each method, functional groups which are suitable to the reaction conditions are used. Functional groups which might interfere with certain reactions are presented in protected forms where necessary, and the removal of such protective groups is completed at appropriate stages by methods well known to those skilled in the art.
- In certain cases compounds can be prepared from other compounds disclosed herein by elaboration, transformation, exchange and the like of the functional groups present. Such elaboration includes, but is not limited to, hydrolysis, reduction, oxidation, alkylation, acylation, esterification, amidation and dehydration. Such transformations can in some instances require the use of protecting groups by the methods disclosed in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis; Wiley: New York, (1999), and incorporated herein by reference. Such methods would be initiated after synthesis of the desired compound or at another place in the synthetic route that would be readily apparent to one skilled in the art.
- In another aspect, provided herein are synthetic intermediates useful for preparing the compounds of Formula I, and pharmaceutically acceptable salts and prodrugs thereof, according to the general preparative methods discussed below and other processes known to those of skill in the art.
- When the following abbreviations and acronyms are used throughout the disclosure, they have the following meanings: CDCl3, chloroform-d; CH2Cl2, methylene chloride; CH3CN, acetonitrile; DIPEA, N,N-diisopropylethylamine; DMAP, 4-dimethylaminopyridine; DMF, N,N-dimethylformamide; DMSO, dimethylsulfoxide; Et, ethyl; Et3N, triethylamine; EtOAc (or AcOEt), ethyl acetate; EtOH, ethanol; h, hour; HCl, hydrochloric acid; 1H NMR, proton nuclear magnetic resonance; H2SO4, sulfuric acid; HPLC, high performance liquid chromatography; K2CO3, potassium carbonate; KOH, potassium hydroxide; LC-MS, liquid chromatography—mass spectroscopy; Me, methyl; MeOH, methanol; min, minute; MS ESI, mass spectroscopy with electrospray ionization; MsOH, methanesulfonic acid; NaH, sodium hydride; NaHCO3, sodium bicarbonate; NaOH, sodium hydroxide; Na2SO4, sodium sulfate; NBS, N-bromosuccinimide; NCS, N-chlorosuccinimide; NH3, ammonia; NIS, N-iodosuccinimide; Pd/C, palladium on carbon; Pd(PPh3)4, tetrakis(triphenylphosphine)palladium(0); Rf, retention factor; TBAF, tetrabutylammonium fluoride; TBAI, tetrabutylammonium iodide; TBDMS, t-butyldimethylsilyl; Tf2O, trifluoromethanesulfonic anhydride; TFA, trifluoroacetic acid; THF, tetrahydrofuran; TLC, thin layer chromatography; TMS, trimethylsilyl; TMSCN, trimethylsilyl cyanide; TsOH, toluenesulfonic acid.
- While it may be possible for compounds to be administered as the raw chemical, it is also possible to present them as a pharmaceutical formulation. Accordingly, provided herein are pharmaceutical formulations which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington: The Science and Practice of Pharmacy, 21st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2003). The pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- A compound as provided herein can be incorporated into a variety of formulations for therapeutic administration, including solid, semi-solid, liquid or gaseous forms. The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
- Pharmaceutical preparations which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
- Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. Also provided are oral formulations in the form of powders and granules containing one or more compounds disclosed herein.
- The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
- The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
- Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.
- For administration by inhalation, compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
- In one embodiment, a compound is prepared for delivery in a sustained-release, controlled release, extended-release, timed-release or delayed-release formulation, for example, in semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established and are well known by those skilled in the art. Current extended-release formulations include film-coated tablets, multiparticulate or pellet systems, matrix technologies using hydrophilic or lipophilic materials and wax-based tablets with pore-forming excipients (see, for example, Huang, et al. Drug Dev. Ind. Pharm. 29:79 (2003); Pearnchob, et al. Drug Dev. Ind. Pharm. 29:925 (2003); Maggi, et al. Eur. J. Pharm. Biopharm. 55:99 (2003); Khanvilkar, et al., Drug Dev. Ind. Pharm. 228:601 (2002); and Schmidt, et al., Int. J. Pharm. 216:9 (2001)). Sustained-release delivery systems can, depending on their design, release the compounds over the course of hours or days, for instance, over 4, 6, 8, 10, 12, 16, 20, 24 hours or more. Usually, sustained release formulations can be prepared using naturally-occurring or synthetic polymers, for instance, polymeric vinyl pyrrolidones, such as polyvinyl pyrrolidone (PVP); carboxyvinyl hydrophilic polymers; hydrophobic and/or hydrophilic hydrocolloids, such as methylcellulose, ethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose; and carboxypolymethylene.
- The sustained or extended-release formulations can also be prepared using natural ingredients, such as minerals, including titanium dioxide, silicon dioxide, zinc oxide, and clay (see, U.S. Pat. No. 6,638,521, herein incorporated by reference). Exemplified extended release formulations that can be used in delivering a compound include those described in U.S. Pat. Nos. 6,635,680; 6,624,200; 6,613,361; 6,613,358, 6,596,308; 6,589,563; 6,562,375; 6,548,084; 6,541,020; 6,537,579; 6,528,080 and 6,524,621, each of which is hereby incorporated herein by reference. Controlled release formulations of particular interest include those described in U.S. Pat. Nos. 6,607,751; 6,599,529; 6,569,463; 6,565,883; 6,482,440; 6,403,597; 6,319,919; 6,150,354; 6,080,736; 5,672,356; 5,472,704; 5,445,829; 5,312,817 and 5,296,483, each of which is hereby incorporated herein by reference. Those skilled in the art will readily recognize other applicable sustained release formulations.
- Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. For topical administration, the agents can be formulated into ointments, creams, salves, powders or gels. In one embodiment, the transdermal delivery agent can be DMSO. Transdermal delivery systems can include, e.g., patches. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Exemplified transdermal delivery formulations that can find use with the compounds disclosed herein include those described in U.S. Pat. Nos. 6,589,549; 6,544,548; 6,517,864; 6,512,010; 6,465,006; 6,379,696; 6,312,717 and 6,310,177, each of which are hereby incorporated herein by reference.
- The precise amount of compound administered to a patient will be the responsibility of the attendant physician. The specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity. The dosage can be increased or decreased over time, as required by an individual patient. A patient initially may be given a low dose, which is then increased to an efficacious dosage tolerable to the patient. Typically, a useful dosage for adults may be from 5 to 2000 mg, but have been known to range from 0.1 to 500 mg/kg per day. By way of example, a dose may range from 1 to 200 mg, when administered by oral route; or from 0.1 to 100 mg or, in certain embodiments, 1 to 30 mg, when administered by intravenous route; in each case administered, for example, from 1 to 4 times per day. When a compound is administered in combination with another therapeutic agent, a useful dosage of the combination partner may be from 20% to 100% of the normally recommended dose, since, as discussed below, even doses of a given drug which would be subtherapeutic if administered on its own may be therapeutic when used in combination with another agent.
- Dosage amount and interval can be adjusted individually to provide plasma levels of the active compounds which are sufficient to maintain therapeutic effect. In certain embodiments, therapeutically effective serum levels will be achieved by administering single daily doses, but efficacious multiple daily dose schedules may be used as well. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration. One having skill in the art will be able to optimize therapeutically effective local dosages without undue experimentation. Additionally, applicable methods for determining an appropriate dose and dosing schedule for administration of compounds such as those disclosed herein are described, for example, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th Ed., Brunton, Lazo and Parker, Eds., McGraw-Hill (2006), and in Remington: The Science and Practice of Pharmacy, 21st Ed., Gennaro, Ed. Lippencott Williams & Wilkins (2003), both of which are hereby incorporated herein by reference.
- In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt, ester, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the compounds herein is hypertension, then it may be appropriate to administer an anti-hypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. By way of example only, in a treatment for HIV dementia involving administration of one of the compounds described herein, increased therapeutic benefit may result by also providing the patient with another therapeutic agent for dementia or inflammation. In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
- Specific, non-limiting examples of possible combination therapies include use of certain compounds disclosed herein with compounds used for treating diseases and conditions which can be affected by SGLT inhibition, such as antidiabetic agents, lipid-lowering/lipid-modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure, atherosclerosis or related disorders.
- In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.
- Examples of agents to be used in combination with compounds disclosed herein include lithium, valproate and other agents used in neuroprotection, PAF receptor antagonists, antioxidants including mitochondrially-targeted antioxidants, activators of SIRTI and other sirtuins, inhibitors of indoleamine 2,3 dehydrogenase (IDO), agents which enhance trans-blood brain bather (BBB) uptake of drugs, including compounds that inhibit drug pumps at the BBB such as, for example, ritonavir; HAART drugs and other agents for use in HIV treatment; agents for the treatment of cardiovascular, heart, and metabolic disorders, such as HMG-CoA reductase inhibitors including statins, insulin and insulin mimetics, and glycogen synthase kinase-3 beta (GSK3β) inhibitors; agents which “normalize” mitochondrial function; antiinflammatory agents including PAF receptor antagonists or PAF acetylhydrolase, cyclooxygenase inhibitors (including COX-2 selective and nonselective) such as aspirin, ibuprofen, naproxen, and celecoxib; and agents for blocking liver cell proliferation, such as JNK inhibitors.
- Also provided are combinations of multiple agents, such as lithium plus a GSK3β blocker, to be used in combination with the compounds provided herein.
- Additionally, agents for neuroprotection and/or neurogenesis include selective serotonin reuptake inhibitors SSRIs and small molecule agonists of neurotrophin receptors.
- Any of the aforementioned agents may be combined with viral vectors that express genes intended to induce neural progenitor cells, as well.
- Treatment with the compounds disclosed here in may also be effective when delivered along with deep-brain stimulation, such as in Parkinsonism and HIV-associated dementia/HIV-associated neurocognitive disorder.
- Thus, in another aspect, certain embodiments provide methods for treating MLK3-mediated disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, in combination with at least one additional agent for the treatment of said disorder that is known in the art. In a related aspect, certain embodiments provide therapeutic compositions comprising at least one compound disclosed herein in combination with one or more additional agents for the treatment of MLK3-mediated disorders.
- Specific diseases to be treated by the compounds, compositions, and methods disclosed herein include: metabolic diseases such as type 1 and type 2 diabetes mellitus, hyperglycemia, diabetic complications (such as retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease), insulin resistance, metabolic syndrome (Syndrome X), hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, hepatic steatosis, non-alcoholic steatohepatitis (NASH), chronic heart failure, and atherosclerosis.
- Compounds disclosed herein may also be useful for the treatment of inflammatory diseases such as bacterial sepsis, otitis media, endotoxemia, mucosal hyperplasia, inflammatory bowel disease, Crohn's disease, irritable bowel syndrome, and ulcerative colitis; and respiratory diseases and conditions such as asthma, chronic obstructive pulmonary disease (COPD), and acute inhalation-induced lung injury.
- Compounds disclosed herein may also be useful for the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, lupus and Crohn's disease.
- Compounds disclosed herein may also be useful for the treatment of proliferative disorders including cancers such as liver cancer. Furthermore, Compounds disclosed herein may also be useful for the treatment of hepatitis, including viral hepatitis, and non-alcoholic steatohepatitis (NASH).
- Compounds disclosed herein may also be useful for the treatment of ischemic injury, including stroke, cerebral ischemia/reperfusion, myocardial infarction, and ischemic heart disease.
- Compounds disclosed herein may also be useful for the treatment of diseases and disorders of the nervous system such as Alzheimer's Disease (AD), Parkinson's Disease, HIV dementia, HIV associated neurocognitive disorder (HAND), neuroinflammatory diseases, and neuropathies including drug-induced peripheral neuropathy, and diabetic neuropathy, and HIV-associated neuropathy, ototoxicity and hearing loss, acute insults to the inner ear, including acoustic trauma, blast noise (for example, as experienced by military personnel), exposure to ototoxic chemotherapeutic agents for cancer therapy (such as cisplatin) and treatment with aminoglycoside antibiotics. Compounds disclosed herein may also be useful for the treatment of traumatic brain injury including stroke.
- Compounds disclosed herein may also be useful for the treatment of pain including inflammatory pain, neuropathic pain, back pain including discogenic pain, the pain of arthritis and autoimmune disorders such as rheumatoid arthritis, and cancer pain including pain due to bone metastasis.
- Compounds disclosed herein may also be useful for the treatment of psychological disorders including depression or major depressive disorder (MDD), bipolar disorder, and post-traumatic stress disorder.
- Compounds disclosed herein may also be useful for enhancement of stem-cell based therapies in the central nervous system (CNS).
- All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications can be made thereto without departing from the spirit or scope of the invention.
- The invention is further illustrated by the following examples, which are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters, which can be changed or modified to yield essentially the same results.
- The structures of compounds synthesized in the examples below were confirmed using the following procedures. LC-MS/UV/ELS analysis was performed on instrumentation consisting of Shimadzu LC-LOAD vp series HPLC pumps and dual wavelength IJV detector, a Gilson 215 autosampler, a Sedex 75c evaporative light scattering (ELS) detector, and a PE/Sciex API 150EX mass spectrometer. The ELS detector was set to a temperature of 40° C., a gain setting of 7, and a N3 pressure of 3.3 atm. The Turbo IonSpray source was employed on the API 150 with an ion spray voltage of 5 kV, a temperature of 300° C., and orifice and ring voltages of 5 V and 175 V respectively. Positive ions were scanned in Q1 from 160 to 650 m/z. 5.0 μL injections were performed for each sample, on a Phenomenex Gemini 5 μm C18 column. Mobile phases consisted of 0.05% formic acid in both HPLC grade water (A) and HPLC grade acetonitrile (B). 5.0 injections were performed for each sample, using gradient elution from 5% B to 100% B in 4 min at a flow rate of 2.0 mL/min with a final hold at 100% B of 1.8 min UV and ELS data is collected for 4.5 min Routine one-dimensional NMR spectroscopy was performed on a 300 MHz Varian Mercury-Plus spectrometer. The samples were dissolved in deuterated solvents obtained from Cambridge Isotope Laboratories, Inc., and transferred to 5 mm ID NMR tubes. The spectra were acquired at 293 K. The chemical shifts were recorded on the ppm scale and were referenced to the appropriate solvent signals, such as 2.49 ppm for DMSO-d6, 1.93 ppm for CD3CN, 3.30 ppm for CD3OD, 5.32 ppm for CD3Cl3 and 7.26 ppm for CDCl3 for 1H spectra.
- Other equipment and techniques standard in the art of chemical analysis and characterization may be used.
-
-
- To a stirred solution of 5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine (0.70 g, 2.2 mmol) in 15 mL of anhydrous THF cooled to 0° C. with an ice bath was added NaH [60% dispersion in mineral oil] (0.13 g, 3.3 mmol). The reaction mixture was stirred for 20 min at 0° C., after which p-toluenesulfonyl chloride (0.47 g, 2.4 mmol) was added. The resulting mixture was stirred at 0° C. for 1.5 hr, after which cold 0.5 M HCl (20 mL) was added. The mixture was partitioned between EtOAc and 0.5 M HCl, after which the organic layer was separated, dried over MgSO4, filtered, and evaporated in vacuo to yield a residue that was triturated with 20% CH2Cl2 in hexanes to yield the title compound (0.84 g, 81%) as a light yellow powder. 1H NMR (DMSO-d6, 300 MHz) δ 8.51 (d, J=2.1 Hz, 1H), 8.22 (s, 1H), 8.02 (d, J=1.2 Hz, 1H), 8.00 (d, J=5.1 Hz, 2H), 7.44 (dd, J=8.7 Hz, 0.6 Hz, 2H), 2.35 (s, 3H); MS ESI (m/z): 477.0/479.0 (M+1)+, calc. 476.
-
- To a stirred suspension of 5-bromo-3-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine (0.35 g, 0.73 mmol) and 1H-indol-5-ylboronic acid (0.14 mg, 0.88 mmol) in CH3CN (10 mL) was added 1 M Na2CO3 (10 mL) followed by bis(triphenylphosphine)palladium(II) dichloride (0.050 g, 0.071 mmol). The resulting mixture was stirred overnight at 60° C. After the mixture was evaporated to dryness in vacuo, it was dissolved in DMF (3 m, absorbed onto Celite, and dried. The residue was purified via silica gel chromatography using CH2Cl2 as the eluent to obtain the title compound (0.26 g, 76%). 1H NMR (CDCl3, 300 MHz): δ 8.48 (d, J=2.1 Hz, 1H), 8.27 (bs, 1H), 8.26 (d, J=2.4 Hz, 1H), 8.08 (d, J=8.1 Hz), 7.85 (s, 1H), 7.81 (m, 1H), 7.50 (d, J=8.7 Hz, 1H), 7.37 (dd, J=1.8, 8.4 Hz), 7.30 (m, 3H), 6.63 (m, 1H), 2.39 (s, 3H); MS ESI (m/z): 466.2/468.2 (M+1)+, calc. 465.
-
- To a solution of 5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (65 mg, 0.14 mmol) in CH3CN (1 mL) in a Personal Chemistry microwave reaction vial was added 3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol), bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and concentrated in vacuo. The residue was dissolved in MeOH (3 mL) and acetone (2 mL), and 2 M NaOH (1.5 mL) was added. The resulting mixture was stirred at 65° C. for 30 min, after which it was partitioned between EtOAc and 1 M NaOH. The organic layer was separated, dried over MgSO4, filtered, and stripped to give a residue purified via preparatory HPLC to give the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 11.78 (s, 1H), 11.03 (s, 1H), 8.51 (d, J=2.1 Hz, 1H), 8.36 (d, J=1.8 Hz, 1H), 7.86 (s, 1H), 7.72 (d, J=2.4 Hz, 1H). 7.45 (s, 2H), 7.32 (m, 1H), 6.92 (s, 2H), 6.45 (m, 1H), 3.85 (s, 6H), 3.70 (s, 3H); HPLC retention time: 2.04 minutes; MS ESI (m/z): 400.4 (M+1)+, calc. 399.
-
- Compound D was prepared by a method analogous to that described in Example 1 by substituting 3,4-dimethoxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 2.33 minutes. MS ESI (m/z): 370.2 (M+H)+, calc. 369.
-
- Compound E was prepared by a method analogous to that described in Example 1 by substituting 4-acetamidophenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.86 minutes. MS ESI (m/z): 367.4 (M+H)+, calc. 366.
-
- Compound F was prepared by a method analogous to that described in Example 1 by substituting 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. 1H NMR (DMSO-d6, 300 MHz): δ 11.73 (d, J=1.8 Hz, 1H), 11.05 (s, 1H), 8.43 (d, J=2.4 Hz, 1H), 8.29 (d, J=1.8 Hz, 1H), 8.27 (d, J=2.1 Hz, 1H), 7.88 (s, 1H), 7.76 (dd, J=2.4, 8.4 Hz, 1H), 7.46 (s, 2H), 7.33 (m, 1H), 6.55 (dd, J=0.6, 8.7 Hz, 1H), 6.46 (m, 1H), 5.99 (s, 2H). HPLC retention time: 1.10 minutes. MS ESI (m/z): 326.2 (M+H)÷, calc. 325.
-
- Compound G was prepared by a method analogous to that described in Example 1 by substituting 4-amino-3-methoxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.54 minutes. MS ESI (m/z): 355.4 (M+H)+, calc. 354.
-
- Compound H was prepared by a method analogous to that described in Example 1 by substituting 6-methoxypyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 2.16 minutes. MS ESI (m/z): 341.4 (M+H)+, calc. 340.
-
- Compound I was prepared by a method analogous to that described in Example 1 by substituting 2-(4-methylpiperazin-1-yl)pyridin-4-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.37 minutes. MS ESI (m/z): 409.4 (M+H)+, calc. 408.
-
- Compound J was prepared by a method analogous to that described in Example 1 by substituting 4-aminophenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.47 minutes. MS ESI (m/z): 325.4 (M+H)+, calc. 324.
-
- Compound K was prepared by a method analogous to that described in Example 1 by substituting 2-aminopyrimidin-5-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.81 minutes. MS ESI (m/z): 327.2 (M+H)+, calc. 326.
-
- Compound L was prepared by a method analogous to that described in Example 1 by substituting 6-(piperazin-1-yl)pyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.15 minutes. MS ESI (m/z) 395.4 (M+H)+, calc. 394.
-
- Compound M was prepared by a method analogous to that described in Example 1 by substituting 4-(methylsulfonamido)phenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.99 minutes. MS ESI (m/z): 403.4 (M+H)+, talc. 402.
-
- Compound N was prepared by a method analogous to that described in Example 1 by substituting 1H-indol-5-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 2.01 minutes. MS ESI (m/z): 349.2 (M+H)+, talc. 348.
-
- Compound O was prepared by a method analogous to that described in Example 1 by substituting 6-(dimethylamino)pyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 1.58 minutes. MS ESI (m/z): 354.4 (M+H)+, calc. 353.
-
- Compound P was prepared by a method analogous to that described in Example 1 by substituting phenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate B. HPLC retention time: 2.49 minutes. MS ESI (m/z): 310.2 (M+H)+, calc. 309.
-
- Compound Q was prepared by a method analogous to that described in Example 1 by substituting 4-aminophenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A. HPLC retention time: 1.45 minutes. MS ESI (m/z): 376.4 (M+H)+, calc. 375.
-
- Compound R was prepared by a method analogous to that described in Example 1 by substituting 4-acetamidophenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A. HPLC retention time: 1.98 minutes. MS ESI (m/z): 418.6 (M+H)+, calc. 417.
-
- Compound S was prepared by a method analogous to that described in Example 1 by substituting 2-aminopyrimidin-5-ylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A. HPLC retention time: 1.98 minutes. MS ESI (m/z): 378.4 (M+H)+, calc. 377.
-
- Compound T was prepared by a method analogous to that described in Example 1 by substituting 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 1H-indol-5-ylboronic acid in the reaction with Intermediate A. 1H NMR (DMSO-d6, 300 MHz): δ 11.82 (s, 1H), 8.53 (d, J=1.8 Hz, 1H), 8.31 (d, J=1.8, 1 H), 8.28 (d, J=1.5 Hz), 7.76 (dd, J=2.1, 8.4 Hz, 1H), 7.70 (d, J=2.4 Hz, 1H), 6.95 (s, 2H), 6.54 (d, J=8.4 Hz, 1H), 5.87 (s, 2H), 3.86 (s, 6H), 3.68 (s, 3H); HPLC retention time: 1.10 minutes. MS ESI (m/z): 377.4 (M+H)+, calc. 376.
-
- Compound U was prepared by a method analogous to that described in Example 1 by substituting 6-(dimethylamino)pyridin-3-ylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A. HPLC retention time: 1.43 minutes. MS ESI (m/z): 405.6 (M+H)+, calc. 404.
-
- Compound W was prepared by a method analogous to that described in Example 1 by substituting 2-aminopyrimidin-5-ylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 2-aminopyrimidin-5-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.17 minutes. MS ESI (m/z): 305.2 (M+H)+, calc. 304.
-
- Compound X was prepared by a method analogous to that described in Example 1 by substituting 6-(dimethylamino)pyridin-3-ylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 6-(dimethylamino)pyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.17 minutes. MS ESI (m/z): 359.4 (M+H) calc. 358.
-
- Compound Y was prepared by a method analogous to that described in Example 1 by substituting 3-chloro-4-fluorophenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 6-(dimethylamino)pyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.73 minutes. MS ESI (m/z): 367.2 (M+H)+, calc. 366.
-
- Compound Z was prepared by a method analogous to that described in Example 1 by substituting 4-aminophenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 6-aminopyridin-3-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 0.68 minutes. MS ESI (m/z): 302.4 (M+H)+, talc. 301.
-
- Compound AA was prepared by a method analogous to that described in Example 1 by substituting 1-methyl-1H-indol-5-ylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A. HPLC retention time: 2.29 minutes. MS ESI (m/z): 414.4 (M+H) talc. 413.
-
- Compound AB was prepared by a method analogous to that described in Example 1 by substituting 4-carbamoylphenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A. HPLC retention time: 1.64 minutes. MS ESI (m/z): 404.6 (M+H)+, calc. 403.
-
- Compound AC was prepared by a method analogous to that described in Example 1 by substituting 4-carbamoylphenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 3,4-dimethoxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.60 minutes. MS ESI (m/z): 374.2 (M+H)+, calc. 373.
-
- Compound AD was prepared by a method analogous to that described in Example 1 by substituting 4-carbamoylphenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 4-amino-3-methoxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.46 minutes. MS ESI (m/z): 359.2 (M+H)+, calc. 358.
-
- Compound AE was prepared by a method analogous to that described in Example 1 by substituting 4-carbamoylphenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.13 minutes. MS ESI (m/z): 330.4 (M+H)+, calc. 329.
-
- Compound AF was prepared by a method analogous to that described in Example 1 by substituting 3-chloro-4-fluorophenylboronic acid for 1H-indol-5-ylboronic acid in the reaction with Intermediate A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine for 3,4,5-trimethoxyphenylboronic acid in the reaction with Intermediate B. HPLC retention time: 1.47 minutes. MS ESI (m/z): 339.4 (M+H)+, calc. 338.
-
-
- To a solution of 5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (40 mg, 0.09 mmol) in CH3CN (1 mL) in a Personal Chemistry microwave reaction vial was added 6-fluoropyridin-3-ylboronic acid (12 mg, 0.09 mmol), bis(triphenylphosphine)-palladium(II) dichloride (5.0 mg, 0.007 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and concentrated in vacuo to give intermediate Q. The residue was dissolved in DMSO (0.5 mL) and methyl amine hydrochloride salt (29 mg, 0.43 mmol), and K2CO3 (95 mg, 0.70 mmol) were added. The resulting mixture was stirred at 80° C. for 48 hr, after which it was diluted with DMF (0.5 mL), filtered, and subjected to preparative HPLC to yield the title compound (6.0 mg, 21%). 1H NMR (DMSO-d6, 300 MHz): δ 11.77 (s, 1H), 11.07 (s, 1H), 8.46 (d, J=2.1 Hz, 1H), 8.34 (dd, J=2.4, 9.3 Hz, 1H), 7.90 (s, 1H), 7.86 (m, 1H), 7.74 (d, J=2.7 Hz, 1H), 7.47 (s, 2H), 7.35 (s, 1H), 6.80 (s, 1H), 6.63 (d, J=8.4 Hz, 1H), 6.48 (m, 1H), 2.84 (d, J=4.5 Hz, 1H). HPLC retention time: 1.10 minutes; HPLC retention time: 1.56 minutes; MS ESI (m/z): 340.2 (M+1)+, calc. 339.
-
- Compound AI was prepared by a method analogous to that described in Example 15 by substituting 2-(pyrrolidin-1-yl)ethanamine for methylamine hydrochloride salt in the reaction with intermediate Q. HPLC retention time: 1.58 minutes MS ESI (m/z): 354.4 (M+H)+, calc. 353.
-
-
- To a solution of 5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine [Intermediate B] (0.20 g, 0.43 mmole) in CH3CN (4 mL) in a Personal Chemistry microwave reaction vial was added 4-formylphenylboronic acid (64 mg, 0.43 mmol), bis(triphenylphosphine)-palladium(II) dichloride (40 mg, 0.057 mmol), and 1 M Na2CO3 (2 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and partitioned between EtOAc and brine. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo to give Intermediate AJ. HPLC retention time: 3.01 minutes. MS ESI (m/z): 492.4 (M+H)+, calc. 491.
-
- To a solution of 4-(3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)benzaldehyde [Intermediate AJ] (0.11 g, 0.214 mmol) in CH2Cl2 (3 mL) was added 1-methylpiperazine (40 μL, 0.40 mmol) and sodium triacetoxyborohydride (68 mg, 0.32 mmol). The reaction mixture was stirred for 1 hr at room temperature, after which it was partitioned between CH2Cl2 and 1 M NaOH. The organic layer was separated, dried over MgSO4, and concentrated in vacuo. The residue was dissolved in 3:2 MeOH:acetone (5 mL), and 2 M NaOH (1.5 mL) was added. The resulting mixture was stirred at 65° C. for 30 min, after which it was partitioned between EtOAc and 1 M NaOH. The organic layer was separated, dried over MgSO4, filtered, and stripped to provide a residue that was subjected to preparatory HPLC to yield the title compound. HPLC retention time: 1.63 minutes; MS ESI (m/z) 422.4 (M+1)+, calc. 421.
-
- Compound AL was prepared by a method analogous to that described in Example 33 by substituting dimethylamine (2 M solution in THF) for 1-methylpiperazine in the reaction with intermediate T. HPLC retention time: 1.66 minutes. MS ESI (m/z): 367.4 (M+H)+, calc. 366.
-
-
- To a solution of 2-(piperazin-1-yl)ethanol (0.78 mL, 6.0 mmol) and triphenylphosphine (1.6 g, 6.0 mmol) in anhydrous THF (20 mL) at 0° C. was added diethyl azodicarboxylate (0.95 mL, 6.0 mmol), followed by 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.0 g, 4.0 mmol). After stirring for 4 h at rt, additional triphenylphosphine (1.6 g, 6.0 mmol) and diethyl azodicarboxylate (0.95 mL, 6.0 mmol) were added. After stirring for an additional 2 h, the resulting mixture was evaporated to dryness in vacuo and the residue was purified via silica gel chromatography eluting with 15% MeOH in CH2Cl2 to yield a yellow oil (1.89 g) which contained approximately 60% of the title compound by HPLC analysis. HPLC retention time: 1.01 minutes. MS ESI (m/z): 363.6 (M+H)+, calc. 362.
-
- To a solution of 5-bromo-3-(1H-indol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine (Intermediate B) (92 mg, 0.20 mmol) in CH3CN (2 mL) in a Personal Chemistry microwave reaction vial was added 1-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperazine (Intermediate AM) (72 mg, 0.20 mmol), bis(triphenylphosphine)-palladium(II) dichloride (20 mg, 0.028 mmol), and 1 M Na2CO3 (2 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 25 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and concentrated in vacuo to give Intermediate AN. The residue was dissolved in MeOH (3 mL) and acetone (2 mL), and 2 M NaOH (1.5 mL) was added. The resulting mixture was stirred at 50° C. for 2 h, after which it was partitioned between EtOAc and 1 M NaOH. The organic layer was separated, dried over MgSO4, filtered, and stripped to give a residue that was subjected to preparatory HPLC to yield the title compound. HPLC retention time: 1.29 minutes; MS ESI (m/z) 468.6 (M+1)+, calc. 467.
-
- Compound AP was prepared by a method analogous to that described in Example 36 by substituting 2-(dimethylamino)ethanol for 2-(piperazin-1-yl)ethanol in the reaction with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol. HPLC retention time: 1.20 minutes. MS ESI (m/z): 427.2 (M+H)+, calc. 426.
-
-
- To a solution of 3,5-dibromopyrazin-2-amine (10 g, 40 mmol), copper(I) iodide (0.91 g, 4.7 mmol), diisopropylethylamine (53 mL, 0.55 mol), and tetrakis(triphenylphosphine)-palladium(0) (2.3 g, 1.9 mmol) in DMF (120 mL) that was de-gassed with Ar was added trimethylsilylacetylene (6.7 mL, 48 mmol). The resulting mixture was stirred under an Ar atmosphere for 1 h at 120° C., after which it was evaporated to dryness in vacuo. The residue was subjected to silica gel chromatography eluting with 35% EtOAc in hexanes to give a brown oil that was triturated with hexanes to give the title compound (5.0 g, 47%). 1H NMR (CDCl3, 300 MHz): δ 8.04 (s, 1H), 5.10 (s, 2H), 0.28 (s, 9H). HPLC retention time: 2.75 minutes. MS ESI (m/z): 270.0, 272.0 (M+H)+, talc. 269.
-
- To a solution of 5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine (5.0 g, 19 mmol) and pyridine (3.8 ml, 46 mmol) in anhydrous THF (75 mL) was added acetyl chloride (1.6 mL, 23 mmol) in a drop-wise manner. After stirring for 48 hr at rt, additional acetyl chloride (0.4 mL 6 mmol) was added and the mixture was stirred for an additional 48 hr at rt. The solvent was removed in vacuo, and the residue was diluted with 30% EtOAc in hexanes. The mixture was filtered, and the filtrate was purified via silica gel chromatography eluting with 30% EtOAc in hexanes to give a yellow-brown solid (1.8 g, 31%). 1H NMR (CDCl3, 300 MHz): δ 8.34 (s, 1H), 8.08 (s, 1H), 2.46 (s, 3H), 0.32 (s, 9H). HPLC retention time: 2.29 minutes MS ESI (m/z): 312.2, 314.2 (M+H)+, talc. 311.
-
- A solution of N-(5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-yl)acetamide [Intermediate AR] (2.6 g, 8.4 mmol) and tetrabutylammonium fluoride [1 M in THF] (18 mL, 18 mmol) in anhydrous THF (26 mL) was heated at 75° C. for 20 h, after which it was partitioned between EtOAc and H2O. The organic layer was washed with brine, dried over Na2SO4, and evaporated in vacuo to yield a residue that was purified via silica gel chromatography eluting with 30% EtOAc in hexanes to give the title compound as a tan solid (0.69 g, 42%). 1H NMR (CDCl3, 300 MHz): δ 8.88 (bs, 1H), 8.34 (s, 1H), 7.62 (t, 0.1=3.3 Hz, 1H), 6.71 (dd, 0.1=3.6 Hz, 3.9 Hz, 1H). HPLC retention time: 1.73 minutes. MS ESI (m/z): 198.2, 200.2 (M+H)+, calc. 197.
-
- To a solution of 2-bromo-5H-pyrrolo[3,2-b]pyrazine [Intermediate AS] (0.68 g, 3.4 mmol) in acetone (17 mL) was added N-iodosuccinimide (0.82 g, 3.6 mmol) and the resulting mixture was stirred for 4 h at rt. The mixture was evaporated in vacuo to yield a residue that was purified via silica gel chromatography eluting with 40% THF in hexanes to give the title compound as a yellow solid (0.99 g, 89%). 1H NMR (DMSO-d6, 300 MHz): δ 12.82 (s, 1H), 8.42 (s, 1H), 8.20 (s, 1H). HPLC retention time: 2.23 minutes. MS ESI (m/z): 324.0, 326.0 (M+H)+, calc. 323.
-
- To a stirred solution of 2-bromo-7-iodo-5H-pyrrolo[3,2-b]pyrazine [Intermediate AT] (1.1 g, 3.5 mmol) in anhydrous THF (20 mL) cooled to 0° C. was added NaH [60% dispersion in mineral oil] (0.17 g, 4.3 mmol). The reaction mixture was stirred for 20 min at 0° C., after which p-toluenesulfonyl chloride (0.73 g, 3.8 mmol) in THF (8 mL) was added. The resulting mixture was stirred at rt for 3 hr. after which it was diluted with EtOAc and washed with H2O and brine. The organic layer was separated, dried over Na2SO4, filtered, and evaporated in vacuo to yield a residue that was triturated with hexanes to yield the title compound (1.6 g, 94%) as a light yellow powder. 1H NMR (DMSO-d6, 300 MHz) 6.8.62 (d, J=7.5 Hz, 2H), 8.03 (s, 1H), 8.00 (s, 1H), 7.47 (d, J=8.1 Hz, 2H), 2.37 (s, 3H). HPLC retention time: 2.84 minutes. MS ESI (m/z): 478.0/480.0 (M+H)+, calc. 477.
-
- To a stirred suspension of 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[3,2-b]pyrazine [Intermediate AU] (0.25 g, 0.52 mmol) and 1H-indol-5-ylboronic acid (0.10 mg, 0.62 mmol) in CH3CN (20 mL) was added 1 M Na2CO3 (20 mL) followed by bis(triphenylphosphine)-palladium(II) dichloride (60 mg, 0.086 mmol). The resulting mixture was stirred for 2 h at 60° C. The title compound was isolated as a yellow solid via filtration from the CH3CN layer (0.23 g, 94%). HPLC retention time: 3.23 minutes. MS ESI (m/z): 467.2/469.2 (M+H)+, calc. 466.
-
- To a solution of 2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine [Intermediate AV] (65 mg, 0.14 mmol) in CH3CN (1 mL) in a Personal Chemistry microwave reaction vial was added 3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol), bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and concentrated in vacuo. The residue was dissolved in MeOH (3 mL) and acetone (2 mL), and 2 M NaOH (1.5 mL) was added. The resulting mixture was stirred at 65° C. for 30 min, after which it was partitioned between EtOAc and 1 M NaOH. The organic layer was separated, dried over MgSO4, filtered, and stripped to give a residue which was purified by preparatory HPLC to give the title compound as a yellow solid. HPLC retention time: 2.25 minutes; MS ESI (m/z) 401.2 (M+1)+, calc. 400.
-
- Compound AX was prepared by a method analogous to that described in Example 38 by substituting 3,4-dimethoxyboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate AV. HPLC retention time: 2.45 minutes. MS ESI (m/z): 371.2 (M+H)+, calc. 370.
-
- Compound AY was prepared by a method analogous to that described in Example 38 by substituting 4-amino-3-methoxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with intermediate AV. HPLC retention time: 2.07 minutes. MS ESI (m/z): 356.4 (M+H)+, calc. 355.
-
- Compound AZ was prepared by a method analogous to that described in Example 36 by substituting 4-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine for 1-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperazine and 2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine for intermediate B. HPLC retention time: 1.59 minutes. MS ESI (m/z): 470.4 (M+H)+, calc. 469.
-
-
- To a stirred solution of aminopyrazine (8.21 g, 86.4 mmol) in anhydrous methylene chloride (215 mL) cooled to 0° C. was added N-bromosuccinimide (32.3 g, 181 mmol) in portions over a six hour period, during which time the temperature of the reaction was kept below 0° C. The resulting mixture was stored at 4° C. overnight, after which it was stirred vigorously and quenched with H2O (100 mL). The organic layer was separated, after which it was washed with saturated aqueous NaHCO3, washed with brine, dried over MgSO4, filtered, and evaporated in vacuo to yield a residue that was triturated with 20% EtOAc in hexanes to yield the title compound (10.3 g, 47%) as a yellow/brown powder. 1H NMR (CDCl3, 300 MHz) δ 8.02 (s, 1H), 5.05 (bs, 2H); HPLC retention time: 1.99 minutes; MS ESI (m/z): 252.0/254.0/256.2 (M+1)+, calc. 251.
-
- To a stirred suspension of 3,5-dibromopyrazin-2-amine (3.48 g, 13.7 mmol) and 1H-indol-5-amine (2.00 g, 15.0 mmol) in EtOH (3.5 mL) was added diisopropylethylamine [DIEA] (2.60 mL, 15.0 mmol). The resulting mixture was stirred for 48 hr at 80° C., after which it was partitioned between EtOAc and H2O. The organic layer was separated, after which it was washed with brine, dried over Na2SO4, filtered, and evaporated in vacuo to yield a residue that was purified via silica gel chromatography eluting with 1:1 EtOAc:hexanes to yield the title compound (1.75 g, 42%) as a red/brown solid. 1H NMR (DMSO-d6, 300 MHz): δ 10.98 (s, 1H), 8.22 (s, 1H), 7.83 (s, 1H), 7.31-7.28 (m, 3H), 7.19 (d, J=8.7 Hz, 1H), 6.43 (s, 2H), 6.36 (s, 1H); HPLC retention time: 2.07 minutes; MS ESI (m/z): 304.2/306.2 (M+1)+, calc. 303.
-
- To a solution of 6-bromo-N2-(1H-indol-5-yl)pyrazine-2,3-diamine (0.450 g, 1.48 mmol) in THF (5 mL) was added carbonyldiimidazole (1.20 g, 7.40 mmol). The resulting mixture was heated at 65° C. for 48 hr, after which it was concentrated in vacuo and partitioned between EtOAc and H2O. The organic layer was separated, dried over MgSO4, filtered, and concentrated in vacuo to yield a residue that was purified via silica gel chromatography eluting with EtOAc to yield the title compound (0.20 g, 41%). HPLC retention time: 2.07 minutes; MS ESI (m/z): 330.2/332.2 (M+1)+, calc. 329.
-
- To a solution of 6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one (27 mg, 0.08 mmol) in CH3CN (1 mL) in a Personal Chemistry microwave reaction vial was added 3,4,5-trimethoxyphenylboronic acid (17 mg, 0.08 mmol), bis(triphenylphosphine)-palladium(II) dichloride (6.0 mg, 0.008 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and concentrated in vacuo. The residue was purified by preparatory HPLC to yield the title compound (6.5 mg, 19%). 1H NMR (DMSO-d6, 300 MHz): δ 12.18 (s, 1H), 11.28 (s, 1H), 8.57 (s, 1H), 7.83 (d, J=1.8 Hz, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.42 (m, 1H), 7.37 (dd, J=1.8, 8.4 Hz, 1H). 7.20 (s, 2H), 6.51 (m, 1H), 3.78 (s, 6H), 3.66 (s, 3H); HPLC retention time: 2.30 minutes; MS ESI (m/z): 418.4 (M+1)+, calc. 417.
-
- Compound BE was prepared by a method analogous to that described in Example 1 by substituting 1-methyl-1H-indol-5-amine for 1H-indol-5-amine in the reaction with Intermediate BA. 4.0 mg recovered. 1H NMR (DMSO-d6, 300 MHz): δ 12.22 (s, 1H), 8.57 (s, 1H), 7.85 (d, J=1.8 Hz, 1H), 7.57 (d, J=8.7 Hz, 1H), 7.45 (d, J=1.8 Hz), 7.41 (m, 2H), 7.20 (s, 2H), 6.50 (d, J=3.0 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 6H), 3.66 (s, 3H); HPLC retention time: 2.50 minutes. MS EST (m/z): 432.4 (M+H)+, calc. 431.
-
- Compound BE was prepared by a method analogous to that described in Example 1 by substituting 1-methyl-1H-indol-5-amine for 1H-indol-5-amine in the reaction with Intermediate BA to prepare 6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one. In a procedure similar to that used to synthesize Compound D, 4-hydroxyphenylboronic acid was substituted for 3,4,5-trimethoxyphenylboronic acid and 6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one was substituted for 6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one to obtain the title compound. 2.2 mg recovered. HPLC retention time: 2.18 minutes. MS ESI (m/z): 358.2 (M+H)+, calc. 357.
-
- Compound BG was prepared by a method analogous to that described in Example 3 by substituting 3,5-dimethylphenylboronic acid for 4-hydroxyphenylboronic acid in the reaction with 6-bromo-1-(1-methyl-1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one. 1.6 mg recovered. HPLC retention time: 3.04 minutes MS ESI (m/z): 370.2 (M+H)+, calc. 369.
-
- Compound BH was prepared by a method analogous to that described in Example 1 by substituting pyridin-4-ylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Compound BC. 1.6 mg recovered. HPLC retention time: 1.10 minutes. MS ESI (m/z): 329.4 (M+H)+, calc. 328.
-
- Compound BI was prepared by a method analogous to that described in Example 1 by substituting by substituting 4-hydroxyphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Compound BC. 13.7 mg recovered. 1H NMR (DMSO-d6, 300 MHz): δ 12.07 (s, 1H), 11.30 (s, 1H), 9.61 (s, 1H), 8.38 (s, 1H), 7.69 (m, 2H), 7.52 (d, J=8.4 Hz, 1H), 7.44 (m, 1H), 7.26 (dd, J=1.8, 8.7 Hz), 6.76 (dd, J=2.4, 12.9 Hz), 6.52 (m, 1H); HPLC retention time: 1.99 minutes. MS ESI (m/z): 344.2 (M+H)+, calc. 343.
-
- Compound BJ was prepared by a method analogous to that described in Example 1 by substituting 3,5-dimethylphenylboronic acid for 3,4,5-trimethoxyphenylboronic acid in the reaction with Compound BC. 4.3 mg recovered. HPLC retention time: 2.80 minutes. MS ESI (m/z): 356.2 (M+H)+, calc. 355.
- Examples 47-119, shown in Table 3 below, were synthesized in parallel according to procedures given below in Schemes 7 and 8, using the reagents in Tables 1 and 2.
-
- To a solution of 6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one (27 mg, 0.08 mmol) in CH3CN (1 mL) in a Personal Chemistry microwave reaction vial was added 3,4,5-trimethoxyphenylboronic acid (17 mg, 0.08 mmol), bis(triphenylphosphine)-palladium(II) dichloride (6.0 mg, 0.008 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and concentrated in vacuo. The residue was purified by preparatory HPLC to yield the title compounds (>3 mg) in table 1, isolated as amorphous solids.
-
TABLE 1 Ex. Boronic Acid Purified Compound Isolated 47 3,4-dimethoxyphenyl 6-(3,4-dimethoxyphenyl)-1-(1H-indol-5- boronic acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 48 3,5-dichlorophenyl boronic 6-(3,5-dichlorophenyl)-1-(1H-indol-5- acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 49 3-fluoro-4-methoxyphenyl 6-(3-fluoro-4-methoxyphenyl)-1-(1H- boronic acid indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 50 3-amino-4-methoxyphenyl 6-(3-amino-4-methoxyphenyl)-1-(1H- boronic acid indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 51 4-methoxy-3,5- 1-(1H-indol-5-yl)-6-(4-methoxy-3,5- dimethylphenyl boronic dimethylphenyl)-1H-imidazo[4,5- acid b]pyrazin-2(3H)-one 52 4-morpholinophenyl 1-(1H-indol-5-yl)-6-(4- boronic acid morpholinophenyl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 53 Indole-5-boronic acid 1,6-di(1H-indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 54 3-hydroxyphenyl boronic 6-(3-hydroxyphenyl)-1-(1H-indol-5-yl)- acid 1H-imidazo[4,5-b]pyrazin-2(3H)-one 55 4-hydroxy-3- 6-(4-hydroxy-3-methoxyphenyl)-1-(1H- methoxyphenyl indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 56 indole-6-boronic 1-(1H-indol-5-yl)-6-(1H-indol-6-yl)-1H- imidazo[4,5-b]pyrazin-2(3H)-one 57 3-methoxy-4-(2- 1-(1H-indol-5-yl)-6-(3-methoxy-4-(2- morpholinoethoxy)phenyl morpholinoethoxy)phenyl)-1H- boronic acid imidazo[4,5-b]pyrazin-2(3H)-one 58 2,5-difluoro-4- 6-(2,5-difluoro-4-hydroxyphenyl)-1-(1H- hydroxyphenyl boronic indol-5-yl)-1H-imidazo[4,5-b]pyrazin- acid 2(3H)-one 59 3,5-difluoro-4- 6-(3,5-difluoro-4-hydroxyphenyl)-1-(1H- hydroxyphenyl boronic indol-5-yl)-1H-imidazo[4,5-b]pyrazin- acid 2(3H)-one 60 4-amino-3-methoxyphenyl 6-(4-amino-3-methoxyphenyl)-1-(1H- boronic acid indol-5-yl)-1H-imidazo[4,5-b]pyrazin- 2(3H)-one 61 3,5-difluorophenyl 6-(3,5-difluorophenyl)-1-(1H-indol-5- boronic acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 62 4-hydroxy-3,5- 6-(4-hydroxy-3,5-dimethoxyphenyl)-1- dimethoxyphenyl (1H-indol-5-yl)-1H-imidazo[4,5- boronic acid b]pyrazin-2(3H)-one 63 2,3- 6-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)- dihydrobenzo[b][1,4]dioxin- 1-(1H-indol-5-yl)-1H-imidazo[4,5- 6-boronic acid b]pyrazin-2(3H)-one 64 4-hydroxy-3,5- 6-(4-hydroxy-3,5-dimethylphenyl)-1- dimethylphenyl boronic (1H-indol-5-yl)-1H-imidazo[4,5- acid b]pyrazin-2(3H)-one 65 3,5-dimethoxyphenyl 6-(3,5-dimethoxyphenyl)-1-(1H-indol-5- boronic acid yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 66 2-(4-methylpiperazin-1- 1-(1H-indol-5-yl)-6-(2-(4- yl)pyridin-4-boronic acid methylpiperazin-1-yl)pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin-2(3H)-one 67 (3-methoxy-4-(2- 1-(1H-indol-5-yl)-6-(3-methoxy-4-(2- (piperazin-1- (piperazin-1-yl)ethoxy)phenyl)-1H- yl)ethoxy)phenyl imidazo[4,5-b]pyrazin-2(3H)-one -
- To a stirred suspension of 3,5-dibromopyrazin-2-amine (3.48 g, 13.7 mmol) and the corresponding alkyl, aryl, or heteroaryl amine (15.0 mmol) in EtOH (3.5 mL) was added diisopropylethylamine [DIEA] (2.60 mL, 15.0 mmol). The resulting mixture was stirred for 48 hr at 80° C., after which it was partitioned between EtOAc and H2O. The organic layer was separated, after which it was washed with brine, dried over Na2SO4, filtered, and evaporated in vacuo to yield a residue that was purified by automated medium pressure silica gel chromatography eluting with 1:1 EtOAc:hexanes to yield the intermediates as amorphous solids.
- Intermediates 2BB (0.450 g, 1.5 mmol) were dissolved in THF (5 mL) and treated with carbonyldiimidazole (1.20 g, 7.40 mmol). The resulting mixture was heated at 65° C. for 48 hr, after which it was concentrated in vacuo and partitioned between EtOAc and H2O. The organic layer was separated, dried over MgSO4, filtered, and concentrated in vacuo to yield a residue that was purified via automated silica gel chromatography eluting with hexane/EtOAc to yield the intermediates 2BC as amorphous solids.
- Individual solutions of intermediates 2BC (0.08 mmol) in CH3CN (1 mL) in a Personal Chemistry microwave reaction vial was added the corresponding Iboronic acid (0.08 mmol), bis(triphenylphosphine)-palladium(II) dichloride (6.0 mg, 0.008 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The organic layer was separated, filtered, and concentrated in vacuo. The residue was purified by preparatory HPLC to yield the title compounds in table 2 (>3 mg) as amorphous solids.
-
Ex. Boronic Acid Amine Purified Compound Isolated 68 3,4,5- 4-methoxy- 1-(4-methoxyphenyl)-6- trimethoxyphenyl aniline (3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 69 3,4- 4-methoxy- 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl aniline (4-methoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 70 3,4- 4-methoxy- 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl aniline (4-methoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 71 pyridin-4-boronic 4-methoxy- 1-(4-methoxyphenyl)-6- acid boronic acid aniline (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 72 3,4,5- 2-methyl-5- 1-(2-methyl-1H-indol-5-yl)- trimethoxyphenyl amino-indole 6-(3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 73 3,5-dichlorophenyl 2-methyl-5- 6-(3,5-dichlorophenyl)-1-(2- boronic acid amino-indole methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 74 3,4,5- 1-amino- 1-cyclopentyl-6-(3,4,5- trimethoxyphenyl cyclopentane trimethoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 75 3,4- 1-amino- 1-cyclopentyl-6-(3,4- dimethoxyphenyl cyclopentane dimethoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 76 4-hydroxyphenyl 1-amino- 1-cyclopentyl-6-(4- boronic acid cyclopentane hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 77 pyridin-4-boronic 1-amino- 1-cyclopentyl-6-(pyridin-4- acid cyclopentane yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 78 3,4,5- Cyclopropane- 1-(cyclopropylmethyl)-6- trimethoxyphenyl methylamine (3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 79 3,4- Cyclopropane- 1-(cyclopropylmethyl)-6- dimethoxyphenyl methylamine (3,4-dimethoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 80 3,5-dichlorophenyl Cyclopropane- 1-(cyclopropylmethyl)-6- boronic acid methylamine (3,5-dichlorophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 81 4-hydroxyphenyl Cyclopropane- 1-(cyclopropylmethyl)-6-(4- boronic acid methylamine hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 82 4-aminopyridine Cyclopropane- 1-(cyclopropylmethyl)-6- boronic acid methylamine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 83 3,4,5- 1H-Indazol-5- 1-(1H-indazol-5-yl)-6- trimethoxyphenyl amine (3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 84 4-hydroxypheny 2-methyl-5- 6-(4-hydroxyphenyl)-1-(2- boronic acid amino-indole methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 85 pyridin-4-boronic 2-methyl-5- 1-(2-methyl-1H-indol-5-yl)- acid boronic acid amino-indole 6-(pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 86 4-morpholinophenyl Cyclopropane- 1-(cyclopropylmethyl)-6-(4- boronic acid methylamine morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 87 3,4- 1H-Indazol-5- 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl amine (1H-indazol-5-yl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 88 4-aminopyridine 1H-Indazol-5- 1-(1H-indazol-5-yl)-6- boronic acid amine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 89 4-morpholinophenyl 1H-Indazol-5- 1-(1H-indazol-5-yl)-6-(4- boronic acid amine morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 90 3,4,5- 1H-Indazol-5- 1-(1H-indazol-6-yl)-6- trimethoxyphenyl amine (3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 91 3,4- 1H-Indazol-5- 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl amine (1H-indazol-6-yl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 92 4-hydroxyphenyl 1H-Indazol-5- 6-(4-hydroxyphenyl)-1-(1H- boronic acid amine indazol-6-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 93 4-aminopyridine 1H-Indazol-5- 1-(1H-indazol-6-yl)-6- boronic acid amine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 94 2,4,6- 1-amino- 1-cyclopentyl-6-(2,4,6- trimethoxyphenyl cyclopentane trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 95 3,5-dimethylphenyl 1H-Indazol-5- 6-(3,5-dimethylphenyl)-1- boronic acid amine (1H-indazol-6-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 96 3,4,5- benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6- trimethoxyphenyl 5-amine (3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 97 4-hydroxyphenyl benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6- boronic acid 5-amine (4-hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 98 4-aminopyridine benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6- boronic acid 5-amine (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 99 3,5-dimethylphenyl benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6- boronic acid 5-amine (3,5-dimethylphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 100 4-morpholinophenyl benzo[d]thiazol- 1-(benzo[d]thiazol-5-yl)-6- boronic acid 5-amine (4-morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 101 3,4,5- 2,3-dihydro-1H- 1-(2,3-dihydro-1H-inden-1- trimethoxyphenyl inden-1-amine yl)-6-(3,4,5- boronic acid trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 102 3,4,5- 1H-benzo[d]imidazol- 1-(1H-benzo[d]imidazol-5- trimethoxyphenyl 5-amine yl)-6-(3,4,5- boronic acid trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 103 3,4- 1H-benzo[d]imidazol- 1-(1H-benzo[d]imidazol-5- dimethoxyphenyl 5-amine yl)-6-(3,4- boronic acid dimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 104 4-morpholinophenyl 1H-benzo[d]imidazol- 1-(1H-benzo[d]imidazol-5- boronic acid 5-amine yl)-6-(4-morpholinophenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 105 3,4,5- aniline 1-phenyl-6-(3,4,5- trimethoxyphenyl trimethoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 106 3,4- aniline 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl phenyl-1H-imidazo[4,5- boronic acid b]pyrazin-2(3H)-one 107 3-methoxy-4-(2- Cyclopropane- 1-(cyclopropylmethyl)-6-(3- morpholino- methylamine methoxy-4-(2- ethoxy)phenyl morpholinoethoxy)phenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 108 3-methoxy-4-(2- 1-amino- 1-cyclopentyl-6-(3-methoxy- morpholino- cyclopentane 4-(2- ethoxy)phenyl morpholinoethoxy)phenyl) - 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 109 3,4,5- 6- 1-(6-morpholinopyridin-3- trimethoxyphenyl morpholino- yl)-6-(3,4,5- boronic acid pyridin-3-amine trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 110 3,4,5- 2,3-dihydro-1H- 1-(2,3-dihydro-1H-inden-2- trimethoxyphenyl inden-2-amine yl)-6-(3,4,5- boronic acid trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 111 3,4- 1H-pyrrolo[2,3- 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl b]pyridin-5- (1H-pyrrolo[2,3-b]pyridin-5- boronic acid amine yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 112 3,4,5- 1H-pyrrolo[2,3- 1-(1H-pyrrolo[2,3-b]pyridin- trimethoxyphenyl b]pyridin-5- 5-yl)-6-(3,4,5- boronic acid amine trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 113 3,4,5- 1H-indol-6- 1-(1H-indol-6-yl)-6-(3,4,5- trimethoxyphenyl amine trimethoxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 114 3,4,5- 4-aminophenol 1-(4-hydroxyphenyl)-6- trimethoxyphenyl (3,4,5-trimethoxyphenyl)- boronic acid 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 115 3,4- 4-aminophenol 6-(3,4-dimethoxyphenyl)-1- dimethoxyphenyl (4-hydroxyphenyl)-1H- boronic acid imidazo[4,5-b]pyrazin- 2(3H)-one 116 4-morpholinophenyl 4-aminophenol 1-(4-hydroxyphenyl)-6-(4- boronic acid morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 117 6-aminopyridin-3- 1-amino- 6-(6-aminopyridin-3-yl)-1- boronic acid cyclopentane cyclopentyl-1H-imidazo[4,5- b]pyrazin-2(3H)-one 118 4-amino-3- 1-amino- 6-(4-amino-3- methoxyphenyl cyclopentane methoxyphenyl)-1- boronic acid cyclopentyl-1H-imidazo[4,5- b]pyrazin-2(3H)-one - Examples 47-118 were physically characterized by electrospray ionization mass spectrometry. Structures and molecular masses are given below in Table 3.
-
TABLE 3 Ex. Structure IUPAC Name MW 47 6-(3,4-dimethoxyphenyl)-1- (1H-indol-5-yl)-1H imidazo[4,5-b]pyrazin- 2(3H)-one 387.13 48 6-(3,5-dichlorophenyl)-1- (1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 395.03 49 6-(3-fluoro-4- methoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 375.11 50 6-(3-amino-4- methoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 372.13 51 1-(1H-indol-5-yl)-6-(4- methoxy-3,5- dimethylphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 371.40 52 1-(1H-indol-5-yl)-6-(4- morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 412.45 53 1,6-di(1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 366.39 54 6-(3-hydroxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 343.35 55 6-(4-hydroxy-3- methoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 373.37 56 1-(1H-indol-5-yl)-6-(1H- indol-6-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 366.39 57 1-(1H-indol-5-yl)-6-(3- methoxy-4-(2- morpholinoethoxy)phenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 486.53 58 6-(2,5-difluoro-4- hydroxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 379.33 59 6-(3,5-difluoro-4- hydroxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 379.33 60 6-(4-amino-3- methoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 372.39 61 6-(3,5-difluorophenyl)-1- (1H-indol-5-yl)-1H- imidazol-4,5-b]pyrazin- 2(3H)-one 363.33 62 6-(4-hydroxy-3,5- dimethoxyphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 403.40 63 6-(2,3- dihydrobenzo[b][1,4]dioxin- 6-yl)-1-(1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 385.39 64 6-(4-hydroxy-3,5- dimethylphenyl)-1-(1H- indol-5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 385.43 65 6-(3,5-dimethoxyphenyl)-1- (1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 387.40 66 1-(1H-indol-5-yl)-6-(2-(4- methylpiperazin-1- yl)pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 426.50 67 1-(1H-indol-5-yl)-6-(3- methoxy-4-(2-(piperazin-1- yl)ethoxy)phenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 485.55 68 1-(4-methoxyphenyl)-6- (3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 408.42 69 6-(3,4-dimethoxyphenyl)-1- (4-methoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 378.39 70 6-(4-hydroxyphenyl)-1-(4- methoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 334.34 71 1-(4-methoxyphenyl)-6- (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 319.33 72 1-(2-methyl-1H-indol-5-yl)- 6-(3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 431.45 73 6-(3,5-dichlorophenyl)-1-(2- methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 410.27 74 1-cyclopentyl-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 370.41 75 1-cyclopentyl-6-(3,4- dimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 340.39 76 1-cyclopentyl-6-(4- hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 296.33 77 1-cyclopentyl-6-(pyridin-4- yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 281.32 78 1-(cyclopropylmethyl)-6- (3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 356.38 79 1-(cyclopropylmethyl)-6- (3,4-dimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 326.36 80 1-(cyclopropylmethyl)-6- (3,5-dichlorophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 335.20 81 1-(cyclopropylmethyl)-6-(4- hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 282.30 82 1-(cyclopropylmethyl)-6- (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 267.29 83 1-(1H-indazol-5-yl)-6- (3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 84 6-(4-hydroxyphenyl)-1-(2- methyl-1H-indol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 357.37 85 1-(2-methyl-1H-indol-5-yl)- 6-(pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 342.36 86 1-(cyclopropylmethyl)-6-(4- morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 351.41 87 6-(3,4-dimethoxyphenyl)-1- (1H-indazol-5-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 388.39 88 1-(1H-indazol-5-yl)-6- (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 329.32 89 1-(1H-indazol-5-yl)-6-(4- morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 413.44 90 1-(1H-indazol-6-yl)-6- (3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 91 6-(3,4-dimethoxyphenyl)-1- (1H-indazol-6-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 388.39 92 6-(4-hydroxyphenyl)-1-(1H- indazol-6-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 344.34 93 1-(1H-indazol-6-yl)-6- (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 329.32 94 1-cyclopentyl-6-(2,4,6- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 370.41 95 6-(3,5-dimethylphenyl)-1- (1H-indazol-6-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 356.39 96 1-(benzo[d]thiazol-5-yl)-6- (3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 435.46 97 1-(benzo[d]thiazol-5-yl)-6- (4-hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 361.38 98 1-(benzo[d]thiazol-5-yl)-6- (pyridin-4-yl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 346.37 99 1-(benzo[d]thiazol-5-yl)-6- (3,5-dimethylphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 373.44 100 1-(benzo[d]thiazol-5-yl)-6- (4-morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 430.49 101 1-(2,3-dihydro-1H-inden-1- yl)-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 418.46 102 1-(1H-benzo[d]imidazol-5- yl)-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 103 1-(1H-benzo[d]imidazol-5- yl)-6-(3,4- dimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 388.39 104 1-(1H-benzo[d]imidazol-5- yl)-6-(4- morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 413.44 105 1-phenyl-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b[pyrazin- 2(3H)-one 378.39 106 6-(3,4-dimethoxyphenyl)-1- phenyl-1H-imidazo[4,5- b]pyrazin-2(3H)-one 348.36 107 1-(cyclopropylmethyl)-6-(3- methoxy-4-(2- morpholinoethoxy)phenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 425.49 108 1-cyclopentyl-6-(3- methoxy-4-(2- morpholinoethoxy)phenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 439.52 109 1-(6-morpholinopyridin-3- yl)-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 464.48 110 1-(2,3-dihydro-1H-inden-2- yl)-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 418.46 111 6-(3,4-dimethoxyphenyl)-1- (1H-pyrrolo[2,3-b]pyridin- 5-yl)-1H-imidazo[4,5- b]pyrazin-2(3H)-one 388.39 112 1-(1H-pyrrolo[2,3- b]pyridin-5-yl)-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 113 1-(1H-indol-6-yl)-6-(3,4,5- trimethoxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 418.42 114 1-(4-hydroxyphenyl)-6- (3,4,5-trimethoxyphenyl)- 1H-imidazo[4,5-b]pyrazin- 2(3H)-one 394.50 115 6-(3,4-dimethoxyphenyl)-1- (4-hydroxyphenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 364.50 116 1-(4-hydroxyphenyl)-6-(4- morpholinophenyl)-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 389.50 117 6-(6-aminopyridin-3-yl)-1- cyclopentyl-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 296.33 118 6-(4-amino-3- methoxyphenyl)-1- cyclopentyl-1H- imidazo[4,5-b]pyrazin- 2(3H)-one 325.37 -
- Example 119 was prepared by a method analogous to that described in Examples 68-118 by substituting 6 chloro-3,5-dibromopyrazin-2-amine for 3,5-dibromopyrazin-2-amine in the reaction with aminomethylcyclopropane. MS ESI (m/z): 390.83 calc
-
-
- To a stirred solution of 7-azaindole (1.18 g, 10.0 mmol) in anhydrous dimethylformamide (10 mL) cooled to 0° C. was added NaH [60% dispersion in mineral oil] (0.480 g, 12.0 mmol) in portions over 15 min. The resulting mixture was allowed to stir for 1 hr at 0° C., after which (2-(chloromethoxy)ethyl)trimethylsilane [SEM-Cl] (2.12 mL, 12.0 mmol) was added over 15 min. The resulting mixture was stirred for 1 hr, after which it was quenched with H2O (50 mL), and pardoned between EtOAc and H2O. The organic layer was separated, washed with brine, dried over MgSO4, filtered, and evaporated in vacuo to yield a yellow oil (2.50 g, 100%). HPLC retention time: 2.66 minutes; MS ESI (m/z): 249.4 (M+1)+, calc. 248.
-
- To a solution of 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (2.50 g, 10.0 mmol) in 1:1 tert-butanol/H2O (140 mL) at room temperature was added bromine (6.40 mL, 126 mmol). After stirring for 3.5 hr at room temperature, an additional portion of bromine was added (6.40 mL, 126 mmol) and the resulting mixture was stirred for 18 hr. The resulting mixture was concentrated in vacuo to yield the title compound, which was used without any further purification. HPLC retention time: 2.97 minutes; MS ESI (m/z): 441.0/443.0/445.2 (Fragment+1)+, calc. 498.
-
- To a solution of 3,3,5-tribromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (4.98 g, 10.0 mmol) in AcOH (50 mL) was added zinc dust (1.28 g, 20.0 mmol). The resulting mixture was stirred at room temperature for 2 hr, after which it was filtered thru Celite and concentrated in vacuo. The resulting residue was purified via silica gel chromatography eluting with 1:1 Hexanes:EtOAc to yield the title compound as a yellow oil (0.85 g, 25% over three steps). HPLC retention time: 2.60 minutes; MS ESI (m/z): 287.2 (Fragment+1)+, calc. 342.
-
- To a solution of 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (0.85 g, 2.5 mmol) in CH3CN (5 mL) was added 3,4,5-trimethoxyphenylboronic acid (525 mg, 2.5 mmol), bis(triphenylphosphine)-palladium(II) dichloride (250 mg, 0.35 mmol), and 1 M Na2CO3 (5 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 80° C. for 2 hr. The reaction mixture was partitioned between EtOAc and H2O, and the organic layer was separated, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with 3:1 EtOAc:Hexanes to yield the title compound (640 mg, 60%). HPLC retention time: 2.51 minutes; MS ESI (m/z): 431.4 (M+1)+, calc. 430.
-
- To a solution of 5-(3,4,5-trimethoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (43 mg, 0.10 mmol) in DMF (2 mL) was added cesium carbonate (0.17 g, 0.50 mmol) and methyl iodide (19 μL, 0.30 mmol). The resulting solution was stirred for 48 hr at room temperature, after which it was partitioned between EtOAc and H2O. The organic layer was separated, dried over MgSO4, filtered, and concentrated in vacuo. The residue was dissolved in 6 N HCl (10 mL) and MeOH (5 mL), and the resulting mixture was stirred at room temperature overnight, after which it was partitioned between EtOAc and H2O. The organic layer was concentrated in vacuo, and the residue was dissolved in EtOH (2 mL). Potassium acetate (100 mg) was then added, and the reaction was stirred for 2 hr. The resulting solution was purified via preparatory HPLC to give the title compound (24 mg, 73%). 1H NMR (CDCl3, 300 MHz): δ 9.72 (s, 1H), 8.35 (d, J=2.1 Hz, 1H), 7.60 (d, J=1.8 Hz, 1H), 6.71 (s, 2H), 3.95 (s, 6H), 3.90 (s, 3H), 1.49 (s, 6H). HPLC retention time: 1.80 minutes; MS ESI (m/z): 329.4 (M+1)+, calc. 328.
-
-
- To a solution of 5-(3,4,5-trimethoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (Compound BN, 43 mg, 0.10 mmol) in DMF (2 mL) was added cesium carbonate (0.17 g, 0.50 mmol) and 1,4-diiodobutane (13 μL, 0.10 mmol). The resulting solution was stirred for 4 hr at room temperature, after which it was partitioned between EtOAc and H2O. The organic layer was separated, dried over MgSO4, filtered, and concentrated in vacuo. The residue was dissolved in 6 N HCl (10 mL) and MeOH (5 mL), and the resulting mixture was stirred at room temperature overnight, after which it was partitioned between EtOAc and H2O. The organic layer was concentrated in vacuo, and the residue was dissolved in EtOH (2 mL). Potassium acetate (100 mg) was then added, and the reaction was stirred for 2 hr. The resulting solution was purified via preparatory HPLC to give the title compound (18 mg, 51%). 1H NMR (CDCl3, 300 MHz): δ 9.53 (s, 1H), 8.32 (d, J=2.1 Hz, 1H), 7.56 (s, 1H), 6.69 (s, 2H), 3.95 (s, 6H), 3.90 (s, 3H), 2.28 (m, 2H), 2.24 (m, 2H), 1.97 (m, 4H). HPLC retention time: 2.00 minutes; MS ESI (m/z): 355.4 (M+1)+, calc. 354.
-
-
- To a solution of 5-(3,4,5-trimethoxyphenyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (43 mg, 0.10 mmol) in DMF (2 mL) was added cesium carbonate (0.17 g, 0.50 mmol), (bromomethyl)cyclopropane (10 μL, 0.10 mmol), and potassium iodide (83 mg, 0.50 mmol). The resulting solution was stirred for 4 hr at room temperature, after which it was partitioned between EtOAc and H2O. The organic layer was separated, dried over MgSO4, filtered, and concentrated in vacuo. The residue was dissolved in 6 N HCl (10 mL) and MeOH (5 mL), and the resulting mixture was stirred at room temperature overnight, after which it was partitioned between EtOAc and H2O. The organic layer was concentrated in vacuo, and the residue was dissolved in EtOH (2 mL). Potassium acetate (100 mg) was then added, and the reaction was stirred for 2 hr. The resulting solution was purified via preparatory HPLC to give the Compound Q (11.4 mg) and Compound R (4.1 mg). Compound BQ: 1H NMR (CDCl3. 300 MHz): δ 8.37 (d, J=2.1 Hz. 1H), 7.71 (s, 1H), 6.72 (s, 2H), 3.96 (s, 6H), 3.91 (s, 3H), 2.04 (m, 2H), 1.69 (m, 2H), 1.26 (m, 2H), 0.88 (m, 2H), 0.40 (m, 2H), 0.29 (m, 2H), −0.07 (m, 2H). HPLC retention time: 2.49 minutes; MS ESI (m/z): 409.4 (M+1)+, calc. 408. Compound BR: 1H NMR (CDCl3, 300 MHz): δ 8.31 (s, 1H). 7.92 (s, 1H), 6.69 (s, 2H), 3.95 (s, 6H), 3.91 (s, 3H), 3.50 (m, 1H), 2.18 (m, 1H), 1.78 (m, 1H), 1.26 (m, 1H), 0.83 (m, 2H), 0.25 (m, 2H). HPLC retention time: 2.32 minutes; MS ESI (m/z): 355.0 (M+1)+, calc. 354.
-
- Commercially available 5-bromopyridine-2,3-diamine 3 was converted to 6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one via treatment with carbonyl diimidazole in THF at 60° C., which was then protected as the monoethoxy carbonyl derivative 4 in a fashion similar to that described in J. Org. Chem., 1995, 1565-1582. Intermediate 4 was subjected to an NOE analysis, and interactions between the 7-position hydrogen and the carbamate ethyl group were apparent, supporting the structure that is shown above. Following protection of the 3-position amine with a tert-butyl carboxylate group and deprotection of the ethyl carboxylate group using isopropyl amine, intermediate 6 was coupled to indole-5-boronic acid using copper acetate in a mixture of DCM/pyridine, after which it was deprotected using TFA/CH2Cl2. To the resulting 6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one in CH3CN (1 mL) in a microwave reaction vial was added 3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol), bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The resulting mixture was partitioned between EtOAc and 1 M NaOH. The organic layer was separated, dried over MgSO4, filtered, and stripped to give a residue that was purified via preparatory HPLC to give 1.8 mg of the title compound. HPLC retention time: 2.36 minutes; MS ESI (m/z): 417.4 (M+1)+, calc. 416.
-
- Intermediate 5 from Example 124 was alkylated with (bromomethyl)cyclopropane using K2CO3 in acetone, after which it was deprotected using TFA/CH2Cl3. To the resulting 6-bromo-1-(cyclopropylmethyl)-1H-imidazo[4,5-b]pyridin-2(3H)-one in CH3CN (1 mL) in a microwave reaction vial was added 3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol), bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The resulting mixture was partitioned between EtOAc and 1 M NaOH. The organic layer was separated, dried over MgSO4, filtered, and stripped to give a residue that was purified via preparatory HPLC to give 3.7 mg of the title compound. HPLC retention time: 1.90 minutes; MS ESI (m/z): 356.2 (M+1)+, calc. 355.
-
-
- Following a method described in Pteridines, 2002, Vol. 13, 65-72, Intermediate BB was heated in anhydrous DMF at 175° C. for 15 min in a Personal Chemistry Optimizer. To the resulting 6-bromo-1-(1H-indol-5-yl)-1H-imidazo[4,5-b]pyrazine 1 in CH3CN (1 mL) in a microwave reaction vial was added 3,4,5-trimethoxyphenylboronic acid (30 mg, 0.14 mmol), bis(triphenylphosphine)-palladium(II) dichloride (7.0 mg, 0.010 mmol), and 1 M Na2CO3 (1 mL). The resulting mixture was de-gassed with Ar for 10 min, after which it was heated at 150° C. for 10 min in a Personal Chemistry Optimizer. The resulting mixture was partitioned between EtOAc and 1 M NaOH. The organic layer was separated, dried over MgSO4, filtered, and stripped to give a residue that was purified via preparatory HPLC to give 4.7 mg of the title compound. HPLC retention time: 2.43 minutes; MS ESI (m/z): 402.8 (M+1)+, calc. 401.
-
- Compound BX was prepared by reacting Example 78 with Lawesson's reagent in refluxing toluene. The resulting mixture was partitioned between EtOAc and 1 M NaHCO3. The organic layer was separated, dried over MgSO4, filtered, and stripped to give a residue that was purified via preparatory HPLC to give 2.0 mg of the title compound. HPLC retention time: 2.29 minutes; MS ESI (m/z): 373.2 (M+1)+, calc. 372.
-
- To a solution of 5-(3,4,5-trimethoxy-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (157 mg, 0.365 mmol) in toluene (2 mL) was added triethylamine (56 μl, 0.365 mmol), molecular sieves 4 Å (100 mg), and 3-pyridinecarboxaldehyde (38 μl, 0.401 mmol). The resulting mixture was stirred overnight at room temperature, after which it was filtered and partitioned between DCM and H2O. The organic layer was separated, dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with 40-70% EtOAc:Hexanes to yield the SEM-protected precursor as a mixture of cis and trans isomers (101 mg, 53%). 41 mg (0.079 mmol) of this material was dissolved in MeOH (1.5 ml), 6 N HCl (3 ml) was added, and the mixture was stirred for 3 hours at 45° C. The reaction was quenched with 1 N NaOH (15 ml), neutralized by the addition of saturated NaHCO3 and extracted with DCM. Silica gel chromatography eluting with 0-5% MeOH:DCM yielded the title compound (22 mg, 72%) as a cis/trans-mixture. 1H NMR (CDCl3, 300 MHz): 9.15 (d, J=4.8 Hz, 1H), 9.11 (bs, 1H), 9.02 (d, J=1.2 Hz, 1H), 8.98 (d, J=1.1, 1H), 8.69 (dd, J=0.9, 2.9 Hz, 1H), 8.66 (dd, J=0.9, 2.8 Hz, 1H), 8.39 (d, J=1.2 Hz, 1H), 8.37 (d, J=1.2 Hz, 1H), 7.95 (m, 1H), 7.93 (s, 1H), 7.87 (d, J=1.1 Hz, 1H), 7.44 (m, 1H), 6.75 (s, 2H), 6.59 (s, 2H), 3.97 (s, 6H), 3.91 (s, 3H), 3.90 (s, 6H), 3.86 (s, 3H).
-
- (E)- and (Z)-3-pyridin-4-ylmethylene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one were prepared by a method analogous to that described in Example 128 by substituting 3-pyridinecarboxaldehyde for 4-pyridinecarboxaldehyde in the reaction with Compound BN. The isomers were separated using silica gel chromatography eluting with 0-5% MeOH:DCM. Assignment of stereochemistry is tentatively based on the 1H NMR spectra. 1H NMR (CDCl3, 300 MHz): E-isomer: δ 8.91 (s, 1H), 8.76 (d, (J=3.6 Hz, 1H), 8.39 (d, J=1.2 Hz, 1H), 8.02 (d, J=3.7 Hz, 1H), 7.91 (d, J=1.2 Hz, 1H), 7.52 (s, 1H), 6.74 (s, 2H), 3.96 (s, 6H). 3.91 (s, 3H). Z-isomer: δ 9.01 (s, 1H), 8.78 (d, (J=3.5 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H), 7.87 (s, 1H), 7.81 (d, J=1.2 Hz, 1H), 7.52 (d, J=6.1 Hz, 1H), 6.56 (s, 2H), 3.89 (s, 6H), 3.88 (s, 3H).
-
- 3-Benzylidene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one was prepared by a method analogous to that described in Example 128 by substituting 3-pyridinecarboxaldehyde for benzaldehyde in the reaction with Compound BN. 15 mg (33%) of the title compound were obtained.
-
- 4-[2-Oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]-benzamideone was prepared by a method analogous to that described in Example 128 by substituting 3-pyridinecarboxaldehyde for 4-formylbenzamide in the reaction with Compound BN. 25 mg (50%) of the title compound were obtained.
-
- 3-[2-Oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]-benzamideone was prepared by a method analogous to that described in Example 128 by substituting 3-pyridinecarboxaldehyde for 3-formylbenzamide in the reaction with Compound BN. 26 mg (52%) of the title compound were obtained.
-
-
- A mixture of 5-bromo-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (200 mg, 0.939 mmol), 3,4,5-trimethoxyphenylboronic acid (239 mg, 1.127 mmol) and dichlorobis(triphenylphosphine)palladium (II) (33 mg, 0.047 mmol) in CH3CN (5 ml) and 1 M Na2CO3 (5 ml) was heated in a microwave reactor for 10 min at 150° C. The reaction mixture was filtered, evaporated, partitioned between water and DCM and purified by silica gel chromatography with 0-10% MeOH:DCM to obtain 85 mg (30%) of compound #. 1H NMR (CDCl3/DMSO-d6, 300 MHz): δ 10.19 (bs, 1H), 8.18 (d, J=1.1 Hz, 1H), 7.54 (s, 1H), 6.57 (s, 2H), 3.80 (s, 6H), 3.75 (s, 3H), 3.47 (s, 2H).
-
- A mixture of 5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (Intermediate BY, 42 mg, 0.14 mmol), 4-cyanobenzaldehyde (22 mg, 0.168 mmol), triethylamine (22 μl, 0.168 mmol) and molecular sieves 4 Å (100 mg) in toluene (2 ml) was reacted at 80° C. for 1 d. The mixture was partitioned between DCM and water, the aqueous phase extracted with DCM, combined organic phases dried, evaporated and purified by silica gel chromatography (0-5% MeOH:DCM) to obtain 31 mg (54%) of the title compound as a mixture of (E)- and (Z)-isomers.
-
- 3-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]-benzonitrile was prepared by a method analogous to that described in Example 133 by substituting 4-cyanobenzaldehyde for 3-cyanobenzaldehyde in the reaction with Intermediate BY. 36 mg (62%) of the title compound were obtained as a mixture of cis- and trans-isomers.
-
- To a solution of 3-pyridin-4-ylmethylene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (50 mg, 0.128 mmol) in MeOH (4 ml) was added ammonium formate (245 mg, 3.85 mmol) and Pd/C (10%, 30 mg). The mixture was stirred at room temperature for 3 hrs after which it was filtered, evaporated, and partitioned between water and DCM. The title compound (33 mg, 66%) was obtained after silica gel chromatography eluting with 0-10% MeOH:DCM. 1H NMR (CDCl3, 300 MHz): δ 10.05 (s, 1H), 8.60 (d, J=2.6 Hz, 1H). 8.45 (d, J=1.1 Hz, 1H), 8.38 (d, J=1.2 Hz, 1H), 7.62 (d, J=4.7 Hz, 1H), 7.35 (dd, J=2.9, 4.7 Hz, 1H), 6.53 (d, J=1.2 Hz, 1H), 6.38 (s, 1H), 3.95 (m, 1H), 3.90 (m, 1H), 3.85 (s, 6H), 3.84 (s, 3H), 3.84 (m, 1H).
-
- 3-Pyridin-4-ylmethyl-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one was prepared by a method analogous to that described in Example 135. The title compound (14 mg, 61%) was obtained after silica gel chromatography eluting with 0-8% MeOH:DCM. 1H NMR (CDCl3, 300 MHz): δ 9.52 (bs, 1H), 8.54 (d, J=3.5 Hz, 1H), 8.32 (d, J=1.1 Hz, 1H), 7.18 (d, J=3.6 Hz, 1H), 7.12 (m, 1H), 6.54 (s, 1H), 3.91 (s, 6H), 3.89 (m, 1H), 3.88 (s, 3H), 3.54 (dd, J=3.1, 8.3 Hz, 1H), 3.03 (dd, J=5.6, 8.3 Hz, 1H).
-
- To a solution of 3-benzylidene-5-(3,4,5-trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (41 mg, 0.106 mmol) in a mixture of MeOH (2 ml), THF (1 ml) and water (0.3 ml) was added sodium borohydride (40 mg, 1.06 mmol). The reaction was stirred at room temperature for 10 min after which it was quenched by the addition of 1 N HCl and partitioned between water and DCM. The residue was purified by preparatory HPLC to yield the title compound (5.2 mg, 13%).
-
- 4-[2-Oxo-5-(3,4,5-trimethoxy-phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-benzamide was prepared from 4-[2-oxo-5-(3,4,5-trimethoxy-phenyl)-1,2-dihydro-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]-benzamideone by a method analogous to that described in Example 137. The title compound (12 mg, 54%) was obtained after silica gel chromatography eluting with 0-10% MeOH:DCM. 1H NMR (DMSO-d6, 300 MHz): δ 11.06 (s, 1H), 8.34 (d, J=1.5 Hz, 1H), 7.88 (s, 1H), 7.75 (d, J=5.0 Hz, 2H), 7.41 (d, J=0.5 Hz, 1H), 7.30 (s, 1H), 7.28 (d, J=5.0 Hz, 2H), 6.74 (s, 2H), 4.03 (m, 1H), 3.82 (s, 6H), 3.67 (s, 3H), 3.44 (dd, J=3.4, 8.2 Hz, 1H), 3.11 (dd, J=4.6, 8.2 Hz, 1H).
-
- 5-(3,4,5-Trimethoxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one (95 mg, 0.316 mmol) and TMEDA (96 μl, 0.623 mmol) were dissolved in anhydrous THF (4 ml) and cooled to −78° C. n-BuLi (1.6 M in hexanes, 415 μl, 0.664 mmol) was added dropwise. After completed addition stirring was continued for 1 hr at −78° C. Benzyl bromide (41.3 μl, 0.348 mmol) was added dropwise as a 10% solution in anh. THF. After completed addition the reaction was allowed to warm up to room temperature while stirring overnight. The reaction was quenched by the addition of MeOH, evaporated and partitioned between water and DCM. Silica gel chromatography eluting with 0-50% EtOAc:Hexanes yielded the title compound (47 mg, 38%). 1H NMR (CDCl3, 300 MHz): δ 8.83 (s, 1H), 8.18 (d, J=1.2 Hz, 1H), 7.19 (d, J=1.2 Hz, 1H), 7.14 (m, 6H), 6.99 (m, 4H), 6.61 (s, 2H), 3.96 (s, 6H), 3.90 (s, 3H), 3.30 (d, J=8.0 Hz, 2H), 3.26 (d, J=8.0 Hz, 2H).
-
- 2-(4-Bromomethyl-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (100 mg, 0.337 mmol). N-acetylpiperazine (47 mg, 0.37 mmol) and K2CO3 (93 mg, 0.675 mmol) were combined in DMF (2.5 ml) and stirred overnight at room temperature. The reaction was quenched by the addition of water, extracted with DCM and dried. The residue was taken up in CH3CN (2 ml), Intermediate B (120 mg, 0.275 mmol) and dichlorobis(triphenylphosphine)palladium (II) (10 mg, 0.013 mmol) were added and the reaction was heated to 150° C. in a microwave reactor for 20 min. The mixture was partitioned between water and DCM, the organic phase dried, evaporated and purified by silica gel chromatography using 0-5% MeOH:DCM. 53 mg (46%) of the title compound were obtained. MS ESI (m/z): 450.4 (M+1)+, calc. 449.
-
- 4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-1-methyl-piperazin-2-one was prepared by a method analogous to that described in Example 140 by substituting N-acetylpiperazine for 1-methyl-piperazin-2-one. The title compound (14 mg, 28%) was obtained after silica gel chromatography eluting with 0-10% MeOH:DCM. MS ESI (m/z): 435.9 (M+1)+, calc. 435.
-
- 4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-piperazin-2-one was prepared by a method analogous to that described in Example 140 by substituting N-acetylpiperazine for piperazin-2-one. The title compound (22 mg, 45%) was obtained after silica gel chromatography eluting with 0-10% MeOH:DCM. MS ESI (m/z): 422.2 (M+1)+, calc. 421.
-
- 4-{3-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-1-methyl-piperazin-2-one was prepared by a method analogous to that described in Example 140 by substituting N-acetylpiperazine for 1-methyl-piperazin-2-one and 2-(4-bromomethyl-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane for 3-(bromomethyl)phenylboronic acid. The title compound (22 mg, 45%) was obtained after silica gel chromatography eluting with 0-10% MeOH:DCM. MS ESI (m/z): 436.4 (M+1)+, calc. 435.
-
- 4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzyl}-piperazine-1-carboxylic acid tert-butyl ester was prepared by a method analogous to that described in Example 140 by substituting N-acetylpiperazine for N-Boc-piperazine. The title compound (20 mg, 33%) was obtained after silica gel chromatography eluting with 0-3% MeOH:DCM. MS ESI (m/z): 508.2 (M+1)+, calc. 507.
-
- 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid (100 mg, 0.403 mmol), EDCI (97 mg, 0.504 mmol) and DMAP (catalytic amount) were combined in CH3CN, stirred for 10 min and treated with N-methylpiperazine (54 μl, 0.484 mmol). The mixture was stirred overnight at room temperature. An aliquot of 650 μl was taken, combined with Intermediate B (50 mg, 0.107 mmol) and dichlorobis(triphenylphosphine)palladium (II) (10 mg, 0.013 mmol) and heated to 150° C. in a microwave reactor for 20 min. The mixture was partitioned between water and DCM, the organic phase dried, evaporated and purified by silica gel chromatography using 0-6% MeOH:DCM. 13 mg (28%) of the title compound were obtained. 1H NMR (DMSO-d6, 300 MHz): δ 11.88 (d, J=1.5 Hz, 1H), 11.08 (s, 1H), 8.57 (d, J=2.1 Hz, 1H), 8.45 (d, J=1.8 Hz, 1H). 7.90 (s, 1H), 7.82 (d, J=8.4 Hz, 1H), 7.77 (d, J=2.4 Hz, 1H), 7.47 (m, 4H), 7.34 (t, J=2.6 Hz, 1H), 6.47 (t, J=2.4 Hz, 1H), 3.58 (bs, 4H), 2.3 (bs, 4H), 2.18 (s, 3H).
-
- 1-(4-{4-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-piperazin-1-yl)-ethanone was synthesized by a method analogous to that described in Example 144 by substituting N-methylpiperazine for N-acetylpiperazine. The title compound (13 mg, 26%) was obtained after silica gel chromatography eluting with 0-5% MeOH:DCM. MS ESI (m/z): 464.2 (M+1)+, calc. 463.
-
- {3-[3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone was synthesized by a method analogous to that described in Example 144 by substituting 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid for 3-carboxyphenylboronic acid. The title compound (23 mg, 49%) was obtained after silica gel chromatography eluting with 5-10% MeOH:DCM. MS ESI (m/z): 436.4 (M+1)+, calc. 435.
-
-
- 5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (Intermediate BZ, 483 mg, 1.01 mmol), 4-aminocarbonylphenylboronic acid (196 mg, 1.22 mmol) and dichlorobis(triphenylphosphine)palladium (II) (71 mg, 0.1 mmol) were combined in CH3CN (10 ml) and 1 M Na2CO3 (10 ml) and stirred at 60° C. for 3 hrs. Water was added and the mixture was extracted with DCM and purified by silica gel chromatography using 0-30% EtOAc/Hexanes. The title compound was obtained in 79% yield (373 mg). 1H NMR (CDCl3, 300 MHz): δ 8.51 (d, J=1.2 Hz, 1H), 8.20 (d, J=1.2 Hz, 1H), 8.11 (d, J=5.1 Hz, 2H), 7.96 (s, 1H), 7.93 (d, J=5.0 Hz, 2H), 7.64 (d, J=5.1 Hz, 2H), 7.31 (d, J=4.8 Hz, 2H), 6.1 (bs, 1H), 5.7 (bs, 1H), 2.39 (s, 3H).
-
- 4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzamide (Intermediate CA, 200 mg, 0.425 mmol), 4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-carboxylic acid tert-butyl ester (212 mmg, 0.51 mmol) and dichlorobis(triphenylphosphine)palladium (II) (15 mg, 0.021 mmol) were combined in CH3CN (5 ml) and 1 M Na2CO3 (5 ml) and reacted in a microwave reactor at 150° C. for 10 min. The mixture was filtered, water was added, extracted with EtOAc and purified by silica gel chromatography using 0-8% MeOH:DCM. The title compound was obtained in 46% yield (102 mg). 1H NMR (DMSO-d6, 300 MHz): δ 12.2 (bs, 1H). 8.63 (d, J=1.1 Hz, 1H), 8.54 (d, J=1.1 Hz, 1H), 8.08 (s, 1H), 7.98 (bs, 1H), 7.96 (d, J=5.1 Hz, 2H), 7.89 (m, 4H), 7.54 (d, J=4.9 Hz, 2H), 7.32 (bs, 1H), 3.6 (bs, 2H), 3.4 (bs), 1.41 (s, 9H).
-
- A solution of 4-{4-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-piperazine-1-carboxylic acid tert-butyl ester (100 mg, 0.19 mmol) in MeOH (3 ml) was treated with 4 N HCl in dioxane (2.5 ml) and stirred at room temperature for 1 hr. The mixture was evaporated, taken up in MeOH and evaporated again. This was repeated twice to give 102 mg (116%) of the title compound. MS ESI (m/z): MS ESI (m/z): 426.4 (M+1)+, calc. 425.
-
- To a solution of 4-{5-[4-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide, hydrochloride salt (19 mg, 0.041 mmol) in MeOH (2 ml) was added triethylamine (400 μl, 2.88 mmol) and acetic anhydride (100 μl, 1.06 mmol). The mixture was stirred for 1 hr at room temperature. EtOAc was added and washed with saturated aqu. NaHCO3, water, brine and dried and evacuated. Purification on silica gel employing 0-10% MeOH:DCM provided 4.7 mg (25%) of the title compound. MS ESI (m/z): 468.3 (M+1)+, calc. 467.
-
- 4-{3-[3-(4-Carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-piperazine-1-carboxylic acid tert-butyl ester was prepared by a method analogous to that described in Example 148 by substituting 4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-carboxylic acid tert-butyl ester for 4-[3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-carboxylic acid tert-butyl ester. The title compound (109 mg, 49%) was obtained after silica gel chromatography eluting with 0-8% MeOH:DCM. 1H NMR (DMSO-d6, 300 MHz): δ 12.18 (bs, 1H), 8.61 (d, J=1.2 Hz, 1H), 8.52 (d, J=1.2 Hz, 1H), 8.07 (s, 1H), 7.96 (m, 3H). 7.89 (m, 3H). 7.80 (s, 1H), 7.57 (t, J=4.6 Hz, 1H), 7.41 (d, J=4.6 Hz, 1H), 7.32 (s, 1H). 3.63 (bs, 2H), 3.4 (bs, 2H), 1.40 (s, 9H).
-
- The hydrochloride salt of 4-{5-[3-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to that described in Example 149 by substituting 4-{4-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-piperazine-1-carboxylic acid tert-butyl ester for 4-{3-[3-(4-carbamoyl-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzoyl}-piperazine-1-carboxylic acid tert-butyl ester. 105 mg (128%) of the title compound were obtained. 1H NMR (DMSO-d6, 300 MHz): δ 12.32 (s, 1H), 9.52 (s, 2H), 8.66 (d, J=1.8 Hz, 1H), 8.59 (d, J=1.8 Hz, 1H), 8.11 (d, J=2.7 Hz, 1H), 7.95 (m, 5H), 7.60 (t, J=7.8 Hz, 1H), 7.52 (d, J=7.2 Hz, 1H), 7.36 (bs, 1H), 3.6-4.0 (bs, 8H).
-
- 4-{5-[3-(4-Acetyl-piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to that described in Example 150 by substituting 4-{5-[4-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide, hydrochloride salt for 4-{5-[3-(piperazine-1-carbonyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide, hydrochloride salt. 3.1 mg (14%) of the title compound were obtained. 1H NMR (CD3OD, 300 MHz): δ 8.56 (d, J=1.2 Hz, 1H), 8.55 (d, J=1.2 Hz, 1H), 7.99 (d, J=4.2 Hz, 2H), 7.86 (m, 4H), 7.81 (d, J=1.8 Hz, 1H), 7.62 (t, J=4.6 Hz, 1H), 7.47 (dd, J=0.7, 3.8 Hz, 1H), 3.5-3.9 (m, 8H), 2.14 (bd, 3H).
-
- 4-[5-(3,4,5-Trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzamide (50 mg, 0.124 mmol), magnesium monoperoxyphthalic acid (80%, 300 mg, 0.46 mmol) and acetic acid (10 drops were combined in EtOH (3 ml) and stirred at 50° C. for 1 hr. After adding EtOAc the mixture was washed with saturated NaHCO3, dried and purified by silica gel chromatography using 0-8% MeOH:DCM to provide 18 mg (33%) of the title compound. 1H NMR (DMSO-d6, 300 MHz): δ 12.9 (bs, 1H), 8.62 (s, 1H), 8.14 (s, 1H), 8.0 (bs, 2H), 7.97 (d, J=5.0 Hz, 2H), 7.89 (d, J=5.0 Hz, 2H), 7.34 (bs, 1H). 7.04 (s, 2H), 3.89 (s, 6H), 3.70 (s, 3H).
-
- 4-{5-[4-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to that described in Example 148 by substituting 4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-carboxylic acid tert-butyl ester for 1-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-piperazine. The title compound (24 mg, 44%) was obtained by precipitation from DCM. 1H NMR (DMSO-d6, 300 MHz): δ 12.1 (s, 1H), 8.57 (d, J=1.2 Hz, 1H), 8.48 (d, J=1.2 Hz, 1H), 8.05 (d, J=1.3 Hz, 1H), 7.98 (bs, 1H), 7.96 (d, J=5.0 Hz, 2H), 7.88 (d, J=5.1 Hz, 2H), 7.73 (d, J=4.5 Hz, 2H), 7.40 (d, J=4.5 Hz, 2H), 7.31 (bs, 1H), 3.50 (s, 2H), 2.2-2.45 (bs, 8H), 2.15 (s, 3H).
-
- 4-{5-[3-(4-Methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to that described in Example 148 by substituting 4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl]-piperazine-1-carboxylic acid tert-butyl ester for 1-methyl-4-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-piperazine. The title compound (8 mg, 15%) was obtained by precipitation from DCM. 1H NMR (DMSO-d6, 300 MHz): δ 12.1 (s, 1H), 8.56 (d, J=1.2 Hz, 1H), 8.46 (d, J=1.2 Hz, 1H), 8.05 (d, J=1.3 Hz, 1H), 7.96 (m, 3H), 7.88 (d, J=5.1 Hz, 2H), 7.66 (m, 2H), 7.45 (m, 1H), 7.31 (m, 2H), 3.55 (s, 2H), 2.2-2.45 (bs, 8H), 2.14 (s, 3H).
-
- 4-{5-[4-(4-Acetyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to that described in Example 140 by substituting Intermediate B with Intermediate CA. Purification by silica gel chromatography using 4-5% MeOH:DCM yielded the title compound (13 mg, 30%). MS ESI (m/z): 454.1 (M+1)+, calc. 453.
-
- 4-{5-[4-(4-Methyl-3-oxo-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to that described in Example 140 by substituting Intermediate B with Intermediate CA and N-acetylpiperazine for 1-methyl-piperazin-2-one. Purification by silica gel chromatography using 4-5% MeOH:DCM yielded the title compound (4 mg, 10%). MS ESI (m/z): 440.3 (M+1)+, calc. 439.
-
-
- 5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (200 mg, 0.419 mmol), 4-aminomethylphenylboronic acid hydrochloride (95 mg, 0.503 mmol) and dichlorobis(triphenylphosphine)palladium (II) (29 mg, 0.042 mmol) were combined in CH3CN (5 ml) and 1 M Na2CO3 (5 ml) and stirred at 60° C. for 3 hrs. EtOAc was added, the organic phase was washed with water, dried and evaporated, to yield 136 mg (71%) of the title compound. MS ESI (m/z): 455.9/458.1 (M+1)+, calc. 455/457.
-
- 4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzylamine (Intermediate CB, 45 mg, 0.1 mmol) was combined with triethylamine (45 μl, 0.3 mmol) and acetic anhydride (11 μl, 0.11 mmol) in anh. DCM (2 ml). The mixture was stirred for 2 hrs, EtOAc, was added and washed with 0.5 N HCl, saturated NaHCO3, water and brine. Evaporation yielded the title compound (48 mg, 96%). MS ESI (m/z): 498.1/500.1 (M+1)+, calc. 497/499.
-
- N-{4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzyl}-acetamide (Intermediate CC, 24 mg, 0.048 mmol), 3,4,5-trimethoxyphenyl boronic acid (13 mg, 0.058 mmol) and dichlorobis(triphenylphosphine)palladium (II) (2 mg, 0.002 mmol) were combined in CH3CN (1 ml) and 1 M Na7CO3 (2 ml) and heated in a microwave reactor at 150° C. for 20 min. EtOAc was added, washed with water, dried and purified by silica gel chromatography eluting with 0-4% MeOH:DCM to give 11 mg (53%) of the title compound. MS ESI (m/z): 432.2 (M+1)+, calc. 431.
-
- 2-Phenyl-N-{4-[5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzyl}-acetamide was prepared by a method analogous to that described in Example 159 by substituting acetic anhydride for phenacetyl chloride. Purification by silica gel chromatography using 0-4% MeOH:DCM yielded the title compound (9 mg, 38%). MS ESI (m/z): 508.3 (M+1)+, calc. 507.
-
- 3-Phenyl-N-{4-[5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-benzyl}-propionamide was prepared by a method analogous to that described in Example 159 by substituting acetic anhydride for phenylpropionyl chloride. Purification by silica gel chromatography using 0-4% MeOH:DCM yielded the title compound (13 mg, 54%). MS ESI (m/z): 522.4 (M+1)+, calc. 521.
-
-
- 5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (200 mg, 0.419 mmol), 1-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-piperazine (160 mg, 0.503 mmol) and dichlorobis(triphenylphosphine)palladium (II) (30 mg, 0.042 mmol) were combined in CH3CN (5 ml) and 1 M Na2CO3 (5 ml) and stirred at 60° C. for 2 hrs. EtOAc was added and the organic phase was washed with water, dried and evaporated. Purification by silica gel chromatography using 0-20% MeOH:DCM yielded 235 mg (104%) of the title compound. MS ESI (m/z): 539.0/541.2 (M+1)+, talc. 538/540.
-
- 5-Bromo-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (Intermediate CD. 70 mg, 0.13 mmol), aminocarbonylphenylboronic acid (26 mg, 0.156 mmol) and dichlorobis(triphenylphosphine)palladium (II) (5 mg, 0.0065 mmol) were combined in CH3CN (2 ml) and 1 M Na2CO3 (2 ml) and reacted in a microwave reactor for 20 min at 150° C. Water was added and the aqueous phase was extracted with DCM, dried and evaporated. Purification by reversed phase chromatography using 0-100% MeOH:water yielded 6 mg (11%) of the title compound. MS ESI (m/z): 426.7 (M+1)+, calc. 425.
-
- 5-(1H-Indol-5-yl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridine was prepared by a method analogous to that described in Example 162 by substituting aminocarbonylphenylboronic acid for indole-5-boronic acid. Purification by silica gel chromatography using 0-10% MeOH:DCM yielded the title compound (28 mg, 60%). MS ESI (m/z): 422.4 (M+1)+, calc. 421.
-
-
- 5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (350 mg, 0.73 mmol), 4-(N-methylaminocarbonyl)phenylboronic acid (160 mg, 0.88 mmol) and dichlorobis(triphenylphosphine)palladium (11) (52 mg, 0.073 mmol) were combined in CH3CN (10 ml) and 1 M Na2CO3 (10 ml) and stirred at 60° C. for 5 hrs. Water was added and the mixture was extracted with DCM, combined organic phases were dried and evaporated to yield 428 mg (121%) of the title compound. 1H NMR (CDCl3, 300 MHz): δ 8.50 (d, J=1.3 Hz, 1H), 8.20 (d, J=1.2 Hz, 1H), 8.09 (d, J=5.1 Hz, 2H), 7.94 (s, 1H). 7.87 (d, J=5.1, 2H), 7.61 (d, J=5.0 Hz, 2H), 7.31 (d, J=5.0 Hz, 2H), 6.21 (bd, J=2.5 Hz, 1H), 3.06, (d, J=2.9 Hz, 3H), 2.39 (s, 3H).
-
- 4-[5-Bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-N-methyl-benzamide (Intermediate CE, 100 mg, 0.206 mmol), 3,4,5-trimethoxyphenylboronic acid (53 mg, 0.248 mmol) and dichlorobis(triphenylphosphine)palladium (II) (9 mg, 0.012 mmol) were combined in CH3CN (2 ml) and 1 M Na2CO3 (2 ml) and reacted in a microwave reactor for 20 min at 150° C. Water was added, the aqueous phase was extracted with DCM and the organic phase was dried and evaporated. Purification by silica gel chromatography using 0-8% MeOH:DCM yielded 40 mg (47%) of the title compound. 1H NMR (CDCl3, 300 MHz): δ 12.09 (s, 1H), 8.59 (d, J=1.2 Hz, 1H), 8.48 (d, J=1.2 Hz, 1H), 8.43 (q, J=2.7 Hz, 1H), 8.04 (s, 1H), 7.94 (d, J=4.0, 2H), 7.91 (d, J=4.0 Hz, 2H), 7.00 (s, 2H), 3.89 (s, 6H), 3.70 (s, 3H), 2.80, (d, J=4.5 Hz, 3H).
-
- N-Methyl-4-{5-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-benzamide was prepared by a method analogous to that described in Example 164 by substituting 3,4,5-trimethoxyphenylboronic acid for 1-methyl-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-piperazine. Purification by precipitation from hot DCM yielded the title compound (46 mg, 51%). NMR (CDCl3, 300 MHz): δ 12.09 (s, 1H), 8.57 (d, J=1.2 Hz, 1H), 8.48 (d, J=1.2 Hz, 1H), 8.43 (q, J=2.7 Hz, 1H), 8.05 (d, J=1.5 Hz, 1H), 7.92 (d, J=5.2 Hz, 2H), 7.89 (d, J=5.2 Hz, 2H), 7.73 (d, J=4.9 Hz, 2H), 7.40 (d, J=4.9 Hz, 2H), 3.50 (s, 2H), 2.81, (d, J=2.7 Hz, 3H), 2.2-2.45 (bs, 8H), 2.15 (s, 3H).
-
-
- 5-Bromo-3-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (70 mg, 0.147 mmol), 4-fluorophenylboronic acid (25 mg, 0.176 mmol) and dichlorobis(triphenylphosphine)palladium (II) (10 mg, 0.015 mmol) were combined in CH3CN (2 ml) and 1 M Na2CO3 (2 ml) and stirred at 60° C. for 3 hrs. EtOAc was added and the mixture was washed with water, dried and evaporated to yield 73 mg (112%) of the title compound. MS ESI (m/z): 445.1/447.2 (M+1)+, calc. 444/446.
-
- 5-Bromo-3-(4-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine (37 mg, 0.083 mmol), 3,4,5-trimethoxyphenylboronic acid (21 mg, 0.1 mmol) and dichlorobis(triphenylphosphine)palladium (II) (3 mg, 0.004 mmol) were combined in CH3CN (1.5 ml) and 1 M Na2CO3 (2 ml) and reacted in a microwave reactor for 20 min at 150° C. EtOAc was added and the mixture was washed with water, dried, evaporated and purified by silica gel chromatography using 0-2% MeOH:DCM to yield 9 mg (29%) of the title compound. MS ESI (m/z): 379.2 (M+1)+, calc. 378.
-
-
- 2-(4-Bromo-phenyl)-1H-imidazole (300 mg, 1.3 mmol), bis(pinacolato)diboron (376 mg, 1.48 mmol), KOAc (400 mg, 4.03 mmol) and PdCl2(dppf).CH2Cl2 (50 mg, 0.067 mmol) were combined in DMSO (8 ml) and stirred t 80° C. overnight. EtOAc was added, washed with water, dried, evaporated and purified by silica gel chromatography eluting with 0-5% MeOH:DCM to give 116 mg (36%) of the title compound. 1H NMR (CDCl3, 300 MHz): δ 7.86 (s, 4H), 7.18 (s, 2H), 1.36 (s, 12H).
-
- 5-Bromo-1H-pyrrolo[2,3-b]pyridine (1.54 g, 7.83 mmol). 3,4,5-trimethoxyphenylboronic acid (1.83 g, 8.61 mmol) and dichlorobis(triphenylphosphine)palladium (II) (275 mg, 0.39 mmol) were combined in CH3CN (10 ml) and 1 M Na2CO3 (10 ml) and reacted in a microwave reactor for min at 150° C. EtOAc was added and the mixture was washed with water, brine, dried, evaporated and purified by silica gel chromatography using 0-2% MeOH:DCM to yield 1.86 g (84%) of the title compound. 1H NMR (CDCl3, 300 MHz): δ 9.9 (bs, 1H), 8.54 (d, J=2.1 Hz, 1H), 8.11 (d, J=2.1 Hz, 1H), 7.41 (t, J=2.1 Hz, 1H), 6.82 (s, 2H), 6.58 (t, J=1.5 Hz, 1H), 3.96 (s, 6H), 3.92 (s, 3H).
-
- To a solution of 5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine (510 mg, 1.79 mmol) in acetone (100 ml) was added N-iodosuccinimide (444 mg, 1.97 mmol) under stirring. After 1 hr the mixture was evaporated and purified by silica gel chromatography using 0-2% MeOH:DCM to give the title compound (870 mg, 118%). MS ESI (m/z): 411.1 (M+1)+, calc. 410.
-
- A solution of 3-iodo-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine (870 mg, 2.12 mmol) in anh. THF (10 ml) was cooled to 0° C. and NaH (60% dispersion, 130 mg, 3.18 mmol) was added. After 20 min tosyl chloride (450 mg, 2.33 mmol) was added and the mixture was allowed to warm to room temperature. After 3 hrs the mixture was cooled to 0° C. and quenched by the addition of 0.5 N HCl. The product was extracted with DCM and purified by silica gel chromatography using DCM as an eluent affording 648 mg (54%). 1H NMR (CDCl3, 300 MHz): δ 8.61 (d, J=2.4 Hz, 1H), 8.12 (d, J=8.4 Hz, 1H), 7.91 (s, 1H), 7.74 (d, J=2.1 Hz, 1H), 7.31 (d, J=8.4 Hz, 2H), 6.73 (s, 2H), 3.94 (s, 6H), 3.90 (s, 3H), 2.39 (s, 3H).
-
- 3-Iodo-1-(toluene-4-sulfonyl)-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine (Intermediate CJ, 30 mg, 0.053 mmol), 2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazole (Intermediate CG, 18 mg, 0.064 mmol) and dichlorobis(triphenylphosphine)palladium (II) (2 mg, 0.003 mmol) were combined in CH3CN (1 ml) and 1 M Na2CO3 (1 ml) and stirred at 60° C. for 2 d. Additional Intermediate CG (18 mg, 0.064 mmol) was added and stirring was continued for another day. EtOAc was added and the mixture was washed with water, dried, evaporated and purified by silica gel chromatography using 0-5% MeOH:DCM to yield 5 mg (22%) of the title compound. MS ESI (m/z): 427.2 (M+1)+, calc. 426.
- The activity of the compounds in Examples 1-138 as MLK inhibitors is illustrated in the following assays. The other compounds listed above, which have not yet been made and/or tested, are predicted to have activity in these assays as well.
- 200 ng (130 nM) MLK3 (Dundee, DU8313) was incubated with 1 μM inactive MKK7b (Dundee, DU703) in the presence of 2 μM cold ATP (Km) and 0.5 μCi/assay 33P ATP and appropriate concentrations of compounds. After a twenty minute incubation, the reactions were washed through filter plates and read on a scintillation counter. Results are shown in Table 4 below, in which +++ indicates ≦0.1 μM, ++ indicates >0.1 μM and ≦1 μM, and + indicates >1 μM.
-
TABLE 4 Ex. MK3 IC50 MW 1 ++ 399.45 2 ++ 369.43 3 +++ 366.50 4 +++ 325.50 5 +++ 354.50 6 ++ 340.39 7 +++ 408.50 8 +++ 324.50 9 +++ 326.36 10 ++ 394.48 11 +++ 402.50 12 ++ 348.41 13 ++ 353.43 14 ++ 309.13 15 +++ 375.43 16 +++ 417.47 17 +++ 377.41 18 +++ 376.42 19 +++ 404.47 20 + 304.32 21 ++ 358.45 22 + 366.83 23 ++ 301.35 24 +++ 413.48 25 +++ 403.44 26 +++ 373.14 27 ++ 358.14 28 ++ 329.13 29 + 338.77 30 +++ 339.15 31 ++ 422.54 32 +++ 421.55 33 +++ 366.47 34 +++ 467.58 35 + 426.52 36 +++ 400.44 37 +++ 370.41 38 +++ 355.40 39 +++ 469.55 40 +++ 417.43 41 ++ 431.16 42 + 357.12 43 + 369.16 44 + 328.11 45 ++ 343.11 46 + 355.14 47 ++ 387.13 48 + 395.03 49 + 375.11 50 ++ 372.13 51 ++ 371.40 52 ++ 412.45 53 ++ 366.39 54 ++ 343.35 55 +++ 373.37 56 + 366.39 57 +++ 486.53 58 ++ 379.33 59 +++ 379.33 60 +++ 372.39 61 + 363.33 62 +++ 403.40 63 ++ 385.39 64 + 385.43 65 + 387.40 66 + 426.50 67 ++ 485.55 68 ++ 408.42 69 + 378.39 70 + 334.34 71 + 319.33 72 +++ 431.45 73 + 410.27 74 +++ 370.41 75 + 340.39 76 ++ 296.33 77 + 281.32 78 ++ 356.38 79 ++ 326.36 80 + 335.20 81 + 282.30 82 + 267.29 83 ++ 418.42 84 ++ 357.37 85 + 342.36 86 + 351.41 87 + 388.39 88 + 329.32 89 + 413.44 90 ++ 418.42 91 ++ 388.39 92 + 344.34 93 ++ 329.32 94 + 370.41 95 + 356.39 96 ++ 435.46 97 ++ 361.38 98 + 346.37 99 + 373.44 100 + 430.49 101 + 418.46 102 +++ 418.42 103 ++ 388.39 104 ++ 413.44 105 ++ 378.39 106 ++ 348.36 107 ++ 425.49 108 ++ 439.52 109 + 464.48 110 +++ 418.46 111 ++ 388.39 112 +++ 418.42 113 +++ 418.42 114 ++ 394.50 115 ++ 364.50 116 ++ 389.50 117 + 296.33 118 ++ 325.37 119 + 390.83 120 ++ 328.37 121 ++ 354.41 122 + 413.40 123 ++ 354.41 124 ++ 416.44 125 + 355.40 126 + 401.43 127 + 372.45 128 ++ 389.40 129 + 389.40 130 + 388.42 131 ++ 431.44 132 + 431.44 133 + 413.43 134 + 413.43 135 + 391.42 136 + 391.42 137 + 390.44 138 + 433.46 139 ++ 480.55 140 + 449.55 141 +++ 435.52 142 +++ 421.49 143 +++ 435.52 144 +++ 507.63 145 ++ 435.52 146 +++ 463.53 147 +++ 435.52 148 +++ 525.60 149 +++ 425.48 150 ++ 467.52 151 +++ 525.60 152 ++ HCl-salt: 461.94 153 ++ 467.52 154 ++ 419.43 155 ++ 425.53 156 +++ 425.53 157 +++ 453.54 158 +++ 439.51 159 +++ 431.48 160 ++ 507.58 161 ++ 521.61 162 +++ 425.53 163 + 421.54 164 + 417.46 165 +++ 439.55 166 ++ 378.40 167 ++ 426.47 - Compounds disclosed herein may be evaluated in pharmacokinetic assays and models to determine absorption, distribution, metabolism, and excretion parameters. The choice and tailoring of in vitro and ex vivo assays and in vivo models will vary according to the route of administration/formulation, indication under study, properties of test compounds, etc., as well as according to such factors as costs, availability of technology and resources, etc. Such parameters are well known in the fields of pharmacology and drug development. It is within the capacity of one skilled in the art to design and carry out, such work, or to outsource it to a capable third party.
- Several compounds disclosed herein were evaluated in a standard murine pharmacokinetic model. Compounds were selected that exhibited reasonable solubility and metabolic stability, and good predicted blood brain barrier penetration, based on low molecular weight, a low number of hydrogen bond donors, log D within a range of 2-4, and low polar surface area.
- Compounds were dissolved in either 5% DMSO, 40% PEG400, and 55% saline (pH=8) or % DMSO, 40% PEG400, and 55% (20% HP-β-CD in deionized water; pH=8) to yield a nominal concentration of 2 mg/mL for intravenous administration. Compounds were administered via a single intravenous (IV) injection in CL57 BL/6 mice at 10 mg/kg in DMSO/PEG400 solution. Three mice in each group were used for blood and brain collection at each time point. Blood samples (300 μL) were collected via the retro-orbital vein predose and at 5 min, 0.25, 0.50, 1, 2, 4, 6, 8, and 24 hours postdose. Blood samples were placed into tubes containing sodium heparin and centrifuged under refrigerated conditions at 8000 rpm for 6 minutes to separate plasma from the samples. The brain of each animal was collected after the final blood collection. The whole tissue was harvested, excised and rinsed by saline, dried by filter paper, and then placed into one tube per tissue per animal. All samples were stored at −20° C. until bioanalysis.
- Compound concentrations in plasma and brain homogenate were determined using a high performance liquid chromatography/mass spectrometry (HPLC/MS/MS) method (Agilent 1100 series HPLC, AB Inc. API4000 triple-quadrupole with an ESI interface and Analyst 1.4 software).
- Results in the form of area under the time-versus-concentration curve (AUC) are given below in Table 5. Additional compounds disclosed herein can be tested according to this method and are expected to exhibit similar results.
-
TABLE 5 AUC Plasma AUC Brain + indicates ≧1500 + indicates ≧500 Ex. − indicates <1500 − indicates <500 1 + + 4 − − 9 + + 17 + − 18 + − 32 + + - Compounds disclosed herein may be tested in any number of well-known and publicly available animal models of efficacy for diseases in which MLK3 inhibition may play a therapeutic role. It is within the capacity of one skilled in the art to select and tailor such a model.
- For example, compounds disclosed herein can be ranked for in vivo efficacy in a mouse model relevant to NeuroAids (D. Eggert, The Journal of Immunology, in press, November 2009.) Test compounds selected may be prioritized based on MLK3 potency and favorable exposure in the brain, but this is not an absolute requirement. Four-week-old male CB-17/IcrCrl-SCIDbr (CB17/SCID) mice may be purchased from Charles River Laboratory. HIV-1ADA-infected MDM (1.5×105 cells infected at an MOI of 0.1 in 5 ml) is stereotactically injected intracranially after 1 day of viral infection and referred to as HIVE mice. The test compound is then administered i.p. daily for 7 days at doses 0.5, 1.0, 1.5, 5.0, and 15.0 mg/kg/d (where, e.g., n=4 mice/treatment group). Vehicle only serves as the control. CB17/SCID mice receive intracranial (i.c.) injections of media (sham-operated) and serve as additional controls. Animals are treated with vehicle or test compound (i.e., a compound as disclosed herein) starting 1 d post-i.c, injection and for 7 d after MDM injections and test compound treatments. Dosing parameters, number per group, etc. may be varied as needed, and such variations are within the skill of one skilled in the art.
- Brain tissue is collected at necropsy, fixed in 4% phosphate-buffered paraformaldehyde, and embedded in paraffin. Paraffin blocks are cut until the injection site of the human MDM is identified. HIV-1 p24 Ag (cloneKal-1; Dako, Carpinteria, Calif.) is used to test for virus-infected human MDM. For each mouse. 30-100 serial (5-mm-thick) sections are cut from the injection site and three to seven sections (10 sections apart) analyzed. Abs to vimentin intermediate filaments (clone VIM 3B4; Boehringer Mannheim, Indianapolis, Ind.) are used for detection of human cells in mouse brains. Mouse microglia are detected by Abs to Iba-1 (WAKO, Osaka, Japan), and astrocytes are detected by Abs for glial fibrillaryacidic protein ([GFAP] Dako). NeuN, MAP-2 (both from Chemicon International), and H chain (200 kDa) neurofilaments (Dako) are used for detection of neurons. All sections are counterstained with Mayer's hematoxylin. The numbers of human MDM and HIV-1 p24 Ag-positive cells are counted with a Nikon Microphot-FXA microscope. All obtained images are imported into Image-Pro Plus, v. 4.0 (Media Cybernetics, Silver Spring, Md.) for quantifying area (%) of GFAP, Iba-1, MAP-2, and NeuN positive staining. Efficacious MLK inhibitors will exhibit a dose-dependent reduction in microgliosis and restoration of normal synaptic architecture relative to control animals. Compounds disclosed herein can be tested according to this method and are expected to exhibit similar results.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (71)
1. A compound of structural Formula II
or a salt thereof, wherein:
dashed lines indicate that a second bond may alternatively be present or absent;
X1 is chosen from CH and N;
X2 is chosen from C and N;
Y1, Y2, and Y3 are independently chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
Y4 is chosen from —(CH2)m, C(O), —(CH2)mO—, and —(CH2)mN—;
m is an integer from 0 to 2;
R1, R2, and R3 are independently chosen from lower alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, lower cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl, amido, amino, alkoxy, hydroxy, cyano, and nitro, any of which may be optionally substituted; or R1 and R2 may each additionally be heteroalkyl, and may be joined together such that R1 and R2 together form an alkylene, alkenylene, or heteroalkyl bridge comprising from 3 to 5 atoms, which may be optionally substituted;
R4 is chosen from hydrogen, (O), and (S);
R5 is chosen from hydrogen, hydroxy, cyano, lower alkyl, lower cycloalkyl, and lower alkoxy, any of which may be optionally substituted;
R13 is chosen from hydrogen, halogen, hydroxy, cyano, nitro, lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower alkoxy, any of which may be optionally substituted; and additionally, R13 and R3 may be joined together to form a lower spiro-cycloalkyl or spiro-phenyl comprising from 3 to 6 atoms, which may be optionally substituted; and
R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
2. The compound as recited in claim 1 , wherein R4 is (O), the second bond linking R4 and the fused bicyclic core is present, and the second bond in the five-membered portion of the fused bicyclic core is absent.
3. The compound as recited in claim 1 , wherein R4 is hydrogen, the second bond linking R4 and the fused bicyclic core is absent, and the second bond in the five-membered portion of the fused bicyclic core is present.
4. The compound as recited in claim 1 , wherein compounds have structural Formula III
wherein:
dashed lines indicate that a second bond may alternatively be present or absent;
X1 and X2 are independently chosen from CH and N;
Y3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
m is an integer from 0 to 1;
R2 and R3 are independently chosen from lower cycloalkyl, heterocycloalkyl, lower aryl, and lower heteroaryl, any of which may be optionally substituted;
R4 is chosen from hydrogen, (O), and (S);
R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
5. The compound as recited in claim 4 , having a structural Formula chosen from Formula IV and Formula V:
or a salt thereof, wherein
X1 and X2 are independently chosen from CH and N;
Y3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
m is an integer from 0 to 1;
R2 and R3 are independently chosen from lower cycloalkyl, lower heterocycloalkyl, lower aryl, and lower heteroaryl, any of which may be optionally substituted; and
R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
6. The compound as recited in claim 5 , wherein Y3 is chosen from a bond, C(O), and lower alkyl.
7. The compound as recited in claim 6 , wherein R3 is chosen from lower cycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
8. The compound as recited in claim 7 , wherein R2 is chosen from phenyl and lower heteroaryl, any of which may be optionally substituted.
9. The compound as recited in claim 7 , wherein R2 is chosen from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused bicyclic heteroaryl, any of which may be optionally substituted.
10. The compound as recited in claim 9 , wherein R2 is chosen from phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally substituted.
11. The compound as recited in claim 10 , wherein R2 is substituted with one or more substituents chosen from halogen, hydroxy, lower amino, C1-C3 alkoxy and C1-C3 alkyl.
12. The compound as recited in claim 11 , wherein R2 is substituted with one or more substituents chosen from fluorine, hydroxy, NH3, NH(CH3), N(CH3)2, methoxy, and methyl.
13. The compound as recited in claim 9 , wherein compounds have a structural Formula chosen from Formula VI, Formula VII, Formula VIII, and Formula IX:
or a salt thereof, wherein
Y3 is chosen from a bond, lower alkyl, lower carboxyl, and lower heteroalkyl;
Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
m is an integer from 0 to 1;
R2 is chosen from phenyl, 6-membered monocyclic heteroaryl, and 5/6-fused bicyclic heteroaryl, any of which may be optionally substituted;
R3 is chosen from lower cycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted;
R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted.
14. The compound as recited in claim 13 , wherein R2 is chosen from phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally substituted.
15. The compound as recited in claim 14 , wherein Y4 is chosen from C(O), O, N, and —CH2—.
16. The compound as recited in claim 13 , wherein R2 is chosen from
wherein
u is an integer from 0 to 3;
Y4 is chosen from C(O), —(CH2)m—, —(CH2)mO—, and —(CH2)mN—;
m is an integer from 0 to 1;
R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted; and
each R15 is independently chosen from halogen, hydroxy, cyano, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, lower amino, lower amido, lower sulfonamido, and lower sulfonyl.
17. The compound as recited in claim 16 , wherein R14 is chosen from null, lower heterocycloalkyl, phenyl, and monocyclic lower heteroaryl, any of which may be optionally substituted.
18. The compound as recited in claim 17 , wherein
Y4 is —(CH2)m—;
m is 0;
R14 is null;
u is an integer from 1 to 3; and
each R15 is independently chosen from fluorine, hydroxy, NH2, NH(CH3), N(CH3)2, NS(O)2CH3, methoxy, and methyl.
19. The compound as recited in claim 17 , wherein
Y4 is —(CH2)m—;
m is 1;
R14 is chosen from null, lower cycloalkyl, lower heterocycloalkyl, phenyl, and lower heteroaryl, any of which may be optionally substituted;
u is an integer from 0 to 2; and
each R15 is independently chosen from fluorine, hydroxy, NH2, NH(CH3), N(CH3)2, NS(O)2CH3, methoxy, and methyl.
20. The compound as recited in claim 17 , wherein each R15 is independently chosen from halogen, hydroxy, lower amino C1-C3 alkoxy and C1-C3 alkyl.
21. The compound as recited in claim 20 , wherein Y4 is chosen from C(O), O, N, and —CH2—.
22. The compound as recited in claim 21 , wherein Y3 is chosen from a bond and lower alkyl.
23. The compound as recited in claim 22 , wherein R14 is chosen from null and lower heterocycloalkyl, either of which may be optionally substituted.
24. The compound as recited in claim 23 , wherein Y3 is chosen from a bond and methyl.
25. The compound as recited in claim 24 , wherein R3 is substituted with one or more substituents chosen from halogen, hydroxy, lower amino, lower amido, lower phenylamido, lower phenylalkylamido, lower heterocycloalkyl, lowerheterocycloalkyl, loweralkylheterocycloalkyl, C1-C3 alkoxy and C1-C3 alkyl.
26. The compound as recited in claim 25 , wherein Y4 is —CH2—.
27. The compound as recited in claim 26 , wherein R3 is chosen from benzothiazolyl, pyrrolopyridinyl, indanyl, cyclopropyl, cyclopentyl, phenyl, pyridinyl, pyrimidinyl, and indolyl, any of which may be optionally substituted.
28. The compound as recited in claim 27 , wherein Y3 is a bond.
29. The compound as recited in claim 28 , each R15 is independently chosen from fluorine, hydroxy, NH2, NH(CH3), N(CH3)2, methoxy, and methyl.
30. The compound as recited in claim 29 , wherein R3 is substituted with one or more substituents chosen from fluorine, chlorine, hydroxy, NH2, NH(CH3), N(CH3)2, C(O)NH2, C(O)NHCH3, morpholino, piperazinyl, methylpiperazinyl, acetamido, methylacetamido, methylpropionamido, phenylacetamidomethylene, benzamidomethylene, phenylpropanamidomethylene, methoxy and methyl.
31. A compound of structural Formula III
or a salt thereof, wherein:
dashed lines indicate that a second bond may alternatively be present or absent;
X1 and X2 are independently chosen from CH and N;
Y3 is a bond;
Y4 is chosen from C(O), CH2, CHF, and CF2;
R2 is chosen from phenyl and 6-membered monocyclic heteroaryl, either of which may be optionally substituted;
R3 is optionally substituted bicyclic heteroaryl;
R4 is chosen from hydrogen, (O), and (S);
R14 is optionally substituted monocyclic heterocycloalkyl.
32. The compound as recited in claim 31 , wherein R3 is an optionally substituted 5/6-fused bicyclic heteroaryl.
33. The compound as recited in claim 32 , wherein Y4 is CH2.
34. The compound as recited in claim 33 , wherein R14 is optionally substituted piperazinyl.
35. The compound as recited in claim compound chosen from Examples 1 to 167.
36. A compound as recited in claim 1 for use as a medicament.
37. A compound as recited in claim 1 for use as a medicament for the treatment of an MLK-mediated disease.
38. The compound as recited in claim 37 , for use as a medicament for the treatment of an MLK3-mediated disease.
39. The compound as recited in claim 38 , wherein said disease is chosen from diabetes mellitus, hyperglycemia, retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, peripheral inflammation, cancer and hepatitis.
40. The use of a compound as recited in claim 1 in the manufacture of a medicament for the treatment of an MLK-mediated disease.
41. The use as recited in claim 40 , wherein said MLK is MLK3.
42. The use as recited in claim 41 , wherein said disease is chosen from diabetes mellitus, hyperglycemia, retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, peripheral inflammation, cancer and hepatitis.
43. A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.
44. A pharmaceutical composition comprising a compound as recited in claim 43 together with a pharmaceutically acceptable carrier.
45. A method of inhibition of MLK comprising contacting MLK with a compound as recited in claim 1 .
46. The method as recited in claim 45 , wherein said MLK is MLK3.
47. The method as recited in claim 46 wherein said inhibition is selective over other kinases.
48. A method of treatment of a MLK-mediated disease comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof.
49. The method as recited in claim 48 wherein said disease is an inflammatory disease or a metabolic disease.
50. The method as recited in claim 49 wherein said disease is chosen from diabetes mellitus, hyperglycemia, retinopathy, nephropathy, neuropathy, ulcers, micro- and macroangiopathies, gout and diabetic foot disease, insulin resistance, metabolic syndrome, hyperinsulinemia, hypertension, hyperuricemia, obesity, edema, dyslipidemia, chronic heart failure, atherosclerosis, and peripheral inflammation.
51. The method as recited in claim 50 wherein said disease is an autoimmune disease.
52. The method as recited in claim 51 wherein said disease is chosen from cancer and hepatitis.
53. A method of treatment of a MLK-mediated disease comprising the administration of:
a. a therapeutically effective amount of a compound as recited in claim 1 ; and
b. another therapeutic agent.
54. A method of achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient, wherein the effect is chosen from:
increased survival of heart cells;
suppression of neuroinflammation or peripheral inflammation;
suppression of activation of immune cells;
suppression of proliferation of hepatocytes following injury; and
suppression of proliferation of cancer cells.
55. The method as recited in claim 54 , wherein said immune cells are chosen from monocytes, macrophages and microglia.
56. A method of treatment of a neuropsychiatric disorder in a patient, comprising the step of administering to said patient an MLK inhibitor.
57. The method as recited in claim 56 , wherein said MLK is MLK3.
58. A method of treatment of a neuropsychiatric in a patient, comprising the step of administering to said patient a compound as recited in claim 1 .
59. The method as recited in claim 58 wherein said disorder a psychological disorder.
60. The method as recited in claim 59 wherein said disease is chosen from depression, bipolar disorder, and post-traumatic stress disorder (PTSD).
61. The method as recited in claim 58 wherein said disorder is a traumatic brain injury.
62. The method as recited in claim 61 wherein said traumatic brain injury is stroke.
63. The method as recited in claim 58 wherein said disorder is chosen from Alzheimer's Disease (AD), Parkinson's Disease, and HIV associated neurocognitive disorder (HAND).
64. The method as recited in claim 58 wherein said disorder is a neurologic disorder of hearing or vision.
65. The method as recited in claim 64 wherein said disorder is chosen from ototoxicity, hearing loss, acute injury to the inner ear, acoustic trauma, and injury resulting from blast noise.
66. The method as recited in claim 2 , additionally comprising the administration of a second therapeutic agent.
67. The method as recited in claim 66 wherein said second therapeutic agent is a selective serotonin reuptake inhibitor (SSRI).
68. The method as recited in claim 66 wherein said second therapeutic agent is CRP 1347.
69. A method of achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient, wherein the effect is chosen from:
increased survival of cells of the nervous system, cochlear cells, vestibular cells or retinal cells;
promotion of neurogenesis;
promotion of synaptogenesis;
prevention or reduction of neuronal damage; and
restoration or improvement of neuronal function.
70. A method of achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient, wherein the effect is chosen from:
increased survival of cells of the nervous system, cochlear cells, vestibular cells or retinal cells;
increased survival of heart cells;
promotion of neurogenesis;
promotion of synaptogenesis;
prevention or reduction of neuronal damage;
restoration or improvement of neuronal function;
suppression of neuroinflammation or peripheral inflammation;
suppression of activation of immune cells;
suppression of proliferation of hepatocytes following injury; and
suppression of proliferation of cancer cells.
71. The method as recited in claim 70 , wherein said immune cells are chosen from monocytes, macrophages and microglia.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/876,345 US20160024087A1 (en) | 2008-11-25 | 2015-10-06 | Mlk inhibitors and methods of use |
US15/172,355 US9814704B2 (en) | 2008-11-25 | 2016-06-03 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11795008P | 2008-11-25 | 2008-11-25 | |
US14875509P | 2009-01-30 | 2009-01-30 | |
US14877809P | 2009-01-30 | 2009-01-30 | |
PCT/US2009/065878 WO2010068483A2 (en) | 2008-11-25 | 2009-11-25 | Mlk inhibitors and methods of use |
US201113131193A | 2011-09-13 | 2011-09-13 | |
US14/508,566 US9181247B2 (en) | 2008-11-25 | 2014-10-07 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
US14/876,345 US20160024087A1 (en) | 2008-11-25 | 2015-10-06 | Mlk inhibitors and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/508,566 Division US9181247B2 (en) | 2008-11-25 | 2014-10-07 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/172,355 Continuation US9814704B2 (en) | 2008-11-25 | 2016-06-03 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160024087A1 true US20160024087A1 (en) | 2016-01-28 |
Family
ID=42243278
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/131,193 Active US8877772B2 (en) | 2008-11-25 | 2009-11-25 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
US14/508,566 Active US9181247B2 (en) | 2008-11-25 | 2014-10-07 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
US14/876,345 Abandoned US20160024087A1 (en) | 2008-11-25 | 2015-10-06 | Mlk inhibitors and methods of use |
US15/172,355 Active US9814704B2 (en) | 2008-11-25 | 2016-06-03 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/131,193 Active US8877772B2 (en) | 2008-11-25 | 2009-11-25 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
US14/508,566 Active US9181247B2 (en) | 2008-11-25 | 2014-10-07 | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/172,355 Active US9814704B2 (en) | 2008-11-25 | 2016-06-03 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors |
Country Status (8)
Country | Link |
---|---|
US (4) | US8877772B2 (en) |
EP (2) | EP2379561B1 (en) |
JP (2) | JP5930278B2 (en) |
CN (1) | CN102264743B (en) |
AU (1) | AU2009324894B2 (en) |
CA (1) | CA2744498C (en) |
ES (1) | ES2554375T3 (en) |
WO (1) | WO2010068483A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018067786A1 (en) | 2016-10-06 | 2018-04-12 | Janssen Pharmaceutica Nv | Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators |
US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
US10233173B2 (en) | 2016-02-10 | 2019-03-19 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
US10323021B2 (en) | 2014-08-15 | 2019-06-18 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
US10377753B2 (en) | 2015-07-09 | 2019-08-13 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
US11161846B2 (en) | 2019-06-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
US11214563B2 (en) | 2019-06-14 | 2022-01-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
US11447503B2 (en) | 2019-06-14 | 2022-09-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GLUN2B receptor modulators |
US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
US11479541B1 (en) | 2022-01-31 | 2022-10-25 | Pioneura Corporation | Acid addition salts, compositions, and methods of treating thereof |
US11530210B2 (en) | 2019-06-14 | 2022-12-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators |
US11618750B2 (en) | 2019-06-14 | 2023-04-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators |
US11661409B1 (en) | 2022-01-31 | 2023-05-30 | Pioneura Corporation | Acid addition salts, compositions, and methods of treating |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
KR101410453B1 (en) | 2006-08-02 | 2014-06-27 | 싸이토키네틱스, 인코포레이티드 | Certain chemical entities, compositions and methods |
JP5513118B2 (en) | 2006-10-19 | 2014-06-04 | シグナル ファーマシューティカルズ,エルエルシー | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
CA2713864A1 (en) | 2008-02-04 | 2009-08-13 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
KR20110039307A (en) | 2008-08-05 | 2011-04-15 | 다이이찌 산쿄 가부시키가이샤 | Imidazopyridin-2-on derivative |
MX2011004953A (en) | 2008-11-10 | 2011-12-14 | Vertex Pharma | Compounds useful as inhibitors of atr kinase. |
US8877772B2 (en) * | 2008-11-25 | 2014-11-04 | University Of Rochester | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
CA2747252C (en) | 2008-12-19 | 2018-09-18 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
WO2011053518A1 (en) | 2009-10-26 | 2011-05-05 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN102947272A (en) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP6086326B2 (en) * | 2010-05-24 | 2017-03-01 | ユニヴァーシティー オブ ロチェスター | Bicyclic heteroaryl kinase inhibitors and methods of use |
CA2803802A1 (en) * | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
DE102010049877A1 (en) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7 - ((1,2,3) triazol-4-yl) -pyrrolo (2,3) pyrazine derivatives |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
CN103562204A (en) | 2011-04-05 | 2014-02-05 | 沃泰克斯药物股份有限公司 | Aminopyrazine compounds useful as inhibitors of TRA kinase |
JP2014520161A (en) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EA028060B1 (en) | 2011-07-13 | 2017-10-31 | Сайтокинетикс, Инк. | Combination amyotrophic lateral sclerosis (als) therapy |
US9035053B2 (en) | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013049722A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EA034512B1 (en) | 2011-10-19 | 2020-02-14 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Treatment of cancer with tor kinase inhibitors |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2015502925A (en) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of ATR kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
BR112014013332B1 (en) | 2011-12-02 | 2022-09-06 | Signal Pharmaceuticals, Llc | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXY-PROPAN-2-YL)PYRIDIN-3-IL)-1-((TRANS)-4-METOXYCYCLOEXYL)-3,4-DIHYDROPYRAZINO [2,3-B] PIRAZIN-2(1H)-ONA, A SOLID FORM OF IT AND METHODS OF ITS USE |
AU2013202305B2 (en) | 2012-02-24 | 2015-03-12 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
CN102627646A (en) * | 2012-03-19 | 2012-08-08 | 苏州四同医药科技有限公司 | Preparation method of 3-iodo-5-bromo-4, 7-diazaindole |
LT2833973T (en) | 2012-04-05 | 2018-02-12 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
US10485800B2 (en) | 2012-11-30 | 2019-11-26 | The University Of Rochester | Mixed lineage kinase inhibitors for HIV/AIDS therapies |
SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo(1,5alpha)pyrimidine-3-carboxamide as inhibitor of atr kinase |
US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
AU2014207641A1 (en) | 2013-01-16 | 2015-08-06 | Signal Pharmaceuticals, Llc | Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith |
CA2901427A1 (en) * | 2013-03-07 | 2014-09-12 | Califia Bio, Inc. | Mixed lineage kinase inhibitors and method of treatments |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
AU2014254058B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer |
CN105324381A (en) | 2013-04-17 | 2016-02-10 | 西格诺药品有限公司 | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
EP2986322A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
CN105392499B (en) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | The combination treatment for including TOR kinase inhibitors and cytidine analog for treating cancer |
MX2015014455A (en) | 2013-04-17 | 2016-07-21 | Signal Pharm Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-yl amino)phenyl)acrylamide for treating cancer. |
ES2944478T3 (en) | 2013-04-17 | 2023-06-21 | Signal Pharm Llc | 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2 (1H)-one to treat glioblastoma multiforme |
NZ629411A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
WO2014181813A1 (en) * | 2013-05-10 | 2014-11-13 | 武田薬品工業株式会社 | Heterocyclic compound |
CA3143529A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
CA2915561C (en) | 2013-06-21 | 2020-09-22 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
EA035601B1 (en) | 2013-06-21 | 2020-07-14 | Зенит Эпидженетикс Лтд. | Bicyclic bromodomain inhibitors |
CN105593224B (en) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | Novel quinazolinones as bromodomain inhibitors |
RU2720408C2 (en) | 2013-12-06 | 2020-04-29 | Вертекс Фармасьютикалз Инкорпорейтед | Method of producing atr kinase inhibitors (embodiments) |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
ES2823756T3 (en) | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
RU2719583C2 (en) | 2014-06-05 | 2020-04-21 | Вертекс Фармасьютикалз Инкорпорейтед | Radiolabelled 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]-pyrazolo [1, 5-a] pyrimidine-3-carboxamide derivatives used as atr kinase inhibitor, preparations based thereon compounds and various solid forms thereof |
CA2950780C (en) | 2014-06-17 | 2023-05-16 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
EA201790189A1 (en) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | METHODS OF TREATING MALIGNANT NUMER FORMATION USING SUBSTITUTED PYRROPYRYMIDIN COMPOUNDS, COMPOSITIONS ON THEIR BASIS |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
WO2016130818A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
WO2016164641A1 (en) * | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP7187308B2 (en) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Methods for treating cancer using combinations of DNA damaging agents and ATR inhibitors |
JP2018531958A (en) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Heteroaryl-substituted benzoic acids and their use as RORγT inhibitors |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
WO2017075182A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
CN110996955A (en) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
WO2019169306A1 (en) * | 2018-03-01 | 2019-09-06 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress |
JP7486478B2 (en) | 2018-09-19 | 2024-05-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof |
JP7345220B2 (en) * | 2019-08-30 | 2023-09-15 | ティーエスディー ライフ サイエンス カンパニー リミテッド | Imidazopyridine derivatives and pharmaceutical compositions containing them as active ingredients |
WO2023050323A1 (en) * | 2021-09-30 | 2023-04-06 | Citrix Systems, Inc. | Automated transfer of peripheral device operations |
CN116925106A (en) * | 2022-04-24 | 2023-10-24 | 上海医药集团股份有限公司 | Bicyclic heterocyclic compound, pharmaceutical composition and application |
CN117447392A (en) * | 2023-09-13 | 2024-01-26 | 广州大学 | Fluorescent material and preparation method and application thereof |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933438A (en) | 1984-02-29 | 1990-06-12 | University Of Florida | Brain-specific analogues of centrally acting amines |
US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
ATE183084T1 (en) | 1991-05-14 | 1999-08-15 | Ernir Snorrason | TREATMENT OF FATIGUE SYNDROME WITH CHOLINESTERASE INHIBITORS |
IT1250421B (en) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES. |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
FR2710265B1 (en) | 1993-09-22 | 1995-10-20 | Adir | Bioadhesive pharmaceutical composition for the controlled release of active ingredients. |
US5618819A (en) | 1994-07-07 | 1997-04-08 | Adir Et Compagnie | 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds |
US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
DE19541260A1 (en) | 1995-11-06 | 1997-05-07 | Lohmann Therapie Syst Lts | Therapeutic preparation for transdermal application of active ingredients through the skin |
US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
EP1017370B1 (en) | 1997-09-11 | 2003-10-29 | Nycomed Danmark ApS | MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6248864B1 (en) | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
SE9802864D0 (en) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as an antimuscarinic agent for the treatment of overactive bladder |
ID27504A (en) | 1998-10-01 | 2001-04-12 | Novartis Ag | NEW ORAL FORMULATION |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
GB9904995D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
US6498176B1 (en) | 1999-03-04 | 2002-12-24 | Smithklinebeecham Corporation | 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
FR2792527B1 (en) | 1999-04-22 | 2004-08-13 | Ethypharm Lab Prod Ethiques | KETOPROFENE MICROGRANULES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS |
US6541020B1 (en) | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
RU2002104496A (en) | 1999-07-21 | 2003-09-27 | Астразенека Аб (Se) | NEW COMPOUNDS |
US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
JP2003508422A (en) | 1999-09-02 | 2003-03-04 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | Controlled release pellet formulation |
US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
US6080736A (en) | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US6482439B2 (en) | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
US6482440B2 (en) | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
EP1975620A3 (en) | 2001-03-02 | 2008-12-24 | GPC Biotech AG | Three hybrid assay system |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
EP1599475A2 (en) * | 2003-03-06 | 2005-11-30 | Eisai Co., Ltd. | Jnk inhibitors |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
US7250417B2 (en) * | 2003-07-02 | 2007-07-31 | Sugen Inc. | Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors |
AR045595A1 (en) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS |
CN101676285A (en) * | 2004-03-30 | 2010-03-24 | 沃泰克斯药物股份有限公司 | Azaindoles useful as inhibitors of JAK and other protein kinases |
US20060011139A1 (en) | 2004-07-16 | 2006-01-19 | Applied Materials, Inc. | Heated substrate support for chemical vapor deposition |
US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
AU2005269386A1 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
CN101027302B (en) * | 2004-07-27 | 2011-05-11 | Sgx药物公司 | Pyrrolo-pyridine kinase modulators |
US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
EP1796467A4 (en) * | 2004-09-24 | 2009-07-01 | Janssen Pharmaceutica Nv | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
US7348432B2 (en) | 2004-10-27 | 2008-03-25 | Janssen Phamaceutica N.V. | Pyridine imidazoles and aza-indoles as progesterone receptor modulators |
EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1h-pyrrolo[2,3-beta]pyridines |
WO2006088836A2 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
US7863288B2 (en) * | 2005-06-22 | 2011-01-04 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP2007108926A (en) | 2005-10-12 | 2007-04-26 | Denso Corp | Operation support device and program |
CA2629822A1 (en) | 2005-12-08 | 2007-06-14 | Irm Llc | Methods and compositions for inhibiting hiv infection |
EP2021496B1 (en) | 2006-05-05 | 2010-08-11 | George Mason Intellectual Properties, Inc. | Methods for detecting hiv infection |
JP2009537621A (en) * | 2006-05-22 | 2009-10-29 | アストラゼネカ アクチボラグ | Indole derivatives |
US7732447B2 (en) * | 2006-06-22 | 2010-06-08 | Cephalon, Inc. | Fused [d]pyridazin-7-ones |
KR101410453B1 (en) * | 2006-08-02 | 2014-06-27 | 싸이토키네틱스, 인코포레이티드 | Certain chemical entities, compositions and methods |
JP5513118B2 (en) * | 2006-10-19 | 2014-06-04 | シグナル ファーマシューティカルズ,エルエルシー | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
WO2008124848A1 (en) | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
MX2009010296A (en) | 2007-04-18 | 2009-12-14 | Kissei Pharmaceutical | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes. |
US8183245B2 (en) | 2007-10-25 | 2012-05-22 | Merck Sharp & Dohme Corp. | Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1 |
MX2010008198A (en) | 2008-02-25 | 2010-08-23 | Hoffmann La Roche | Pyrrolopyrazine kinase inhibitors. |
KR20110039307A (en) * | 2008-08-05 | 2011-04-15 | 다이이찌 산쿄 가부시키가이샤 | Imidazopyridin-2-on derivative |
US8592448B2 (en) * | 2008-11-20 | 2013-11-26 | OSI Pharmaceuticals, LLC | Substituted pyrrolo[2,3-b]-pyridines and -pyrazines |
US8877772B2 (en) * | 2008-11-25 | 2014-11-04 | University Of Rochester | Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors |
WO2010068899A1 (en) | 2008-12-12 | 2010-06-17 | Creighton University | Nanoparticles comprising combinations of antiretroviral agents and use thereof |
JP6086326B2 (en) | 2010-05-24 | 2017-03-01 | ユニヴァーシティー オブ ロチェスター | Bicyclic heteroaryl kinase inhibitors and methods of use |
CA2816123A1 (en) | 2010-11-02 | 2012-05-10 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
US10485800B2 (en) | 2012-11-30 | 2019-11-26 | The University Of Rochester | Mixed lineage kinase inhibitors for HIV/AIDS therapies |
-
2009
- 2009-11-25 US US13/131,193 patent/US8877772B2/en active Active
- 2009-11-25 ES ES09832359.5T patent/ES2554375T3/en active Active
- 2009-11-25 JP JP2011537733A patent/JP5930278B2/en active Active
- 2009-11-25 CN CN200980152665.1A patent/CN102264743B/en active Active
- 2009-11-25 CA CA2744498A patent/CA2744498C/en active Active
- 2009-11-25 WO PCT/US2009/065878 patent/WO2010068483A2/en active Application Filing
- 2009-11-25 AU AU2009324894A patent/AU2009324894B2/en active Active
- 2009-11-25 EP EP09832359.5A patent/EP2379561B1/en active Active
- 2009-11-25 EP EP15186751.2A patent/EP3037421A3/en not_active Withdrawn
-
2014
- 2014-10-07 US US14/508,566 patent/US9181247B2/en active Active
- 2014-11-14 JP JP2014232195A patent/JP5873544B2/en active Active
-
2015
- 2015-10-06 US US14/876,345 patent/US20160024087A1/en not_active Abandoned
-
2016
- 2016-06-03 US US15/172,355 patent/US9814704B2/en active Active
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE49517E1 (en) | 2014-08-15 | 2023-05-02 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
US10323021B2 (en) | 2014-08-15 | 2019-06-18 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
US10377753B2 (en) | 2015-07-09 | 2019-08-13 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
US10233173B2 (en) | 2016-02-10 | 2019-03-19 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
US10766880B2 (en) | 2016-02-10 | 2020-09-08 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
EP3523311A4 (en) * | 2016-10-06 | 2020-03-18 | Janssen Pharmaceutica NV | Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators |
US10617676B2 (en) | 2016-10-06 | 2020-04-14 | Janssen Pharmaceutica Nv | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators |
CN110062761A (en) * | 2016-10-06 | 2019-07-26 | 詹森药业有限公司 | Substituted 1H- imidazo [4,5-b] pyridine -2 (3H) -one and its purposes as GLUN2B receptor modulators |
WO2018067786A1 (en) | 2016-10-06 | 2018-04-12 | Janssen Pharmaceutica Nv | Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators |
US11207298B2 (en) | 2016-10-06 | 2021-12-28 | Janssen Pharmaceutica Nv | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators |
US11759455B2 (en) | 2016-10-06 | 2023-09-19 | Janssen Pharmaceutica Nv | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators |
US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
US11161846B2 (en) | 2019-06-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
US11530210B2 (en) | 2019-06-14 | 2022-12-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators |
US11618750B2 (en) | 2019-06-14 | 2023-04-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators |
US11447503B2 (en) | 2019-06-14 | 2022-09-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GLUN2B receptor modulators |
US11214563B2 (en) | 2019-06-14 | 2022-01-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
US11993587B2 (en) | 2019-06-14 | 2024-05-28 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
US11479541B1 (en) | 2022-01-31 | 2022-10-25 | Pioneura Corporation | Acid addition salts, compositions, and methods of treating thereof |
US11661409B1 (en) | 2022-01-31 | 2023-05-30 | Pioneura Corporation | Acid addition salts, compositions, and methods of treating |
Also Published As
Publication number | Publication date |
---|---|
EP2379561A2 (en) | 2011-10-26 |
US9181247B2 (en) | 2015-11-10 |
CN102264743A (en) | 2011-11-30 |
AU2009324894B2 (en) | 2015-04-09 |
AU2009324894A1 (en) | 2011-11-24 |
US9814704B2 (en) | 2017-11-14 |
EP3037421A1 (en) | 2016-06-29 |
JP5873544B2 (en) | 2016-03-01 |
EP2379561A4 (en) | 2012-10-03 |
CA2744498A1 (en) | 2010-06-17 |
CN102264743B (en) | 2015-02-11 |
CA2744498C (en) | 2017-10-24 |
WO2010068483A2 (en) | 2010-06-17 |
WO2010068483A3 (en) | 2010-09-30 |
US20160317509A1 (en) | 2016-11-03 |
JP2015052009A (en) | 2015-03-19 |
ES2554375T3 (en) | 2015-12-18 |
US8877772B2 (en) | 2014-11-04 |
JP2012509903A (en) | 2012-04-26 |
US20120053175A1 (en) | 2012-03-01 |
JP5930278B2 (en) | 2016-06-08 |
EP2379561B1 (en) | 2015-11-04 |
US20150105401A1 (en) | 2015-04-16 |
EP3037421A3 (en) | 2016-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9814704B2 (en) | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | |
US8846909B2 (en) | Bicyclic heteroaryl kinase inhibitors and methods of use | |
US11932643B2 (en) | Substituted heterocyclic inhibitors of PTPN11 | |
US10485800B2 (en) | Mixed lineage kinase inhibitors for HIV/AIDS therapies | |
US10800769B2 (en) | Heterocyclic inhibitors of ATR kinase | |
US10800774B2 (en) | Heterocyclic inhibitors of ATR kinase | |
US11046649B2 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
US20180057507A1 (en) | Inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease | |
US20160002248A1 (en) | Gls1 inhibitors for treating disease | |
US20240076291A1 (en) | Modified isoindolinones as glucosylceramide synthase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE UNIVERSITY OF ROCHESTER, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GELBARD, HARRIS A.;DEWHURST, STEPHEN;GOODFELLOW, VAL S.;AND OTHERS;SIGNING DATES FROM 20110720 TO 20110728;REEL/FRAME:037372/0245 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |